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Cluster headache (CH) is a highly disabling primary headache disorder, characterized 
by strictly unilateral, excruciating pain in the distribution of the trigeminal nerve with 
associated cranial autonomic symptoms, that has a significant impact on patients’ 
health-related quality of life (HRQoL). There has been great interest over the years in 
elucidating the pathogenesis of this disorder.  
This thesis adopted a mixed methods approach, using saccadometry and functional 
magnetic resonance imaging (fMRI) studies to gain better insight to the underlying 
processes involved, whilst also studying the disability and resultant impact it has on 
patients’ HRQoL. Arterial spin labeling (ASL) was utilized to identify changes in 
regional cerebral blood flow (rCBF) relating to brain responses to a greater occipital 
nerve block (GONB), which is a widely used transitional treatment. Significant 
activations were observed during the interictal period in several brain regions known 
to be involved in pain processing, including the posterior hypothalamus, a structure 
that has been hypothesized to have a crucial role in CH. This implies that a central 
permissive state exists during a bout, with subsequent deactivations following the 
GONB. A study of visual saccadic latencies revealed that CH patients have longer 
mean latencies with high variability and reduced number of fast saccades. This 
suggests that there is a delay in decision-making in CH patients, possibly stemming 
from basal ganglia dysfunction, with high variability of latencies arising from 
probable dysfunction within the noradrenergic system. This corresponds with the 
fMRI findings, therefore suggesting a pivotal role of these systems in CH 
pathophysiology.  
Due to the lack of a specific HRQoL measure for CH, a 28-item CH specific HRQoL 
(CHQ) scale was developed and validated, showing good internal consistency, 
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validity and test-retest reliability. An assessment made of the HRQoL confirmed the 
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Chapter 1  Introduction 
 
Cluster headache (CH) is a rare primary headache disorder that is largely 
stereotypical, characterized by the presence of an excruciatingly severe unilateral pain 
accompanied by marked cranial autonomic symptoms. The disorder is said to be one 
of the most painful conditions known to mankind, with patients typically describing 
them as the worst pain they have ever felt (1). Female patients who have undergone 
childbirth invariably report that each attack is worse than labour pain (2). The intense 
nature of the pain often leaves patients feeling helpless and suicidal, and thus warrants 
early diagnosis and effective pain management. The headache can be quite disabling 
and can have a significant impact on patients’ daily life, and subsequently on their 
health-related quality of life (HRQoL) (3, 4). Despite the numerous studies on CH to 
date, the pathophysiology of this disorder still remains poorly understood. Thus, this 
thesis adopted a mixed methods approach in the assessment of this disorder. With 
regards to treatment, a study utilizing functional magnetic resonance imaging (fMRI) 
is discussed in chapter 2, which intends to explore the central effects of the greater 
occipital nerve block (GONB), a well-known and used transitional form of treatment 
in CH. Chapter 3 discusses the use of saccadometry to study reaction times in CH 
patients to gain a wider understanding of the functional changes in this disorder. In 
chapter 4, the development and validation of the first health-related quality of life 
scale specific for CH sufferers is discussed, whilst from the same dataset, an 
assessment of the health-related quality of life in CH patients of episodic and chronic 
variant was made and is described in chapter 5. The final chapter (chapter 6) provides 
a general discussion of the findings from these studies, together with its limitation and 
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future direction. It is anticipated that via this approach, there will be a greater breadth 
of understanding of this highly disabling disorder, which in turn, may allow better 
management and future development of novel treatment strategies. 
1.1 Cluster headache 
1.1.a Diagnostic criteria  
The revised International Classification of Headache Disorders (ICHD-3 beta) 
describes CH as a rare primary headache characterised by attacks of severe, strictly 
unilateral pain, which is orbital, supraorbital or temporal in location. Each attack 
typically lasts 15-180 minutes and may occur from once every other day to eight times 
daily (5). The diagnostic criteria of CH are presented in Table 1.1. Pain is often 
described as thermal or punctate in character, like ‘a hot red poker in the eye’ (6). CH 
is sometimes known as ‘suicide headaches’ as patients are known to develop suicidal 
ideations. The attacks are associated with marked ipsilateral cranial autonomic 
symptoms, including lacrimation, conjunctival injection, nasal congestion, 
rhinorrhoea, forehead and facial sweating, miosis, ptosis or eyelid oedema (7). 
Patients may also describe feelings of restlessness or agitation with the attacks, often 
reporting banging their head against the wall or floors. Attacks may be accompanied 
by migrainous symptoms such as nausea, vomiting, photophobia and phonophobia (8). 
Although ICHD-3 beta defines the headache as being strictly unilateral, up to 15% of 
patients may experience side shifting of their headaches between attacks, with each 
individual attack remaining strictly unilateral (1). 
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Table 1-1 The International Classification of Headache Disorders (ICHD-3 beta) 
Diagnostic Criteria for Cluster Headache (5) 
 
A. At least 5 attacks fulfilling B - D. 
B. Severe or very severe unilateral orbital, supraorbital and/or temporal pain lasting 15 
to 180 minutes if untreated. 
C. Headache is accompanied by at least one of the following: 
1. ipsilateral conjunctival injection and/or lacrimation 
2. ipsilateral nasal congestion and/or rhinorrhoea 
3. ipsilateral eyelid oedema 
4. ipsilateral forehead and facial sweating 
5. ipsilateral miosis and/or ptosis 
6. a sense of restlessness or agitation 
D. Attacks have a frequency from 1 every other day to 8 per day. 
E. Not attributed to another disorder. 
 
1.1.b Classification 
Cluster headache typically occurs in bouts, which last for weeks or months and is 
termed as the episodic variant. These cluster bouts are separated by remission periods 
that can last months or years. On average, patients will experience bouts lasting 1-2 
months, with 1-2 cluster bouts per annum. However, about 10 per cent of patients 
have chronic cluster headache, where they either have no remission periods for one 
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year, or their remission periods last less than a month (7). During its lifespan, CH can 
switch forms, with transition between the two variants being bidirectional. 
1.1.c Epidemiology 
Cluster headache has been estimated to affect about 1 in 1000 of the adult population, 
although a review of recent studies have indicated that its prevalence may be as high 
as 1 per 500 of the population, which the authors speculate may be because some 
patients with short attack duration or infrequent cluster bouts may not seek medical 
treatment (1, 9). The disorder has a predisposition for males, with a male: female ratio 
reported to be 2.5-7.2: 1 (1). Although it can present at any age, the usual age of onset 
is around 20-30 years (10). There have been reports of CH occurring in monozygotic 
twins, with an increased familial risk of having CH found in first-degree relatives of 
up to 39-fold. Meanwhile there is an 8-fold increased risk in second-degree relatives, 
suggesting a possible genetic component, although no particular genes have been 
identified to date (9, 11-13). 
1.1.d Clinical features 
The clinical features of CH are relatively stereotyped, although variations can occur. 
Pain is mainly focused in areas under the distribution of the ophthalmic division of the 
trigeminal nerve (V1), although it may present in or radiate to other areas within the 
trigeminal nerve (V2 or V3) distribution (8, 14). Pain is usually rapid in onset, reaching 
peak intensity within minutes, and may either end abruptly or subside gradually. One 
of the striking features of CH is its tendency to exhibit circadian and circannual 
periodicity. The attacks tend to occur at specific times of the day, and patients often 
report having an attack an hour or so after falling asleep at night, during the first rapid 
eye movement (REM) sleep phase (1). Similarly, the cluster bouts tend to occur 
! 25!
around the same month/s of the year, with preponderance for onset in spring or 
autumn (1). During a bout, certain triggers such as alcohol, heat and the smell of 
volatile substances such as perfumes or solvents are known to trigger attacks (6, 15). 
Nitroglycerin is another well-known trigger and is commonly used to precipitate 
attacks in experimental studies (16-19). 
1.1.e Pathophysiology 
The pathophysiology of CH is still incompletely understood, however several theories 
have been put forward in an attempt to explain it. Taking into account the trigeminal 
distribution of the pain and the associated autonomic symptoms, the neurological 
pathways involved are presumed to be the trigeminal, cervical (C2 and C3) sensory 
nerves and the parasympathetic system routed mainly via the otic, ciliary and pterygo 
palatine ganglia (via ninth, third and fifth cranial nerves respectively) (1, 20). CH was 
initially thought to be a vascular headache originating from inflammation within the 
cavernous sinus (6, 20). The resulting venous stasis caused pressure on the trigeminal 
nerve, which simultaneously activated the intersecting parasympathetic and 
sympathetic nerves, eliciting pain and the autonomic symptoms respectively (6, 20-
22). Moreover, the efficacy of Sumatriptan, a 5-hydroxytryptamine agonist, which has 
vasoconstrictive effects in aborting these attacks further supported this notion (23, 24). 
However, this theory could not explain the circadian rhythmicity of the attacks.  
The circadian and circannual periodicity of CH indicated a possible central nervous 
system involvement, with the human biological clock implicated as a potential site. 
This is situated in the suprachiasmatic nucleus within the hypothalamus, which is also 
responsible for regulating hormonal activities. Interestingly, studies have shown 
hormonal abnormalities in CH patients, such as a significant decrease in plasma 
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testosterone levels in male CH patients and a reduced response to thyrotropin-
releasing hormone (25, 26). Furthermore, a blunted nocturnal peak in melatonin, a 
circadian system biomarker, has been found in patients with CH (27, 28). This concept 
of a possible central nervous system involvement has therefore led to several 
neuroimaging studies in this disorder. 
1.1.f Neuroimaging studies in cluster headache 
 
i Nitroglycerin: a reliable trigger? 
The first positron emission tomography (PET) study on CH was performed by Hsieh 
and colleagues using [15O]butanol as the tracer for regional cerebral blood flow 
(rCBF) on a limited sample size (17). They studied four right-handed patients during 
their active cluster period, two with right-sided and two with left-sided attacks. The 
headaches were elicited within 18-35 minutes of administration of 1 mg sublingual 
nitroglycerin and successfully terminated following subcutaneous administration of 
Sumatriptan (17). A 100 mm visual analogue scale (VAS) was used to enable patients 
to rate their headache intensity. Each patient underwent six scans: two at baseline (10 
minutes apart), one following nitroglycerin administration, two following onset of the 
CH (10 minutes apart) and lastly following pain relief with Sumatriptan. The authors 
reported that there was a preferential role of the right, non-dominant hemisphere, 
especially the anterior cingulate cortex, in the affective-cognitive processing of pain in 
these patients (17). Other brain areas consistently involved in the central processing of 
pain were activated, but there were no changes seen in the brainstem or diencephalon 
(17). Furthermore, they found a marked increase in rCBF in the cavernous sinus 
region, which suggested a possible blood flow disturbance and hence a role of the 
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cavernous sinus in the pathophysiology of CH (17). However, this hypothesis is 
challenged following further studies, as will be discussed in the following section. 
May and colleagues performed a similar study on 17 CH patients (18). Nine of them 
were in their active cluster period, whilst eight who were in a remission phase acted as 
controls. In this study, the headaches were provoked by inhalation of 1.0-1.2 mg 
nitroglycerin, although one patient developed attacks spontaneously in the scanner 
(18). H215O was used as a tracer and each patient underwent 12 or 13 consecutive 
scans with VAS ratings. All patients reported similarity of the triggered attacks to 
their usual headaches. Increases in rCBF were reported in the cerebellum, bilateral 
anterior cingulate cortex and insula, the contralateral posterior thalamus and ipsilateral 
basal ganglia in these patients (18). A distinctive finding from this study was increase 
in rCBF in the ipsilateral hypothalamic grey, which was not seen in the control group 
(18). This implies that this area is specifically activated only during a CH attack, 
therefore providing substantial evidence of hypothalamic involvement (18). An 
increase signal in the cavernous sinus region of patients who were in their active 
cluster period was seen, with no differences noted between the spontaneous and 
evoked attacks (18).  
Sprenger and colleagues presented an incidental case of a spontaneous cluster attack 
in a patient whilst undergoing H215O PET scanning to study the effects of deep brain 
stimulation (29). The areas showing increases in rCBF were comparable to the earlier 
studies done with nitroglycerin-induced CH (17, 18). Hence, the authors concluded it 
was unlikely that the use of nitroglycerin to trigger the attacks confounded the 
imaging data (29). 
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ii The cavernous sinus theory 
Cluster headache has long been coined a vascular headache with the cavernous sinus 
being implicated as the focal generator of symptoms. Early studies looking at the 
cerebral blood flow of patients with CH reported inconsistent results, with some 
reporting an increase, some a decrease whilst others showed no changes in cortical 
blood flow (16, 30, 31). Gawel and colleagues studied six CH patients using gallium 
SPECT (single photon emission computerised tomography) during an active cluster 
period (32). There was an increased activity seen in the parasellar region in three of 
the cases, however, due to the limited resolution, the exact location could not be 
defined, but the authors believe that it lies in close relation to the cavernous sinus (32). 
On the contrary, no definite pathology was found in the cavernous sinus region in a 
magnetic resonance imaging (MRI) study of 14 CH patients (33). A repeat gallium 
SPECT study done on 30 CH patients and seven migraineurs showed the marked 
activity within the parasellar region was not limited to CH only but was also seen in 
migraine (34). Likewise, Schuh-Hofer and colleagues found no evidence for an 
inflammatory process in the cavernous sinus of six CH patients investigated using 
99mTc-human serum albumin and SPECT (35). These findings thus question the role of 
the cavernous sinus as the pathophysiological focus in CH. 
Despite the consistent findings of significant increases in rCBF within the cavernous 
sinus region in PET studies, experimental pain studies have also reported similar 
findings (36). A H215O PET study performed observed the effects of cranial pain 
elicited by capsaicin (36). Seven healthy subjects had a small amount of capsaicin 
injected to their forehead, in an attempt to elicit pain of the ophthalmic division of the 
trigeminal nerve. Increased rCBF was observed bilaterally in the anterior insula, the 
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ipsilateral anterior cingulate cortex, the contralateral thalamus and bilaterally in the 
cerebellum as well as in the cavernous sinus (36).  
Similar findings were reported by May and colleagues who performed a magnetic 
resonance angiography (MRA) study in addition to the H215O PET study above (19). 
Four volunteers had capsaicin subcutaneously administered to the forehead to elicit 
pain. The patient who developed the spontaneous cluster attack during the H215O PET 
study was also included. A significant increase in blood flow was observed in the 
ipsilateral internal carotid artery in all subjects (19). The fact that there is increased 
activity in the cavernous sinus in experimental pain, during cluster attacks and in 
migraineurs implies that this activation is not specific to CH (19). The vascular 
changes seen are thus more likely to be an epiphenomenon in response to the 
trigeminal pain, rather than an initiator of the attacks, hence dispelling the cavernous 
sinus hypothesis (19). Moreover, no activation of the hypothalamus was reported in 
the experimental pain study, further suggesting its specificity to CH (36). 
iii The hypothalamic hypothesis 
In the wake of the direct evidence found for a possible hypothalamic involvement, 
other neuroimaging modalities have been used which aims to shed further light to this 
hypothesis. Morelli and colleagues performed the first blood oxygen dependent level 
(BOLD) fMRI study on four patients with episodic CH (ECH) (37). The patients had a 
regular recurrence of their attacks, thus their scans were timed accordingly to allow 
spontaneous attacks to be captured. Significant activation in the ipsilateral 
hypothalamic grey matter was observed, though any inferences should be treated with 
caution due to the small sample size (37). 
May and colleagues performed a voxel-based morphometric analysis on MRI scans of 
25 CH patients and 29 healthy controls (38). Fourteen of the CH patients were in an 
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active bout, whilst 11 patients were in their remission period. A significant increase in 
grey matter density localised to the inferior posterior hypothalamus was found 
bilaterally in these patients compared to controls. No difference was detected between 
patients with active headache and in the headache-free state, indicating that these 
changes are specific to the disorder (38). However, a repeat study by Matharu as part 
of his PhD thesis failed to replicate these findings, and he identified several limitations 
of the original study (39). These included methodological issues related to data 
processing and analysis, such as an outdated version of software used, failing to 
correct for motion artefacts and incidental pathology, and patients and controls not 
correctly matched for age and gender (39). 
Lodi and colleagues performed a proton magnetic resonance spectroscopy (1H-MRS) 
localized to hypothalamic gray matter bilaterally, on 26 pain-free patients with CH 
(40). Biochemical levels of N- acetylaspartate (NAA), creatine-phosphocreatine (Cr) 
and choline (Cho) were assessed. The level of NAA, a neuronal biomarker was 
permanently reduced in the hypothalamus of these patients, with such abnormalities 
usually identifiable in pathologies like stroke, degenerative disorders and multiple 
sclerosis (40). Similar findings were reported from another proton magnetic resonance 
spectroscopy study of 47 ECH patients (41). In addition to a reduction in NAA/Cr, a 
change in the Cho/Cr levels was also detected (41). These neurochemical changes are 
consistent with the increased grey matter density and a hypothalamic dysfunction in 
patients with CH, thus providing further evidence for the central role of the 
hypothalamus in this disorder. 
However, it has recently been argued that the hypothalamic derangements observed in 
CH may not be specific to the disorder (42). Hypothalamic activation and structural 
alterations are not exclusively observed in CH but can also be found in other primary 
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headache disorders including migraine, hemicrania continua and hypnic headache (42-
45). In migraine, bilateral hypothalamic activation was observed during spontaneous 
migraine attacks using PET imaging, whereas in hemicrania continua, the activation 
was observed contralateral to the side of pain, therefore suggesting that this region 
may be simply involved in the general processing of pain (44, 45).  A VBM study in 
hypnic headache reported a decrease in grey matter volume within the posterior 
hypothalamus (43). Whilst these observations question the specificity of hypothalamic 
involvement in CH, the converging evidence from neuroimaging, neuroendocrine and 
genetic studies, taken together with the clinical presentation of the disorder, and the 
emergence of deep brain stimulation (which will be discussed below), highlights the 
importance of the hypothalamus in CH pathophysiology.  
1.1.g From neuroimaging to treatment modality 
Neuroimaging studies have provided considerable insight into the pivotal role of the 
hypothalamus in the pathogenesis of CH. As previously described, this has brought 
about advancements in treatment modalities, namely deep brain stimulation (DBS), 
which has been reported to be beneficial in medically-intractable patients (46). H215O 
PET studies performed on 10 CH patients with implanted hypothalamic DBS 
electrodes demonstrated that stimulation induced changes in rCBF in cerebral areas 
normally involved in the pain-processing network and in acute CH attacks (47). In 
particular, increases in rCBF were reported in the ipsilateral hypothalamic gray (the 
site of the stimulator tip), the ipsilateral thalamus, somatosensory cortex and 
precuneus, the anterior cingulate cortex, and the ipsilateral trigeminal nucleus and 
ganglion. Reductions in rCBF were observed in the middle temporal gyrus, posterior 
cingulate cortex, and contralateral anterior insula (47). There was no evidence found 
for an antinociceptive effect or a pure inhibition of hypothalamic activity as the mode 
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of action of DBS in CH, thus suggesting the possibility of a yet unknown functional 
modulation of the processes involved in pain generation (47). 
1.1.h Management 
The majority of patients with CH receive pharmacological treatment for their 
headaches, and only a small proportion of chronic CH (CCH) patients that are deemed 
medically intractable are offered surgical interventions.  The three main categories of 
medical management of this disorder are acute, preventive or transitional therapies.  
As the name suggests, acute or abortive treatment is aimed at aborting each individual 
attack and should be given at the onset of an attack. Preventive medications are used 
to suppress attacks during a bout and ideally to achieve and maintain remission whilst 
the patient is still in a bout. They generally need to be titrated to an optimum dose and 
thus their beneficial effect may not become apparent until after a few days to weeks of 
starting the medication. Transitional treatments can therefore be very helpful during 
this period as they can bridge this gap by rapidly suppressing the attacks, although 
they are only generally effective for a few days to weeks. 
i Medical management 
a Acute treatments 
The acute treatments of choice in CH include inhalation of high-dose and high-flow-
rate oxygen (100% at 7-15 L/min via a non-rebreathing face mask) and subcutaneous 
Sumatriptan 6mg, which can usually abort an attack within 15-30 minutes. However, 
there is also evidence for efficacy of intranasal triptans (Sumatriptan 20 mg or 
Zolmitriptan 5mg and 10 mg) or oral Zolmitraptan 10 mg (only in ECH) as alternate 
abortive treatments (48, 49). 
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b Preventative treatments 
The prophylactic treatment of CH is largely empirical based, due to the limited 
numbers of controlled trials to provide evidence-based guidelines and the lack of 
understanding of its pathophysiological basis (48-52). The first drug of choice is 
Verapamil (50, 51), due to its efficacy and relative safety profile, which is used 
clinically at dosages of 240 - 960 mg daily, with close electrocardiographic 
monitoring (48). Randomised-controlled trials and open-label studies have been 
reviewed and Lithium, Topiramate, Methysergide, Sodium Valproate, Gabapentin, 
Melatonin and Baclofen have been reported to be efficacious in CH (50, 52). 
c Transitional treatments 
Transitional therapy allows a short-term solution in controlling the CH attacks whilst 
waiting for the preventive medication to take effect, and can thus be thought of as a 
short-term preventative. Theoretically, it should be quick-acting, providing almost 
immediate pain relief and should last long enough to allow the preventive medication 
to be increased to an effective level (53). On the other hand, it can also be used in 
patients who remain refractory to the other medications or are unable to tolerate their 
adverse effects (54). The types of transitional treatments available for CH are short 
courses of oral corticosteroids and injectable treatments including greater occipital 
nerve blocks (GONBs) and multiple cranial nerve blocks.  
• Greater occipital nerve blocks 
The GONB is one of the most common peripheral nerve block used in headache 
management. It involves a simple procedure with minimal side effects and has been 
suggested to provide pain relief in a number of headache disorders, including CH (55, 
56). However, although the technique has long been used in clinical practice, its 
mechanism of action is poorly understood. 
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A proposed hypothesis is centred on the convergence between the cervical and 
trigeminal systems at the level of the trigeminal nucleus caudalis (53, 56-58). The 
GON is the main sensory nerve of the occipital area, deriving most of its fibres from 
the C2 dorsal root (59). Blocking the GON is thought to reduce the cervical afferent 
input to the nucleus, which then modulates central processes and alters nociceptive 
processing, with possible interruption of the trigeminal autonomic reflex pathway (53, 
56-58). This functional connectivity or convergence of the nociceptive trigeminal and 
cervical afferents is supported by a decrease in nociceptive blink reflex and increased 
R2 latency on the injection side, following an occipital nerve blockade in CCH 
patients and headache-free controls (55, 60). Furthermore, an experimental trial of a 
GONB containing sterile water induced immediate pain not only over the injection 
site but also projecting to unilateral areas innervated by the ophthalmic division of the 
trigeminal nerve (V1), with associated cranial autonomic features (61). Within the 
clinical setting, CH patients also often report of having associated neck tenderness or 
stiffness with their headaches or vice versa. 
A randomized, double-blind, placebo-controlled study has reported 11 out of 13 
(85%) CH patients were attack-free one week following the procedure, compared to 
none in the placebo group, with eight patients (61%) remaining headache-free at 4 
weeks (62). In another study that included 14 CH patients, 64% had either a good or 
moderate response to the block and remained attack-free for 3-70 days (53). Afridi 
and colleagues performed an audit study of GONBs administered to 101 patients with 
different forms of primary chronic daily headache, including 19 CH patients, and 
found that 53% of patients had complete pain relief whilst 16% had partial pain relief 
after being administered a GONB (56). Of the CH patients, 59% had either a complete 
or partial response to the GONB. Leroux and colleagues carried out a randomized, 
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double-blind, placebo-controlled trial and showed that in 43 CH patients who have 
frequent daily attacks, giving repeated GONB with steroid (cortivazol) is an effective 
transitional therapy (63). In their study, there was a reduction in the number of daily 
attacks, reduced need for Sumatriptan injections and Verapamil and a higher patient 
satisfaction score in those receiving the steroid injection compared with placebo (63). 
A retrospective, open-label study confirmed the efficacy of 121 GONBs given to 60 
ECH and CCH patients, with almost 80% of infiltrations resulting in a positive 
response; 43.7% showed a complete response, with effect lasting an average of 3.5 
weeks (64). Our group recently carried out a prospective study on a large cohort of 
CCH patients (83 patients) and found that 57% had a positive response lasting a 
median of 21 days (range 7 – 504 days). Of those that responded to the GONB, 42% 
had a complete response whilst 15% had a partial response with ≥ 50% improvement 
in headache characteristics (frequency, duration or severity). Furthermore, we showed 
that repeated GONB given every three months produces a consistent and reproducible 
response in a subgroup of responders (65). These positive findings thus suggest that 
GONB is an effective transitional treatment in CH. 
d Surgical management 
In view of the trigeminal pain and cranial autonomic features characteristic of CH, a 
number of surgical interventions targeting the trigeminal and parasympathetic 
pathways have been tried over the years.  These procedures are mostly ablative or 
destructive, with sparse benefit, and include glycerol or local anaesthetic injections to 
the Gasserion ganglion, partial or complete sectioning of the trigeminal root, 
radiofrequency rhizotomy of the Gasserion ganglion and microvascular 
decompression (66, 67). However, technological advances and knowledge of possible 
underlying mechanisms in CH, as discussed above, has led to the advent of 
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neurostimulation procedures, which are non-destructive and have been shown to have 
good efficacy. These have considerably broadened the arsenal of therapeutic options 
available and include occipital nerve stimulation, hypothalamic deep brain stimulation 
and sphenopalatine ganglion stimulation (46, 66-69). 
 
Therefore with regards to treatment, there is accumulating evidence for the efficacy of 
the GONB in CH, although little is known about the mechanisms relating to its 
treatment effect. Previous neuroimaging studies in CH have provided useful insights 
into the structures that may have pivotal roles in the pathophysiology of the disorder. 
Hence, similarly, it may also be a useful modality in understanding the effects of the 
GONB in this patient group. 
1.2 Saccadometry and cluster headache 
Although our understanding of CH has improved over the years, its medical 
management is still empirically based, whereas surgical interventions have been based 
on research studies that provided evidence of structures likely to be involved in its 
pathogenesis. Since the former remains the mainstay for management of this disabling 
disorder, there is clearly a need for better understanding of the underlying 
pathophysiology to allow improvement in its management. Saccadometry- the study 
of saccadic eye movements has been utilised in a variety of neurological disorders 
including Huntington’s and Parkinson’s disease to gain insight into the effects of those 
conditions on neural function (70-73). Saccades are the spontaneous rapid eye 
movements made to targets of interest within our visual environment (73). They are 
the fastest and most frequent movements produced by the body- the eyes make two or 
three saccades per second (74). Since saccadic movements are highly stereotyped, 
useful information can be gained by studying abnormalites within them due to disease 
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states (74). One of the parameters used in describing saccadic movements is its 
latency, which is the time taken from the onset of a stimulus to the onset of eye 
movement, or in other words, reaction time. Saccadic latencies vary randomly from 
trial to trial, and therefore a meaningful analysis should take into account this 
variation by reporting not only its mean or median value but also the whole 
distribution, which can only be achieved from large datasets (75). The development of 
a portable head mounted saccadometer now permits fast acquisition of such large 
datasets, enabling up to 100 saccades to be collected over a two to three minute period 
(73). Furthermore, head restraints are not required, meaning that studies can now be 
easily performed outside of the laboratory setting (73).  
1.2.a Generation of a saccade 
In theory, saccadic latencies should be very short, around 60-80 milliseconds, since it 
reflects the time taken for a visual stimulus to elicit an oculomotor response (Figure 
1.1). Visual input from the retina is conveyed to the superior colliculus (SC) - a 
midbrain structure that is responsible for coding information about ‘where to look’, 
which triggers the oculomotor nuclei within the brainstem to initiate movement. 
However, in reality, saccadic latencies usually last up to three times longer, because 
the visual information are also projected to and further analysed in cortical areas. 
These structures are mainly tonically inhibitory and hence, the delay in reaction time 
is due to the descending inhibitory inputs from these higher structures to the SC, 
whilst a decision is made on ‘what to look at’, and as such reaction time is 
fundamentally decision time (73). 
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Figure 1-1 A schematic illustration of saccadic control showing the neural 
pathways involved in generation of saccades. The shortest pathway for generation of a 
saccade is from the retina-superior colliculus-brainstem-oculomotor muscle, which 
should last 60-80 msecs. However, in reality, saccades last much longer (about three 
times longer) as visual input from the retina is conveyed to the cerebral cortex via the 
lateral geniculate nucleus in the thalamus, where decisions are made on what to look 
at. The superior colliculus receives descending inputs from the cerebral cortex and 
basal ganglia, which then triggers the brainstem saccade generator to make a saccade. 
Adapted from Carpenter (http://www.cudos.ac.uk/later.html) 
 
1.2.b The LATER model 
Carpenter (1995) (76) developed the LATER model (Linear Approach to Threshold 
with Ergodic Rate) to describe the decision-making process involved in the generation 
of saccades. He suggested that a decision signal S, rises linearly at a constant rate r, in 
response to incoming information from the stimulus, until it reaches a criterion or 
threshold level ST, for triggering initiation of a response (77). Since latency or 
reaction time and rate is reciprocally related, then if the rate of rise r, varies from trial 
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to trial as a normal distribution, with mean µ and variance σ2, then this explains the 
recinormal distribution of latency, as explained below (76). 
 
Figure 1-2 Diagram illustrating the LATER model which describes the decision-
making process in the saccadic generation. A decision signal S, rises linearly at a 
constant rate r, in response to incoming information from the stimulus, until it reaches 
a criterion or threshold level ST, for triggering initiation of a response. When plotted 
on a histogram, latency is positively skewed (shaded area), however its reciprocal, rate 
(r) varies from trial to trial as a normal distribution, with mean µ and standard 
deviation σ (inset). Adapted from Chandna and colleagues (75). 
 
 
1.2.c Reciprobit plots 
As previously mentioned, saccadic latencies are highly variable from trial to trial and 
thus will always have a skewed distribution (77). However, this can be normalised by 
applying a reciprocal transformation (yielding a recinormal distribution), which when 
plotted on a cumulative histogram with latency on a reciprocal scale and probability 
on a probit scale, will transform a normal distribution to a straight line, as shown in 
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Figure 1.3. This plot is known as a reciprobit plot as it combines both reciprocal and 
probit scales (73, 77). The line can be defined by its intercept at the 50% axis and its 
slope, which is the mean and standard deviation of latency respectively. Occasionally, 
there is a sub-population of fast (early) saccades that lie on another line of shallower 
slope, which can be described by its standard deviation, σE (77). 
 
Figure 1-3 Graph showing a reciprobit plot with latency on a reciprocal scale (x-
axis) and cumulative probability on a probit scale (y-axis), illustrating that the 
reciprocal of latency follows a normal distribution. A small subpopulation of early or 
very fast saccades is generated by some individuals, which lie on another line with 
shallower slope. Reprinted from Chandna and colleagues (75). 
 
1.2.d Saccadic reaction time in headache disorders 
To date, there have been only studies of saccadic reaction time in migraine, whereas 
other headache disorders have not been evaluated. The interest in studying saccadic 
eye movements in migraineurs in this past decade arose following evidence from 
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genetic and neuroimaging studies that suggested the cortical areas implicated during a 
migraine attack were also associated with saccadic control (78-80). These authors 
therefore hypothesized that this would be reflected by an abnormal saccadic 
behaviour, but they failed to provide any evidence for abnormal saccadic eye 
movements in migraineurs with and without aura, compared to headache-free controls 
(79, 80).  Similarly, no significant differences in saccadic latency between migraine 
groups were found by Cambron and colleagues (78). However, compared to controls, 
they found significant differences in several parameters of saccadic latency. A 
possible reason for this may be due to methodological differences, whereby the latter 
study included three different saccadic tasks that were more challenging compared to 
the earlier studies, and that they looked at the whole distribution of latency (78). In 
particular, they found a significant difference in the standard deviation of latencies in 
the “pro-overlap” and “pro-gap” tasks. In the “pro-overlap” task, the subject is 
instructed to look as quickly as possible to an extra stimulus, whilst the original 
fixation point stays on, whereas in the “pro-gap” task, there is a short gap between the 
fixation point disappearing and the stimulus appearing. The authors suggested that this 
difference reflects the high variability in the parietal cortex-collicular input, which 
subsequently reflects changes in visual attention (78). Moreover, there were 
significantly more errors made in the “anti-saccade” task, where subjects had to move 
their eyes in the opposite direction to the stimulus, suggesting a dysfunction in 
inhibitory control of reflexive saccades involving the prefrontal or cingulate cortices 
(78). Conversely, a recent study using a different task found that migraineurs had 
reduced variability in their saccadic latency compared to controls, and had less 
incidence of early saccades (75). The authors hypothesize that these differences that 
were restricted only to variability of saccadic latencies, without significantly affecting 
! 42!
its mean, may reflect changes in noradrenergic activity in migraineurs, thus ultimately 
providing insight into the underlying neural mechanisms in migraine. Furthermore, 
they speculate that the high discriminative power of saccadometry in this disorder 
may potentially lead to its use as a diagnostic tool within the clinical setting (75). Due 
to the discrepancies in the findings of saccadic reaction time distributions from these 
studies, further work is clearly needed to clarify the nature and scope of any 
impairment. 
Saccadometry has therefore allowed some understanding of the possible functional 
changes associated with migraine. However, there have been no studies examining 
saccadic reaction time in other headache disorders, in particular CH, which could 
potentially characterize its neurological function and allow better understanding of its 
pathophysiological basis.  
1.3 Quality of life in primary headache disorders 
Quality of life (QoL) is a measure of an individual’s general well-being, whilst health-
related quality of life (HRQoL) measures the impact of an illness on the patients’ 
physical, emotional and social functioning (81). Over the past decades, the importance 
of measuring HRQoL in patients with chronic disorders has become an area of interest 
in clinical practice, as it provides the patient’s subjective experience of the impact of 
their disorder, incorporating the biopsychosocial model of health (81, 82). Within the 
headache field, much of the work relating to HRQoL has focused mainly on migraine, 
as it is one of the most frequent primary headache diagnoses. Despite the lack of any 
physical abnormality in headache disorders, the nature of the attacks with their 
recurring pain and associated symptoms often influences the patients’ ability to 
function normally. Indeed, the World Health Organization (WHO) in their Global 
Burden of Disease study conducted in 2010 reported that tension-type headache and 
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migraine are the second and third most common diseases in the world respectively. 
Migraine ranked highest amongst all neurological diseases and in seventh place as 
specific causes of disability worldwide (83).  
Several conceptual models of HRQoL exist that serves to describe the underlying 
dimensions or elements that are defined by and included within this construct. The 
three most common models used in the literature are the Wilson and Cleary, Ferrans 
and colleagues, and the World Health Organisation International Classification of 
Functioning, Disability and Health (WHO ICF) models (84). Wilson and Cleary 
integrates biological and social science paradigms into their HRQoL model, which are 
divided across five domains, namely biological/physiological variables, symptom 
status, functional status, general health perceptions and overall quality of life, with 
characteristics of the individual and their environment feeding into and influencing the 
four latter domains (84, 85). The authors proposed that measures of health exist on a 
continuum of increasing complexity from the biological/physiological domains on one 
end to the general health perceptions on the other end (85). This model was then 
revised and simplified by Ferrans and colleagues, whilst still retaining the five original 
domains, and suggested that individual and environmental characteristics also 
influences biological function (86). Meanwhile, the WHO ICF model provides a 
description of health states, in particular the interaction of functioning and disability 
on health, which serves more as a classification framework rather than as a guide for 
HRQoL (84, 87). 
Inclusion of HRQoL as an outcome measure is increasingly recognized in clinical 
trials and in cost-effective analysis of interventions, as is its use in routine clinical 
practice for monitoring purposes. However, there are a number of challenges that can 
be encountered in measuring HRQoL. This includes choosing a suitable instrument to 
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assess HRQoL for a particular disorder, with straightforward data analysis and 
interpretation, and that ideally allows incorporation of findings into clinical decision 
making (88). As the underlying aim of measuring HRQoL is to gain a patients’ 
perspective of their illness on their wellbeing, HRQoL measures should be based on 
and reflect the patients’ point of view, rather than purely those of clinicians or health 
care professionals (88, 89). HRQoL measures should therefore be designed with 
patients in mind, as discrepancies may exist on areas of life or wellbeing that are 
deemed important by them compared to clinicians, thus ensuring that the items 
covered in the measure truly reflects how the disorder affects their lives (90, 91). 
HRQoL measures must be valid, reliable, and responsive, as well as be simple to 
administer, score and interpret to have clinical usefulness (88, 90-92). 
Over the years, various instruments have been developed to evaluate HRQoL, which 
include generic and disease-specific measures. Generic HRQoL instruments can be 
used to measure HRQoL in many different disorders, allowing comparisons with other 
medical conditions and with healthy controls (48, 93). Whilst these measures provide 
a good overview of the impact of a disease on HRQoL, the general broad nature of the 
items within these instruments limits their ability to detect changes that are specific to 
a particular disorder and they may not be sensitive enough to detect small, clinically 
important changes in HRQoL, for example following treatment in a particular disorder 
(90-92). Hence, disease-specific measures have been developed to overcome these 
shortcomings, and thus includes items that are important and relevant only to patients 
suffering from the particular disorder being studied (90-92). 
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1.3.a Generic HRQoL instruments 
The most frequently used generic HRQoL measures include the Short Form-36 item 
(SF-36) Healthy Survey, the Nottingham Health Profile (NHP) and the European 
Quality of Life (EQ-5D) scales.  
The SF-36 Health Survey is a generic HRQoL measure with excellent reliability and 
validity (94). It contains 36 self-administered items, measuring functions in eight 
domains. Physical functioning (PF) has ten items measuring the ability to perform a 
variety of physical activities. Role-physical (RP) measures the extent to which 
physical health interferes with usual daily activities (four items). Bodily pain (BP) 
assesses the extent of bodily pain in the past four weeks (two items). General health 
(GH) contains five items and is an overall rating of health in general. Vitality (VT) 
measures general energy over the past four weeks (four items). Social role functioning 
(SF) assesses the extent to which health interferes with normal social activities (two 
items). Emotional role functioning (EF) has three items measuring the extent to which 
emotional problems interfere with usual daily activities, and mental health (MH) is a 
measure of general mood in the past four weeks (five items). The subscales are scored 
on a scale of 0 to 100, with higher scores indicating better HRQoL in the domain 
being measured (94). 
The Nottingham Health Profile (NHP) is a 45 item self-administered instrument 
divided into two parts. The first part assesses areas related to health, including sleep, 
physical mobility, energy, pain, emotional reactions and social isolation, whereas the 
second part assesses areas of daily life most often affected by health. These include 
paid work, household chores, social life, personal relationships, sex life, hobbies and 
interest, and holidays (95). 
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The European QoL (EQ-5D) Questionnaire is a generic measure of current health 
status. It consists of five domains; mobility, self-care, usual activities, pain/discomfort 
and anxiety/depression. Each of these domains has three possible response options; no 
problems, some or moderate problems or extreme problems. In addition, there is a 
visual analogue scale, with 0 being the worst imaginable and 100 being the best 
imaginable current health state (96). Recently, the EQ-5D has been revised in an 
attempt to improve the instruments’ sensitivity (97). The revised scale includes five 
possible response options for each item (EQ-5D 5L); no problems, slight problems, 
moderate problems, severe problems and unable to/extreme problems, and has been 
shown to be a valid extension to the previous 3-level system (98). 
1.3.b Migraine-specific HRQoL instruments 
Migraine-specific HRQoL scales have been developed to measure the unique 
symptoms or areas of life that may be affected in this patient group. This includes the 
Migraine-Specific Quality of Life scale (MSQOL) (99), the Migraine-Specific Quality 
of Life Questionnaire (MSQ) (100, 101), and the 24-hour Migraine Quality of Life 
Questionnaire (24-hr-MQoLQ) (102).  
The MSQOL is a 20-item questionnaire covering three domains; avoidance, 
relationships and feelings (99, 103). The 24-hr-MQoLQ contains 15 items measuring 
five domains associated with an acute headache; work functioning, social functioning, 
energy/vitality, migraine headache symptoms and feelings and concerns (102). 
Meanwhile, the MSQ v2.1 is a 14-item measure, divided across three domains; role 
restrictive, role preventive and emotional functioning. Role restrictive contains seven 
items assessing the degree to which the performance of normal activities is limited by 
migraine, whereas role preventive (four items) measures the degree to which the 
performance of these activities is interrupted by migraine. Three items assess the 
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emotional impact due to migraine (emotional functioning). This questionnaire has 
been shown to have good internal consistency and construct validity (101). The total 
possible score ranges from 14 to 84, with higher scores indicating poorer HRQoL. 
Furthermore, a number of headache disability scales that assesses impact and 
disability due to headaches are available, which include the Migraine Disability 
Assessment Scale (MIDAS), the Headache Impact Test (HIT-6) and the Henry Ford 
Headache Disability Inventory (HDI). Although disability and HRQoL are 
independent constructs, they are closely related and assessment of disability are often 
included as part of HRQoL measures (104). 
1.3.c HRQoL by headache diagnoses 
 
i Migraine  
Studies assessing HRQoL in migraine demonstrated that, overall, migraineurs had 
significantly diminished HRQoL in both physical and mental health domains of the 
SF-36 compared to healthy controls (105-119). Physical functioning, social 
functioning, mental health and role disability due to emotional problems were the 
domains found to be least affected (106, 109, 111, 113, 115, 119). No differences 
were reported in HRQoL between migraine subtypes, namely migraine with aura, 
migraine without aura, and migraine with and without aura (107). The tendency of 
having a fairly intact mental health score had led some authors to suggest that physical 
impairment has a greater role in influencing poorer HRQoL than mental impairment 
(109, 120). However, whilst migraineurs have reported difficulties in physical 
activities such as mobility, driving, lifting and carrying objects, the majority report 
their impairments are related to mental functions (107, 113, 121-123), with 87% 
reporting difficulties with activities requiring mental effort, compared to 47% 
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reporting limitations of physical activity (124). 
Taking into account that migraine usually affects individuals during their productive 
years, two studies evaluated HRQoL impairment in groups of employed individuals 
with migraine, namely nurses and French workers. The nurses suffering from 
migraine showed lower HRQoL compared with non-headache participants, especially 
in the physical role and bodily pain subscales, which are sensitive to headache 
severity. Consequently, this affected their work, leading to missed workdays, arriving 
late, and reduced function and productivity at work (105). Conversely, a comparative 
study among French workers showed that absenteeism among migraine sufferers was 
not statistically different from controls, although performance was greatly reduced 
(106). 
This goes in line with the general finding that migraine sufferers tend to attend school 
or paid work despite having a headache, with more days of reduced productivity at 
school or work than actual days of missed activity (111, 113, 122-128). Studies 
utilizing the MIDAS and HIT-6 questionnaires have found that the majority of 
migraineurs (up to 70%) (111, 122, 125, 126, 129-133) were moderately to severely 
disabled or impacted by their headaches (MIDAS and HIT-6 grades III and IV), with a 
trend of more missed days reported for household work, followed in order by family, 
social and leisure activities and school or paid work respectively (134, 135). Days of 
reduced productivity in household chores (with productivity reduced by at least half) 
were also greater than in school or paid work (111, 113, 122, 124-128, 136). Hence, 
reduced work productivity and absenteeism amongst migraineurs are well reported, 
and this can have a substantial economic impact (105, 137-139). Moreover, even 
between attacks, the individual’s well-being is impaired, which can be disruptive on 
social and family relationships. 
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This tendency of missing family time over paid work can lead to disruption in family 
relationships. Ruiz de Velasco and colleagues found this to be a central issue raised by 
patients and relatives in their study, whereby both parties reported that family 
environment was the area most affected by migraines (123). Patients and their spouses 
also expressed their concern regarding the impact of migraines on emotional 
development of their children (123). Indeed, a study exploring the relationship 
between maternal migraine and child functioning found that migraine may be related 
to dysfunctional parenting patterns, with the risk of parent-child reversal roles and 
inappropriate parents’ expectation of their children increasing as a mother’s migraine 
becomes disabling (140).  
With regards to migraine amongst the paediatric and adolescent population (116, 141-
143), there was an overall impairment in HRQoL domains. Adolescents reported more 
impairment in school functioning, whereas social functioning was reportedly more 
impaired in younger children (aged 5-7 years) (141, 142). Adolescent autonomy and 
coping mechanisms plays a significant role in determining their HRQoL; the more 
able a child is in coping with their pain, the better their HRQoL. Moreover, having a 
successful adaptive family routine, whereby families adapt and organize their daily 
activities in a positive way for all members, predicts a better outcome for HRQoL 
(144, 145).   
In view of the emotional and mental impairments associated with migraine, much 
attention has been focused on the association between psychological wellbeing and 
HRQoL (109, 110, 115-117, 142, 146-151). These studies showed that most 
migraineurs exhibited anxiety and/or depressive symptoms, and comorbidity with 
both anxiety and depression was positively correlated to headache-related disability 
(115, 147). These psychiatric disorders have a negative influence on HRQoL 
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independent of each other; however migraineurs with combined anxiety and 
depression have significantly poorer HRQoL scores, with the greatest impact being on 
the mental health domains (110, 115, 116). The presence of these affective disorders 
also affects perceived migraine, treatment satisfaction and efficacy (115). Conversely, 
Mula and colleagues reported no differences in HRQoL scores between migraineurs 
with and without comorbid psychiatric disorders (150). Moreover, it has been 
suggested that the psychological response to severe migraine, particularly 
catastrophizing, has a greater impact on HRQoL impairment than the mere presence 
of comorbid anxiety and/or depression (149).  
The HRQoL of migraine patients has been compared to those with other chronic 
conditions to allow a better overview of the degree of impairment in this disorder. In 
comparison to asthmatics, migraineurs scored significantly lower on social 
functioning, role emotional, mental health, bodily pain and vitality domains. However, 
compared to patients with chronic musculoskeletal pain and juvenile fibromyalgia, 
migraineurs had a better overall HRQoL (107, 142). Similarly, children with primary 
headache disorders scored significantly worse on all aspects of HRQoL, except 
physical functioning and general health perception subscales, when compared to 
children with asthma, and had generally worse HRQoL than children with attention 
deficit hyperactivity disorder (ADHD) (152). In comparison to hypertension, diabetes 
and osteoarthritis, migraineurs scored lower in most domains, particularly those 
measuring wellbeing (mental health, emotional and social functioning) (112). 
Furthermore, migraineurs were also found to have higher comorbidity, especially with 
hypertension, irritable bowel syndrome, ulcers, and hearing and vision problems, 
compared to headache-free controls, which is a significant predictor of headache-
related disability (147). 
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In summary, it is clear that much work has been devoted to assessing HRQoL in 
migraineurs within the headache field. These studies have demonstrated that migraine 
is associated with impairment in HRQoL, with reduced productivity and 
psychological comorbidity. 
ii Tension-type headache (TTH) 
The studies assessing HRQoL in TTH showed that, as expected, TTH was more 
prevalent compared to other headache disorders (130, 153-156), and patients with 
TTH had poorer HRQoL than healthy controls (153-155, 157). In episodic tension-
type headache (ETTH), defined as having fewer than 15 TTH days per month, vitality 
and bodily pain scores of the SF-36 were significantly lower than controls (158), 
whereas in chronic tension-type headache (CTTH), with more than 15 TTH days per 
month, physical, social and role functioning were markedly impaired (3, 157). There 
was no significant difference in overall HRQoL between ETTH and CTTH patients, 
although work performance and physical health were more severely affected in the 
latter (159). Interestingly, patients with CTTH reported greater pain than episodic 
migraineurs, which may reflect headache chronicity rather than individual attack 
severity (3). 
This goes in line with the finding that even though the majority of CTTH patients had 
a generalized impairment in functioning, which persists even outside of attacks (153), 
this was usually of moderate severity, without necessarily forcing cancellations of 
work or social commitments. Only a minority (up to 6%) rated their work 
performance as severely impaired and only 9% reported severe impairment in social 
functioning (157, 158). The greatest impairment was related to sleep, energy levels 
and emotional well-being (157). The degree of impairment in TTH is comparable to 
or greater than those with back problems or arthritis (157). 
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Holroyd and colleagues found that anxiety or mood disorders were three to 15 times 
as frequent in CTTH patients as controls (157). The observed depression was mild to 
moderate in severity, however anxiety was sufficiently high to impair functioning 
(157). The association between anxiety/depression and HRQoL in CTTH was 
investigated in one study, which suggested that anxiety has a mediating effect between 
headache frequency and vitality, social functioning and mental health, whilst 
depression had a modulatory effect on these same domains (160).  
Although ETTH is the most prevalent headache disorder in the general population, 
most of the studies have focused on HRQoL in CTTH. This may be because the pain 
in ETTH is usually infrequent and mild, thus it is less likely to cause significant 
impairment. Even so, these studies indicate that TTH has a major impact on HRQoL, 
which is significantly worse relative to healthy controls, and also relative to episodic 
migraine sufferers on some HRQoL domains.   
iii Cluster headache  
The studies examining the impact of CH on HRQoL suggest that during active 
periods, CH patients have poorer HRQoL compared to the general population, with 
impairment being greater for patients with older age of onset of CH (161). This was 
most significant for the bodily pain, role physical, role emotional, general health, 
mental health, vitality and social functioning subscales of the SF-36 (4, 162). The 
higher pain score correlated with marked limitations in role and emotional functioning 
(4). Furthermore, CCH and active ECH patients were found to be more incapacitated 
compared to migraineurs (161), with significantly worse pain scores (3). Interestingly, 
ECH patients during a bout were found to have lower SF-36 scores compared to 
patients with previous myocardial infarction (4). 
Comparing the different forms of CH, there was no significant difference in 
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impairment and HRQoL between ECH patients during a bout and CCH patients (161, 
162). During the remission period of ECH patients, their HRQoL score tended to 
improve and became similar to headache-free groups (4). Conversely, Jurgens and 
colleagues found that disability remained high in ECH patients outside the bout, 
despite the absence of pain, which they speculate may have arisen due to the lack of a 
specified timeframe in the questionnaire used (The Henry Ford Disability Inventory) 
(161). Thus patients may have actually completed the questionnaire with their past 
bout in mind, rather than in their current headache-free condition. However, 13% of 
patients in another study also reported inhibition outside the cluster period, therefore 
raising the possibility that there is indeed a degree of impairment that extends beyond 
the cluster period, which could be attributed to unpredictability of the next bout, 
though further studies are required to confirm this (163).  
Evaluation of the functional impact of this disorder using the HIT-6 questionnaire 
showed that 74% were severely impacted, whilst another study using a semi structured 
telephone interview found that 78% of CH patients reported restrictions in daily living 
and 96% reported having to make some form of lifestyle change (163, 164). Social 
and leisure activities, family life and housework were disrupted, with a high 
dependence placed on family and friends. In terms of paid work, 82% reported 
reduced ability to work, 16% lost their job and 8% had to retire early due to their 
headaches. Moreover, up to a third found that the disorder limited their career (161, 
163). Taking into account this significant disability and the pain severity, it is 
therefore not surprising that agoraphobic and depressive symptoms, and suicidal 
tendencies are more prevalent in CCH (161, 164). 
The excruciating pain coupled with night-time attacks affecting sleep and the agitation 
and restlessness during attacks are all assumed to have a major impact on HRQoL in 
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CH. Patients have reported that the impairment of their CH continues even outside of 
the cluster bout, with considerable impact on social and family life, having to 
frequently miss social events and family gatherings (163). Surprisingly however, the 
effect of CH on HRQoL is less marked, either when compared to headache-free 
controls or migraineurs, though this should be treated with caution, as the sample sizes 
of these studies were small (4, 161). Moreover, the lack of a specific CH HRQoL 
measure that can truly capture the inherent disabling and debilitating nature of this 
disorder may also account for the results seen.    
iv Chronic daily headache  
Chronic daily headache (CDH) is not a specific headache entity but is a term often 
used to describe any headaches that occur on 15 or more days per month, for at least 
three months. The most common types of CDH are chronic migraine (CM) and 
chronic tension-type headache (CTTH) (7).  
The studies assessing HRQoL in CDH demonstrate that these patients have poorer 
HRQoL compared to the general population and patients suffering from severe 
episodic headache disorders (116-118, 146, 159, 165, 166). Mental health was 
markedly impaired, with reports of feeling irritated, fed up, frustrated and a tendency 
of giving up (166). Role physical, social functioning, role emotional, general health 
and vitality domains of the SF-36 in CM were significantly reduced compared to EM, 
with higher levels of depressive symptomatology exhibited (116). This impaired 
functioning correlates with the greater disability reported in CDH compared to their 
episodic counterpart, with reduced productivity at school and home (146, 159, 167). 
Headache frequency and comorbid depression has been found to have an independent 
and additive influence on HRQoL in CDH, with significantly reduced HRQoL in 
patients with CDH compared to those that suffer its episodic variant, suggesting that 
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chronicity of the headache may contribute greatly to HRQoL (117). To the best of my 
knowledge, HRQoL in hemicrania continua and new daily persistent headache has not 
been assessed.  
1.3.d Predictors of HRQoL in primary headache disorders 
Understanding the factors that influence HRQoL may enable us to manage and 
improve patients’ symptoms and subsequently their HRQoL. Headache characteristics 
such as pain intensity (130, 134-136, 168-171), duration (144, 172) and (171, 172) 
frequency (107, 110, 117, 134, 144, 167, 171, 173) were found to be significant 
predictors of HRQoL. Likewise, presence of migrainous symptoms, particularly 
nausea, were also found to be important predictors in HRQoL (130, 134, 143, 149, 
168), whereas combined photophobia and phonophobia are predictors of missed 
activity due to a headache (143). Greater headache-related disability was also a 
significant predictor of poor HRQoL, which was unsurprising as these concepts are 
inextricably linked (174). Comorbidity with other pain conditions negatively 
influences HRQoL (175, 176). Furthermore, the patients’ psychological response to 
the pain experience and their coping mechanism has a great influence on HRQoL, and 
potentially may have a role in headache progression (134, 144, 149). Psychiatric 
comorbidity is associated with poorer HRQoL, with comorbid depression shown to 
have an independent and additive influence on headache-related disability (117). In 
CH, impairment worsened with increasing clinical severity and refractoriness of the 
headaches (161). However, it is important to note that even though all these factors 
can affect HRQoL, there is a marked individual impact, thus each patient will respond 
uniquely to these predicted factors. 
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1.3.e HRQoL across headache diagnoses 
Primary headache disorders and their effect on one’s ability to function in school, 
work or daily life in general, imposes a burden not only on the sufferers’ themselves, 
but also on society, notably in terms of economic productivity and healthcare costs. 
Absenteeism and reduced work productivity, together with family and social restraints 
can lead to disruptions in occupational and personal domains, potentially creating a 
vicious cycle with worsening of headache, thus increasing its negative impact on 
HRQoL. Studies showed no significant differences in HRQoL between episodic 
migraine and TTH (119, 152, 155, 177), suggesting that the greater pain intensity of 
migraine is counterbalanced with the greater frequency of TTH (177). Although there 
is little variation in HRQoL between these headache groups, migraineurs report 
greater disability due to their headaches compared to TTH (106, 135, 171, 178-181) 
especially in work or school functioning (153). More missed days at school or work 
were reported by migraineurs, whereas reduced productivity at school or work were 
more prevalent amongst TTH patients (105, 167, 182, 183).  
Solomon and colleagues found that patients with CH had significantly worse pain 
scores with limited social functioning compared to the other groups, although physical 
functioning was preserved. On the other hand, migraineurs had the least pain with 
greatest impairment in role functioning. Meanwhile patients with CTTH had reduced 
mental health scores with a generalized impairment in functioning (3). Furthermore, 
although HRQoL is lower in patients with CH compared to healthy controls, in 
comparison to migraineurs, their HRQoL is lower in two domains only; patients with 
ECH have shown significantly lower bodily pain and social functioning relative to 
migraineurs (4). Nonetheless CCH patients and ECH patients in a bout were found to 
be more disabled and incapacitated than migraineurs (161). 
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Primary headache disorders, irrespective of diagnosis, significantly diminishes 
HRQoL. Different types of headache affect different HRQoL domains. However, once 
it becomes chronic, the overall HRQoL significantly reduces. Furthermore, there is an 
increased prevalence of psychological comorbidity in headache disorders, which 
needs to be recognized and managed accordingly. These symptoms are likely to arise 
as a result of the pain and functional impairment associated with the headaches and 
the unknown fear of the next attack. Psychiatric comorbidity is associated with poorer 
HRQoL, with comorbid depression shown to have an independent and additive 
influence on headache-related disability (117). Thus, proper headache management 
requires attention not only to the headache pain itself, but also any associated 
comorbidity.  
In terms of the instruments used, studies have show that there is moderate correlation 
(r > 0.4) between the generic and headache-specific HRQoL scales, indicating that 
there are measuring the same underlying construct i.e. HRQoL (184). The bodily pain 
and role physical domains of the SF-36 were most significantly affected in 
migraineurs, which correlated well with the impaired functioning seen, with more 
days of reduced productivity reported by these patients rather than days of actual 
missed activities (184). However, as previously mentioned, disease-specific HRQoL 
instruments have only been developed for migraine. CH has different headache 
characteristics compared to migraine and therefore specific instruments need to be 
developed to truly capture the impact of this disorder. In terms of number of studies 
done to date, there are only a handful of studies focusing on CH, which is considered 
to be one of the most painful conditions known to mankind, hence the need to explore 
this further.  
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1.4 Aim and objectives 
From the discussion above, it is clear that CH is an excruciatingly painful and highly 
disabling disorder that warrants effective patient management. However, due to 
limited understanding of the pathophysiology involved, treatment is still largely 
empirically based. Most of the treatment arsenals used have sparse evidence and often 
are based on open label studies and consensus agreement. Thus, an insight into the 
treatment effects of the GONB, which is a commonly used efficacious transitional 
treatment in CH, may improve our knowledge in this field. In addition, a study of 
saccadic reaction times, which have been successfully used to improve understanding 
of other neurological disorders like Parkinson’s and Huntington’s disease, may be 
valuable in explaining the functional processes underlying CH. Finally, much work 
has been focused on assessing the HRQoL in migraine, with little attention devoted to 
CH. A number of disease-specific HRQoL scales have already been developed for 
migraine, whereas none are currently available for CH. Hence, this thesis attempts to 
address these gaps in knowledge by adopting a multifaceted approach, with the aim 
that it will broaden our understanding of this painful disorder. 
1.4.a Aim 
• To improve understanding of underlying mechanisms in CH and its impact on 
HRQoL.  
1.4.b Objectives 
• To perform functional magnetic resonance imaging (fMRI) to map and 
identify treatment effects of a GONB, by assessing changes in rCBF that relate 
to brain responses prior to and following a GONB. The main hypothesis of the 
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study was that the GONB would induce changes in the brain, as measured by 
rCBF, with specific changes postulated within the hypothalamus. 
• To perform saccadometry to study saccadic reaction times, which may reveal 
meaningful insights into neural functioning in CH patients. 
• To develop and validate a HRQoL measure specific for CH, which can be used 
within the clinical setting and in clinical trials as an objective patient-reported 
outcome measure. 
• To assess the HRQoL of a large sample of CH sufferers, using a number of 
commonly used and validated HRQoL, disability and psychometric scales, 
specifically evaluating for differences between CH patients with episodic and 
chronic variants, with the hypothesis that patients with chronic CH will be 
more severely impacted by the disorder compared to their episodic 
counterparts.  
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Chapter 2  Functional neuroimaging study 
 
2.1 Introduction 
CH is an excruciatingly painful disorder, thus it is crucial that patients are well 
managed from the onset. As previously discussed in Chapter 1, currently there are 
both medical and surgical interventions available for these patients.  However, 
because of our limited understanding of the pathophysiological basis of the 
disorder, treatments are largely empirical based (2). Hence, although there are a 
number of treatments available, some patients can still be poorly managed and be 
difficult to treat.  
To recap from the previous chapter, the medical treatment available includes acute, 
preventive and transitional therapies, whereby the latter allows a short-term 
solution in controlling the CH attacks. This includes the use of a GONB, which has 
been shown to provide pain relief in CH (55, 56).  Several studies have 
demonstrated that this procedure is highly effective, rendering at least half of CH 
patients pain-free for up to four weeks. Furthermore, it has been shown to have a 
minimal side effect profile (53, 56, 62, 63, 65). These positive findings support the 
use of GONBs in clinical practice and thus it has been widely used as a standard 
form of treatment in patients with CH, as part of their headache management plan. 
However, the mechanism of action of this intervention is poorly understood. There 
have been speculations that its mode of action is centred at the level of the 
trigeminal nucleus caudalis, where the cervical and trigeminal systems converge, 
with the GONB reducing cervical afferent input to the nucleus and possibly 
interrupting the trigeminal autonomic reflex pathway (53, 56-58). 
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Due to this gap in knowledge, the effect of a GONB on brain function in CH 
patients was explored using a perfusion magnetic resonance imaging technique, 
specifically arterial spin labeling, with the aim of developing a better understanding 
of the mechanisms by which this transitional therapy exerts its therapeutic effect. In 
particular, the GONB was hypothesized to induce changes in brain function, as 
measured by changes in rCBF. Due to a priori knowledge of the possible pivotal 
role of the hypothalamus in CH pathophysiology, the changes in rCBF were thus 
hypothesized to specifically include this region. 
2.1.a  Perfusion magnetic resonance imaging  
Perfusion imaging is a functional neuroimaging modality that allows measurements 
of cerebral perfusion, which is the rate of change of blood flow per unit of cerebral 
tissue per unit of time (ml/100g/min). Although electrophysiological studies, such 
as microelectrode recordings, allows a direct measure of brain function, the 
invasive nature of the technique limits it use in human research. Other methods 
such as electroencephalography (EEG) and optical imaging techniques also have 
their limitations in terms of poor spatial resolution and risk of toxicity (185, 186). 
Hence, whilst functional neuroimaging provides an indirect measure of neural 
function, the close coupling between cerebral perfusion and metabolism, or neural 
activity, means that measurements of the former is a sensitive indicator of regional 
brain function (187) The fundamental basis for functional neuroimaging lies within 
the complex interaction between increased metabolic requirements during neuronal 
activity and the supply of this energy indirectly via the vascular system, in the form 
of oxygen and glucose, through an increased blood flow to the required site (186). 
A previous study combining intracortical measurements of brain activity and 
functional imaging in monkeys have provided evidence of the tight link between 
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this haemodynamic response and neural activity (185). Moreover, it has also 
demonstrated that the response may be related to the incoming neural input and 
intracortical processing, rather than its output or spiking activity, thus shedding 
light on the aspect of neuronal excitation that is being measured (185). 
Studies of brain function are invaluable in advancing our understanding of the 
human brain in healthy and diseased states. Several perfusion imaging techniques 
are available, with positron emission tomography (PET) scanning being one of the 
earliest available modality (187, 188). However, drawbacks of this technique 
include the need to use an exogenous radioactive tracer and exposure to ionising 
radiation, thus limiting its use in studies investigating treatment effects that require 
repeated assessments. Moreover, PET scanning is costly and suffers from relatively 
poor temporal resolution (188). 
An alternative perfusion imaging modality is functional magnetic resonance 
imaging (fMRI), which has gained popularity due to its lower cost, non-invasive 
nature, lack of exposure to ionising radiation and superior temporal and spatial 
resolution (189). Blood oxygen level dependent (BOLD) fMRI is the most 
commonly used technique, with haemoglobin being used as an endogenous tracer 
(190). This technique relies on changes in cerebral blood flow (CBF) and oxygen 
consumption as a marker of neuronal activity, with the functional contrast derived 
from changes in relative quantities of oxygenated and deoxygenated haemoglobin, 
which have different magnetic properties (190, 191). Despite its excellent 
sensitivity to functional stimulation, the BOLD signal is unstable over time and 
thus is best suited for measuring CBF changes over the course of several seconds 
only (188).  Moreover, it only provides a relative, rather than an absolute measure 
of CBF and lacks an absolute baseline measure, thus reducing the interpretability of 
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data across scanning sessions (188, 190-192). Hence, traditional ‘evoked-response’ 
BOLD fMRI has significant limitations for use in studies measuring treatment 
effects. An alternative approach is arterial spin labelling. 
2.1.b  Arterial spin labelling  
Arterial spin labelling (ASL) is an fMRI technique that allows a quantitative and 
reproducible measurement of regional cerebral blood flow (rCBF) throughout the 
brain and is ideal for investigating ongoing pain states (193-198). A recent test-
retest reliability study has shown that it has good potential for comparing within- 
and between-subject differences in ongoing pain (194). Arterial blood water is 
utilised as an endogenous tracer, which is magnetically labelled by application of 
radiofrequency pulses prior to the tissue of interest, as shown in Figure 2.1. This 
process, known as inversion, alters the magnetisation of the protons within arterial 
blood water, such that it differs from the static tissue magnetisation (187, 188). The 
inflowing labelled protons, which acts as a diffusible tracer, passes into the cerebral 
tissue and exchanges with the unlabelled protons in cerebral tissue water, thus 
changing the tissue magnetisation in that region, with change being proportional to 
cerebral perfusion (188, 199). An MRI image is then acquired, which is referred to 
as the tagged image. A control image of the region is subsequently acquired 
without labelling of arterial blood water, and a measure of rCBF in units of 
ml/g/min at each voxel obtained by pairwise subtraction of the control image from 
the tagged image (187). 
! 64!
Figure 2-1 Diagram of arterial spin labeling. Arterial blood water is magnetically 
labelled (white arrows) by applying radiofrequency pulses prior to the tissue of 
interest. These inverted spins acts as a diffusible tracer, which exchanges with the 
unlabelled protons in cerebral tissue water and changes tissue magnetisation in that 
region. An MRI image is acquired, referred to as the tagged or labelled image. A 
control image of the region is subsequently acquired without labelling of arterial blood 
water, and a measure of rCBF in units of ml/g/min at each voxel obtained by pairwise 





i Comparison of ASL to other perfusion imaging modalities 
Studies comparing rCBF measurements between ASL and 15O-PET within the 
same subjects, both at rest and with functional stimulation have shown excellent 
correlation between the two modalities (187, 188). Meanwhile in comparison to 
BOLD fMRI, ASL generally suffers from low signal-to-noise ratio (SNR) and thus 
is less sensitive (187, 188, 192). As a result, thicker image slices are often acquired 
and scanning performed in higher magnetic field strengths to improve sensitivity 
(188, 189). Additionally, due to the time delay (between 4 – 6 seconds) between 
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acquisition of the tagged and control images, ASL also suffers from lower temporal 
resolution (187, 188, 190). However, spatial resolution of ASL fMRI may be 
relatively superior to BOLD fMRI, owing to the rapid decay time of its tracer 
(arterial blood water), which is approximately 1 second, thus limiting its 
accumulation in venous structures. Consequently, there is better localisation of 
signal changes over activated cortex (188, 189). Moreover, since tagged and 
control images are usually acquired in an interleaved manner, motion artefacts and 
baseline drift are reduced in ASL, thus offering better temporal stability (188, 189). 
ii Methods for labelling  
Several methods are available for labelling of arterial blood water, which can be 
grouped into continuous ASL (CASL) and pulsed ASL (PASL) techniques. As the 
name suggests, in CASL, there is a continuous inversion of arterial blood water as 
it flows through a specified plane, commonly using flow driven adiabatic inversion, 
with a constant radiofrequency pulse (187). Meanwhile, in PASL, a volume of 
arterial blood water is inverted instantaneously proximal to the tissue of interest 
(187, 188). Even though there is a greater perfusion contrast and higher signal-to-
noise ratio (SNR) with CASL compared to PASL technique, technical restraints 
associated with application of a constant radiofrequency pulse is a limiting factor 
(188, 201). Furthermore, possible deposition of significant radiofrequency power to 
subjects from the use of a constant pulse can be limiting at high magnetic field 
strengths (188). Therefore, pseudocontinuous labelling paradigms have been 
developed for CASL to overcome these limitations, termed pulsed continuous 




2.2.a  Subjects 
Fifteen patients seen at the headache clinic at The National Hospital for Neurology 
and Neurosurgery, Queen Square, with a diagnosis of CH, according to the ICHD-
II diagnostic criteria, and were receiving their first GONB as part of their headache 
management plan were recruited in the study (7). Two patients failed to attend their 
follow up scan, and therefore their data were not included in the final analysis. 
Patients were instructed to abstain from alcohol for 24 hours and from caffeine-
containing products for 12 hours prior to each scanning session. In addition, they 
were asked to abstain from the use of tobacco- or nicotine-containing products for 
4 hours prior to admission until discharge for each session. Ethical approval for the 
study was obtained from the National Research Ethics Service London-Queen 
Square Research Ethics Committee (reference: 12/LO/0419). Written informed 
consent for study participation was obtained from all subjects prior to the study.  
2.2.b  Inclusion and exclusion criteria 
Subjects had to meet all of the following inclusion criteria to be eligible for 
enrollment into the study: 
• Male subjects diagnosed with CH in accordance with the ICHD-II 
diagnostic criteria. This study is limited to male participants only, as CH is 
more common in males than females (male to female ratio 2.5-7.2:1), and 
also to exclude any possible influence of the female hormone cycle on pain 
perception and response (1, 202). 
• Aged between 18 and 65 years inclusive. 
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• Receiving their first GONB as part of their headache management plan. 
• Body Mass Index (BMI) of approximately 18 to 30 kg/m2; and a total body 
weight 50-100 kg, due to the weight limit and restrictions of the scanner 
used. 
• Able to lie still within the environment of the MRI scanner for the required 
period to perform the study, with no contraindications to MRI scanning 
(e.g. metal, pacemaker, etc). 
• Should be on a stable dose of preventive medications for at least a month, if 
on preventives. 
• Has not used an abortive treatment within the last 12 hours prior to the 
study.  The use of oxygen as an abortive was permitted up to 1 hour prior to 
the scan.  
• No history of psychosis or psychological disease. 
• No evidence of a history or current use of drugs of abuse. 
• Does not consume more than six cups of caffeinated drinks per day. 
• No existing medical problems, for example, uncontrolled hypertension, 
renal failure, cancer, liver disease, severe spinal trauma, active thyroid 
disease, congestive heart failure, etc. 
! 68!
2.2.c  Psychometric measures 
A range of psychometric and pain disability measures were utilised, providing 
measures of personality, trait and state anxiety, depression, and coping strategies 
for pain. 
The McGill Pain Questionnaire (MPQ) provides quantitative information of a 
patient’s subjective pain experience that can then be treated statistically.  It gives a 
multidimensional reflection of how patients perceive their pain, allowing 
measurements of the sensory, affective and evaluative aspects of pain (203, 204). 
A number of different emotions are incorporated within the emotional aspect of 
pain.  However, they are primarily negative, with anxiety and depression being the 
most common.  It has been reported that up to 50% of patients with chronic pain 
suffer from depression, and within the primary care setting, almost one third of 
headache sufferers have symptoms of depression (205, 206). The Hospital Anxiety 
and Depression Scale (HADS) is an instrument that has been widely used in the 
clinical setting to screen for the separate symptoms of anxiety and depression.  It 
consists of a seven-item depression score alternating with seven items that assesses 
anxiety, and has been found to be comparable to other comprehensive measures of 
anxiety disorders and depression (207). 
Cognitive and behavioural responses to pain form important determinants of the 
pain experience, with higher catastrophising being associated with greater 
headache pain (208).  An assessment of coping strategies was conducted using the 
Cognitive Coping Strategies Inventory Revised scale (CCSI-R).  This consists of 
six subscales of items measuring different specific coping strategies and a seventh 
subscale to assess catastrophising (209). 
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The patients’ quality of life was assessed using the SF-36, which is a self-
administered, 36-item health-related questionnaire measuring functions in eight 
domains.  This includes physical functioning, physical role functioning, bodily 
pain, general health, vitality, social functioning, emotional role functioning and 
mental health (210).  
An assessment of the patients’ personality was made using the short form of the 
revised version of the Eysenck Personality Questionnaire (EPQ-R).  This is a 48-
item questionnaire that evaluates three dimensions of personality, namely 
extraversion-introversion, neuroticism-stability and psychoticism-socialisation 
(211).  This instrument has been widely used and is one of the best validated 
instruments in the personality literature (212). 
The emotional and functional impact of the patients’ headaches on daily living was 
assessed using the Henry Ford Disability Inventory (HDI). This is a 25-item 
questionnaire, which can be repeated periodically to give a measure of 
effectiveness of management strategy over time. 
The adverse impact of the patients’ headaches will be made using the six-item 
Headache Impact Test (HIT-6). This evaluates six aspects namely the adverse 
impact of their headaches on social, role and cognitive functioning, vitality, 
psychological distress as well as providing a measure of the severity of their pain 
(213). This tool was developed for use in both clinical research and practice, to 
allow monitoring of patients with headaches.  Patients attending the headache 
clinic at The National Hospital for Neurology and Neurosurgery are routinely 
required to fill this questionnaire during each clinical visit as part of their pain 
disability measure. 
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2.2.d  Study design 
The study was a prospective, open-label design, comprising of two scanning 
sessions, with each visit involving a stay of approximately two hours at the study 
site. The first session served as baseline scans; to map the cerebral representation 
of the interictal state of CH patients, whilst the second session were follow-up 
scans following response to the GONB. A comparison across these sessions should 
determine the effects of treatment on brain function of CH patients. The timeline 
for the scanning sessions is shown in Figure 2.2. 
The scanning sessions were performed at the Centre for Neuroimaging Sciences, 
Institute of Psychiatry, King’s College London. Patients’ pulse rate and blood 
pressure were recorded at each session. Prior to the start of each scanning session, 
all patients had to provide a urine sample to screen for any abnormalities on 
standard urinalysis test and for evidence of use of drugs of abuse, and also 




Figure 2-2 Timeline for scanning sessions 
fMRI = functional magnetic resonance imaging, GON = greater occipital nerve, 


















































i Scanning session 1 
Patients initially underwent a mock scanning session in a dummy scanner to allow 
them to become accustomed to the MRI environment, whilst also simultaneously 
being trained to operate the hand-held joystick, which was used during the 
scanning session to rate their pain and alertness level on a computerised VAS. A 
complete psychometric analysis was also performed and patients given a daily 
headache diary for them to record the frequency, duration and intensity of their 
headaches.  They were expected to continue recording their headaches until the day 
of their follow up scanning session. Patients then underwent a series of scans, 
including an initial localiser scan to register their head to the scanner, T2 structural 
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scans for image registration and four consecutive CASL scan examinations, with 
each CASL lasting approximately six minutes. 
ii Scanning session 2 
To allow for response to the GONB, this visit was scheduled at approximately 7-21 
days following the injection, although there was some flexibility according to 
treatment response.  The headache diary was collected from all patients during this 
visit, as well as pain and headache disability measures and anxiety/depression 
scores. During this session, patients again underwent a series of scans, including an 
initial localiser scan to register their head to the scanner, T2 structural scans and 
four consecutive CASL scan examinations.  
2.2.e  Image acquisition 
Qualified radiographers conducted all image acquisitions using a 3T General 
Electric Signa HDX whole-body MRI scanner, fitted with an 8 channel, receive-
only, phased-array head coil. Following an initial localizer scan to register patients’ 
head to the scanner, high-resolution T1- and T2-weighted images were acquired for 
image registration. Whole-brain resting perfusion measurements were made with a 
pulsed continuous arterial spin labelling (pCASL) sequence, which was labeled 
using a train of Hanning radiofrequency (RF) pulses of 500 µs duration, 1500 µs 
pulse gap and 1.5 seconds total labeling duration. Each imaging session did not 
exceed 60 minutes and patients were instructed to lie still with their eyes open. 
Quantification of whole brain resting state rCBF using CASL was repeated four 
times within a session for determination of the temporal, short-term variation of 
rCBF. Visual analogue scale estimates of perceived pain intensity and alertness 
were acquired using a computerized scale.  The VAS was controlled by the user 
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using a hand-held joystick to alter the position of a ‘needle’ on a screen in front of 
them.  The scale has a data range of 0-100, anchored at 0 (no pain/very sleepy) and 
100 (worst pain imaginable/wide awake). VAS responses of perceived pain 
preceded and followed each CASL acquisition.  
2.2.f  Data analysis 
 
i Clinical characteristic, headache diary and psychometric data analysis 
Clinical characteristics and headache diary data as well as scores from the 
psychometric and quality of life questionnaires were entered into and analyzed 
using SPSS version 21. Clinical characteristics, headache diary data and scores 
from the SF-36 Health Survey, CCSI-R, EPQ-R, MPQ, HIT-6, HDI and HAD 
scales were described using descriptive statistics. 
ii fMRI data analysis 
The sample size calculation for this study was powered on a recent neuroimaging 
research study using the third molar surgery model (195). All preprocessing and 
data analyses were conducted using perfusion analysis toolboxes available in FSL 
suite version 4.1.8 (FMRIB’s Software Library, http://www.fmrib.ox.ac.uk). Pre-
processing procedures were applied to the images acquired prior to any analysis to 
remove unwanted variability from the data, such as any artifacts or noise, to allow 
for motion correction, to correct for anatomical variations between patients and 
standardize the images to allow for between-subject comparisons, and in doing so, 
prepares the data for statistical analysis (186).  
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a Pre-processing of images 
The BET, FLIRT, FNIRT and SUSAN command tools were used to preprocess the 
images. The steps involved included skull stripping, registration, normalization and 
smoothing. 
Registration is the spatial alignment of two or more image volumes, and relies on 
an image similarity measure between pairs of voxels in the same position (186). 
This step is essential to ensure that each voxel represents the same region of the 
brain within patients, as any amount of movement within the scanner can 
potentially cause changes in voxel intensity, which can subsequently be 
misinterpreted as signal activations. Thus, rigid body transformation was used for 
correction of head movements within patients. This assumes that the size and shape 
of their heads remain constant, and that head movement can only occur either by 
translation or rotation (186). However, taking into account variations in brain sizes 
and shapes between patients, images have to be transformed into a standard 
reference space to allow for comparisons across patients. This is known as spatial 
normalization and consists of both linear and non-linear transformations. The 
Montreal Neurological Institute (MNI) brain was utilized as the standard brain 
template in this study. 
Prior to registration, the T2 structural scan was skull stripped to extract brain tissue 
from the acquired images and a mask created. The skull stripped T2 structural 
image was then normalized into standard MNI space. Each of the four CASL scans 
acquired per patient in each session were initially realigned to the first scan to 
correct for the small amounts of movement, and then coregistered to the skull 
stripped T2 structural image. Coregistration overcomes the low-resolution 
! 75!
limitations of functional images by allowing an overlap between the structural and 
functional data, so that any areas of activation can be correctly correlated to their 
anatomical position (186). A matrix was then created and the T2 skull stripped 
mask used to extract brain from the CASL scans and normalize them into standard 
MNI space. Finally, the images were spatially smoothed using the SUSAN 
command tool, which applies a non-linear filtering algorithm, averaging voxels to 
nearby voxels with similar intensity, to accommodate for structural variability 
across patients and to improve the normality and the SNR of data (186). 
b First level analysis 
In the first level analysis, the four CASL series for each patient in each session that 
have undergone preprocessing were merged to create a 4D image and a grey matter 
mask, derived from the probabilistic MNI grey matter template was applied. This 
removes white matter voxels from the image, and voxels with a greater than 20% 
likelihood of being grey matter were included in the mask. The merged four CASL 
series was then averaged using the FLAME (FMRIB’s Local Analysis of Mixed 
Effects) tool, and a mean image with its calculated variance was generated for the 
second level analysis.  
c Second level analysis 
Individual patient data from first level analyses provided inputs to second level 
analysis to allow comparisons across patients, in order to determine the treatment 
effects of the GONB in the brain by detecting changes in rCBF before and after 
treatment. A higher-level mixed effects general linear model (GLM) analysis was 
computed using the FLAME tool. The GLM, at each voxel in the image, models 
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the observed fMRI signal as the sum of the effects of a series of predictor variables 
plus residual random error, and can be expressed by the following equation: 
Y = β0 + β1X1 + β2X2 +…..+ βnXn + ε  
where Y = observed fMRI data (dependent variable) 
β0 = a constant, reflecting the baseline signal intensity 
β = variable weight (parameter estimate) 
X = predictor variable (independent variable) 
ε = residual error 
The GLM analysis used a paired t-test design at each voxel (univariate analysis), to 
determine if there is a significant relationship between the predictor variables 
(design matrix) and the observed fMRI signal (186). Patients and scanning sessions 
(pre-GONB and post-GONB) were defined as the predictor variables to assess 
changes in rCBF following the GONB. Global blood flow effects were accounted 
for by mean centering the global blood flow measurements across subjects, which 
was then added to the model as a covariate (predictor variable) to reduce the 
amount of error and thus increase the statistical power to detect changes in rCBF 
between pre- and post- GONBs (Figure 2.3). 
Since fMRI data contains thousands of voxels, multiple comparisons testing of 
each voxel is likely to yield a high number of false positive results. Thus to 
overcome this, multiple comparison correction measures must be applied. 
Bonferroni correction takes into account the number of independent statistical tests 
(voxels). Considering that nearby voxels are highly correlated and therefore are not 
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truly independent, the number of independent statistical tests will be overestimated 
and Bonferroni correction will be much too conservative. Alternatively, Gaussian 
random field theory provides a better estimate of independent tests based on the 
spatial resolution of the data (186). After appropriate statistical thresholding (Z > 
2.3 and cluster-corrected alpha < 0.05), resulting statistical parametric maps were 
generated and anatomical brain/brainstem atlases were used to identify the 
anatomical locations of the observed clusters (214, 215). Post-thresholding, the 
brain regions with voxels that have the highest Z-score (peak Z-scores) within the 
observed clusters were identified using mri3dX software (version 7.79). The 
anatomical locations of these clusters were identified using the Talairach Daemon 
software in mri3dX and Duvernoy’s brain and brainstem atlases (214, 215). 
d Region of interest analysis 
Based on previous neuroimaging findings of hypothalamic activation in CH 
patients, which is speculated to have a pivotal role in the pathophysiology of the 
disorder, a region of interest (ROI) was created for the hypothalamus using 
Duvernoy’s brain and brainstem atlases (214-216). The hypothalamus was 
hypothesized to show reductions in rCBF following a response to the GONB. 
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      Figure 2-3 Second level analysis design matrix. Matrix corresponds to the 
experimental design, with columns for each predictor variable. The column on the 
far left illustrates the two scanning session i.e. pre-GONB (top half of matrix) and 
post-GONB (bottom half of matrix), followed by one column each per patient, to 
assess changes in rCBF following the GONB. Demeaned global CBF was added to 




 Post GONB  
Subjects Demeaned 
 global CBF 
 
CBF = cerebral blood flow, GONB = greater occipital nerve block 
2.3 Results 
 
2.3.a  Subjects 
Following preprocessing, data from one patient had to be excluded due to presence of 
artifacts from head movement that could not be corrected for, thus only data from 12 
patients were included in the final analysis. Data from these patients are presented in 
Table 2.1. The patients had a mean age of 39.8 ± 9.8 years (range 29 – 64 years). 
Eight patients (66.7%) had ECH whilst four (33.3%) had the chronic variant. Nine 
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patients (75.0%) had strictly left-sided headaches, two (16.7%) had strictly right-sided 
headaches and one patient (8.3%) had unilateral side-variable headaches, with more 
frequent attacks on the left. Five patients had a complete response to the GONB and 
were rendered pain-free for at least a week; four had a partial response, with 
improvement in headache symptoms (either frequency, duration or intensity) by ≥ 
30%, whilst three patients had no benefit from the GONB. The mean number of days 
between the two scanning sessions was 13.8 days (range 6 – 25 days). 
 









1 39 L ECH 16 P 
2 29 L ECH 9 P 
3 37 R CCH 24 N 
4 46 L ECH 4 C 
5 34 R ECH 18 C 
6 50 L CCH 8 C 
7 64 L ECH 43 C 
8 35 L ECH 8 P 
9 32 L+R CCH 11 N 
10 34 L ECH 12 P 
11 34 L CCH 7 N 
12 43 L ECH 27 C 
Mean ± 
SD 
39.8 ± 9.8   15.6 ± 11.1  
CH = cluster headache, ECH = episodic cluster headache, CCH = chronic cluster 
headache, GONB = greater occipital nerve block, L = left, R = right, C = complete 
response, N = no response, P = partial response, SD = standard deviation 
 
2.3.b  Headache diary data 
The headache characteristics at baseline and following the GONB are shown in Table 
2.2 and illustrated as box plots in Figure 2.4. There were trends for improvement in 
headache frequency, duration and severity after the GONB, with reduction in median 
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frequency of headaches from 2.4 attacks per day to 0.5 attacks daily. Median duration 
of attacks were reduced from 49.2 minutes at baseline to nil after treatment, and 
median severity of CH attacks reduced from visual rating scale (VRS) 7.9 (denoting 
severe pain) at baseline to 1.0 (denoting mild pain) after the GONB. 
 
Table 2-2 Headache characteristics at baseline and following the GONB 
 
Headache characteristic Pre-GONB Post-GONB 
Frequency per day 
Mean ± SD 
 
3.0  ± 2.0 
 
1.2 ± 1.6 
95% confidence interval 1.5 – 4.5 0.1 – 2.3 
Median (range) 2.4 (1.2 – 7.7) 0.5 (0 – 4.5) 
Duration (minutes) 
Mean ± SD 
61.6 ± 45.5 27.3 ± 38.6 
95% confidence interval 22.0 – 88.1 -2.4 – 57.0 
Median (range) 49.2 (13.1 – 120) 0 (0 – 90) 
Severity (VRS) 
Mean ± SD 
7.6 ± 1.8 2.5 ± 3.1 
95% confidence interval 6.0 – 8.7 -0.2 – 4.5 
Median (range) 7.9 (4.7 – 10) 1.0 (0 – 8.5) 
GONB = greater occipital nerve block, VRS = visual rating scale, SD = standard 
deviation 
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Figure 2-4 Box plots illustrating the frequency, duration and severity of CH 
attacks before and after the GONB. Dark horizontal lines represent the median, 
with the box representing the upper and lower quartiles, the whiskers the minimum 
and maximum values, and outliers represented by dots.  




































































2.3.c  Psychometric and quality of life data 
The mean scores from the psychometric and quality of life measures used in this study 
are shown in Table 2.3. Patients had moderate scores on all the three subscales of the 
CCSI-R scale and the EPQ-R scale. Patients scored lowest for role physical, role 
emotional and bodily pain domains of the SF-36 Health Survey, reflecting the high 
degree of pain and functional impact associated with their headaches. This 
corresponds to the high disability scores on the HDI, mean ± SD (68.2 ± 25.6) and 
HIT-6 scales (63.8 ± 4.2), with a trend for improvement seen on the HDI scale 
following the GONB (49.5 ± 30.6) (Figure 2.5). In terms of patient-reported measures 
of anxiety and depression, which was measured by the HADS, patients had borderline 
symptoms (mean score ≥ 8) prior to the GONB, with a trend for improvement after 
treatment, as shown in Figure 2.6. 
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Table 2-3 Mean scores from the psychometric and quality of life measures 
 
Scale Mean score ± SD pre 
GONB 
Mean score ± SD post 
GONB 
CCSI_R   
Distraction 2.1 ± 0.6  
Catastrophising 2.8 ± 0.7  
Coping 2.8 ± 0.5  
EPQ-R   
Psychoticism 6.7 ± 2.9  
Neuroticism 12.2 ± 4.2  
Extraversion 10.6 ± 5.2  
Lie 12.0 ± 2.8  
SF-36 Health Survey   
Physical 
functioning 
78.8 ± 20.5  
Role physical 6.3 ± 11.3  
Bodily pain 22.4 ± 22.3  
General health 61.4 ± 22.2  
Vitality 36.3 ± 18.7  
Social functioning 41.7 ± 30.3  
Role emotional 36.1 ± 43.7  
Mental health 53.0 ± 25.7  
HDI total  68.2 ± 25.6 49.5 ± 30.6 
HIT-6 63.8 ± 4.2 61.2 ± 6.6 
MPQ total  21.5 ± 14.0 12.1 ± 11.5 
MPQ VAS  5.9 ± 3.9 2.9 ± 3.1 
HADS    
Anxiety 8.4 ± 5.4 7.9 ± 4.3 
Depression 8.7 ± 5.4 7.1 ± 4.3 
SD = standard deviation, GONB = greater occipital nerve block, CCSI-R = Cognitive 
Coping Strategy Inventory-Revised, EPQ-R = Eysenck Personality Questionnaire-
Revised, SF-36 = Short-Form-36, HADS = Hospital Anxiety and Depression Scale, 
HDI = Henry Ford Headache Disability Inventory, HIT-6 = Headache Impact Test, 
MPQ = McGill Pain Questionnaire, VAS = visual analogue scale 
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Figure 2-5 Box plot showing improvement in mean HDI total score following the 
GONB. Dark horizontal lines represent the median, with the box representing the 
upper and lower quartiles, the whiskers the minimum and maximum values. 



















Figure 2-6 Box plots showing anxiety and depression scores before and after the 
GONB. Dark horizontal lines represent the median, with the box representing the 
upper and lower quartiles, the whiskers the minimum and maximum values. 









































2.3.d  Neuroimaging data 
Global blood flow was measured and averaged across patients in each scanning 
session. A comparison of mean global blood flow before and after the GONB 
demonstrated that there were no significant differences between the scanning sessions; 
t(11) = -0.65, p = 0.53 (Figure 2.7). Therefore, since global CBF was not affected by 
treatment, it was justifiable to add it as a covariate in the design matrix.  
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Figure 2-7 Bar chart comparing mean global CBF before and after the GONB. 
Error bars represents standard deviation. CBF = cerebral blood flow, GONB = greater 





























There were two distinct clusters of brain region that showed significant increases in 
rCBF in CH patients prior to having their GONB, in particular, within the left basal 
ganglia and the brainstem bilaterally, as shown in Figure 2.8. The cluster 
encompassing the left basal ganglia extended from left orbitofrontal cortex anteriorly, 
including medial orbital gyrus, olfactory sulcus, cingulate gyrus, posterior orbital 
gyrus, extending superiorly to putamen, globus pallidus, circular insular sulcus, 
ventral pallidum, nucleus accumbens, anterior perforated substance, posterior 
hypothalamus (Figure 2.9), head of caudate nucleus and subcallosal cortex. The 
cluster was constrained by the lateral border of putamen, extending posteriorly 
towards long insular gyrus and bounded posteriorly by the posterior borders of 
putamen, globus pallidus and pallidum, extending ventrally to include left amygdala, 
hippocampus and parahippocampal gyrus. The peak Z-scores and MNI coordinates of 
these regions are shown in Table 2.4. 
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Figure 2-8 Nuclei within the basal ganglia showing increases in rCBF prior to a 
GONB. rCBF increases at baseline are indicated in yellow (cluster corrected, p < 
0.05), whilst masks of nuclei within the basal ganglia are illustrated in blue. 
rCBF = regional cerebral blood flow, GONB = greater occipital nerve block 
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Table 2-4 Regions showing increased regional cerebral blood flow during the 




Left%Putamen% 4.73 6125 316 8 4
Left%Globus%Pallidus%%%%%%%%%%%% 4.49 7508 312 10 32
Left%Caudate%%%%%%%%%%%%%%%%%%%%%%%%%%% 4.44 1794 312 10 0
Left%Pons%%%%%%%%%%%%%%%%%%%%%% 4.26 11983 32 312 322
Left%Ventral%Pallidum%%%%%%%%%%%%% 4.06 870 314 8 313
Left%Long%Insular%Gyrus%%%%%%%%%%%%%%%%%%%%%%%%%%%% 3.81 928 329 317 14
Left%Amygdala%%%%%%%%%%%%%%%%%%%%%%% 3.71 1244 325 10 314
Left%Inferior%Frontal%Gyrus%%%%%%%%%% 3.64 916 318 24 320
Left%Middle%Frontal%Gyrus%%%%%%%%%%%% 3.62 56 319 26 320
Left%Head%of%Caudate%Nucleus%%%%%%%%% 3.49 296 32 14 34
Right%Inferior%Colliculus%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 3.33 216 10 333 319
Left%Parahippocampal%Gyrus%%%%%%%%%%%%%% 3.26 297 330 38 314
Left%Thalamus%%%% 3.12 255 322 320 10
Left%Medial%Frontal%Gyrus%%%%%%% 3.10 86 312 24 320
Left%Rectal%Gyrus%%%%%%%%%%%%%%%%%%% 3.09 16 310 22 322
Left%Locus%Coeruleus%%%%%%%%%%%%%%%%%%%%%%%%% 3.09 108 39 333 328
Left%Superior%Temporal%Gyrus 3.02 32 335 326 6
Left%Transverse%Temporal%Gyrus%% 2.95 44 333 326 10
Red%Nucleus%(midline)%%%%%%%%%%%%%%%%%%%% 2.90 30 0 313 38
Left%Posterior%Hypothalamus 2.90 5 0 312 38
Left%Nucleus%Accumbens%%%%%%%%%%%%%%%%%%%%%%%%%%%% 2.77 24 4 6 32
Left%Orbital%Gyrus%%%%%%%%%%%%%%%%%%% 2.76 24 314 24 326
Left%Parahippocampal%Gyrus 2.65 2 321 10 321
Left%Cerebellar%Tonsil%%%% 2.58 1 311 333 345
Left%Subcallosal%Cortex%%%%%%%%%%%%%%% 2.52 64 2 18 4
Right%Cerebellar%Tonsil%%%% 2.30 4 12 334 345
MNI*Coordinates
Each location indicates voxel with highest Z-stat score within the cluster (p < 0.05) 
Coordinates presented are in MNI space. 
GONB = greater occipital nerve block, MNI = Montreal Neurological Institute
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Figure 2-9 Hypothalamic activation observed during the interictal state. Axial 
view showing significant increases in rCBF (cluster corrected, p < 0.05) within the left 
basal ganglia and the left posterior hypothalamus (hypothalamic mask illustrated in 
blue). 
rCBF = regional cerebral blood flow 
 
 
Within the brainstem, bilateral increases in rCBF were observed which extended 
superiorly from the red nucleus, including substantia nigra, crus cerebri, basilar pons, 
pontine nuclei, medial leminiscus, right inferior colliculus and locus coruleus, 
extending inferiorly to right superior cerebellar peduncle and right central tegmental 
tract, crossing the midline to include left middle cerebellar peduncle (Figure 2.10). 
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Figure 2-10 Cluster corrected statistic map showing significant increases in rCBF 
in the brainstem prior to the GONB. Bilateral increases in rCBF (shown in yellow) 
seen in red nucleus, substantia nigra and pons. 
GONB = greater occipital nerve block, rCBF = regional cerebral blood flow 
 
 
A narrow strip of cluster was also seen in the left ventral posterolateral thalamic nuclei 
that extended to the lateral borders of left lateral posterior thalamic nucleus and 
pulvinar nucleus prior to the GONB, as shown in Figure 2.11. 
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Figure 2-11 Significant rCBF increases in the left thalamus before the GONB  
(cluster corrected, p < 0.05) shown in yellow whilst mask of thalamus is illustrated in 
blue  




Meanwhile, following the GONB, there were several discrete clusters indicating 
significant increases in rCBF identified in left superior frontal gyrus and sulcus, left 
middle frontal gyrus, right superior temporal gyrus, bilaterally in middle and inferior 
temporal gyri, left superior parietal gyrus and bilaterally within the occipital cortex in 
inferior, fourth, middle and superior orbital gyri, including intraparietal and calcarine 
sulci, as shown in Figure 2.12. The peak Z-scores and MNI coordinates of these 
regions are shown in Table 2.5. 
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Figure 2-12 Lightbox view showing post-GONB increases in rCBF observed bilaterally in several brain cortices. Cluster corrected Z-
statistical maps (p < 0.05) showing significant increases in rCBF (shown in yellow) in frontal, temporal, parietal and occipital cortices after 
having the GONB  
GONB = greater occipital nerve block, rCBF = regional cerebral blood flow 
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Table 2-5 Regions showing increased regional cerebral blood flow during the 
interictal period following the GONB 
 
 
Each location indicates voxel with highest Z-stat score within the cluster (p < 0.05) 
Coordinates presented are in MNI space. 
GONB = greater occipital nerve block, MNI = Montreal Neurological Institute 
 
Based on our a priori hypothesis of reductions in rCBF in the hypothalamus following 
the GONB, we compared the mean rCBF in the left hypothalamus across patients 
between the two scanning sessions. This showed that there was a reduction in rCBF 
following the GONB, as shown in Figure 2.13, although this did not reach statistical 
significance; t(11) = 0.78, p = 0.45. 
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Figure 2-13 Difference in mean rCBF before and after the GONB in left 
hypothalamus. Error bars represents standard deviation. 


























Significant increases in rCBF were identified in several brain structures of CH patients 
prior to the GONB, which were subsequently reduced at the follow-up scanning 
session, following response to the GONB. Of particular interest was the increase in 
rCBF in the left posterior hypothalamus, which is a structure that has been implicated 
to have a pivotal role in CH pathophysiology, thus supporting the hypothesis made of 
change in rCBF in this region following treatment. Moreover, significant increases 
were also observed in the left orbitofrontal cortex, left basal ganglia, left amygdala, 
left hippocampus and parahippocampal gyrus, left lateral posterior thalamic and 
pulvinar nuclei and bilaterally in the brainstem. Similar findings have been reported in 
previous neuroimaging studies in CH patients, with activations reported in the 
orbitofrontal cortex, ipsilateral inferior/posterior hypothalamus, ipsilateral basal 
ganglia and ipsilateral/contralateral posterior thalamus, although in those studies, 
patients were scanned during spontaneous or triggered attacks (18, 19, 37). On the 
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other hand, patients in this study were scanned during the interictal state, thus it begs 
the question of whether these structures actually have an important role in the 
pathophysiology of CH. 
Neuroimaging studies in CH have led to advances in our understanding of the 
underlying mechanisms in this disorder, specifically the potential role of the 
hypothalamus as the central generator of CH (18, 19, 29, 37). A recent study has 
shown that hypothalamic activation persists even between attacks in CH patients 
following occipital nerve stimulation (ONS) (217). Our study supports this 
observation of activation of the posterior hypothalamus in CH patients during the 
interictal state. Interestingly, the significant increase in rCBF was only observed in the 
left posterior hypothalamus, possibly echoing the higher proportion of patients who 
had left sided attacks that were recruited in this study, thereby likely reflecting 
ipsilateral posterior hypothalamic activation. However, future work will need to be 
done to ascertain this finding, as will be discussed in Chapter 6. 
Magis and colleagues performed an 18FDG-PET (fluorodeoxyglucose-positron 
emission tomography) study in between attacks in CCH patients who underwent ONS 
and found significant hypermetabolism in ipsilateral hypothalamus, ipsilateral 
pulvinar and brainstem compared to healthy controls (217). The brainstem has 
previously been found to be consistently activated in migraine and was therefore 
suggested to have a crucial role in its pathophysiology (218, 219). However, 
brainstem activations have also been observed in CH and in hemicrania continua 
(HC), whose clinical phenotype overlaps with both migraine and the trigeminal 
autonomic cephalalgias (TAC) (44, 156, 217). The brainstem activations seen in 
previous CH studies included ipsilateral trigeminal root entry zone, the bilateral red 
nucleus and ventral pons, whereas in HC, activations were observed in ipsilateral 
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dorsal rostral pons, extending to the red nucleus and substantia nigra (44, 156). 
Additionally, there has been a single report of brainstem activation in spontaneous 
attacks of SUNCT (short-lasting unilateral neuralgiform headache attacks with 
conjunctival injection and tearing), which also belongs to the TACs (220). 
Taking into account the hypothesized involvement of the trigeminal-autonomic reflex 
in the pathophysiology of TACs, including CH, this brainstem activation has been 
postulated to represent the connection between the caudal part of the trigeminal 
nucleus and the hypothalamus, even though Morelli and colleagues speculated that 
given the role of these structures in motor function, it may equally be associated with 
a defence “fight-or-flight” mechanism, which is characteristic of CH (156, 220). 
Therefore, whilst the brainstem may have a role as the possible generator in migraine, 
it may reflect the functional connectivity between the spinal trigeminal nucleus and 
hypothalamus in CH and the TACs. Unfortunately, the trigeminal nucleus caudalis 
cannot be visualized in this study, as the imaging volume did not extend inferiorly to 
this portion of the hindbrain. 
The increase in rCBF in the basal ganglia is also of particular interest. The basal 
ganglia are composed of a number of subcortical nuclei including caudate nucleus and 
putamen (often collectively termed as striatum), globus pallidus and substantia nigra 
(221). The substantia nigra is the main source of dopamine in the brain, which is one 
of the principal neurotransmitters within the basal ganglia. The basal ganglia is now 
known to play a role in pain processing and in particular, is involved in the sensory-
discriminative, affective/emotional and cognitive dimensions of pain, as well as 
having a role in pain modulation and acting as a gating mechanism to regulate 
transmission of nociceptive information to higher centres (222). The basal ganglia is 
well connected to all cortical areas, including hippocampus, amygdala and thalamus 
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and receives nociceptive information from two major sources (221, 223). From the 
spinal cord and brainstem, the basal ganglia can receive afferent inputs via direct (e.g. 
spino-basal ganglia) or indirect (e.g. spino-thalamic-basal ganglia) pathways, whilst 
inputs from cortical and subcortical brain regions are transmitted via the basal ganglia-
thalamic-cortical loop (221). Cortical regions within this loop are known to have 
important roles in pain processing, including the anterior cingulate cortex, 
orbitofrontal cortex, dorsolateral prefrontal cortex, insula and hippocampal regions 
(221). 
Neuroimaging studies in migraine have recently suggested the possible involvement 
of the basal ganglia in the pathophysiology of the disorder. These studies have shown 
structural and functional brain changes in the basal ganglia associated with migraine 
(223-226). In particular, increases in rCBF in the basal ganglia have been reported in 
migraneurs during a spontaneous headache attack, with decreased grey matter density 
in the globus pallidus and putamen, which correlated with disease duration and attack 
frequency respectively (224, 226). Decreased volumes in the caudate and nucleus 
accumbens have also been reported in migraineurs compared to healthy controls, 
which was negatively correlated to disease duration (225). Furthermore, they found an 
interictal increase in resting state functional connectivity in migraineurs compared to 
healthy controls, with increased connectivity between the caudate and nucleus 
accumbens with several brain areas known to be involved in nociceptive and sensory 
processing, specifically putamen, parahippocampal gyrus, insula, amygdala, 
orbitofrontal cortex, and anterior and posterior cingulate cortices (225). Conversely, 
an increase in grey matter volume in the caudate nucleus has been observed in 
migraineurs with high attack frequency (8-14 headache days per month) compared to 
those with low attack frequency (1-2 headache days per month), with increased 
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functional connectivity between the basal ganglia (putamen and pallidum) and anterior 
insula, temporal lobe and hippocampus, and reduced connectivity between caudate 
and middle frontal cortex and pallidum (223). 
It is also noteworthy that dopaminergic involvements have also been reported from 
PET studies in chronic orofacial pain conditions, specifically burning mouth 
syndrome and atypical facial pain. In the former, decreased dopaminergic function in 
the putamen was observed, whereas in the latter, there was an increased availability of 
dopamine receptors in the putamen in patients compared to healthy controls (221). 
Therefore, taking these studies into account, it is likely that the recurring activations 
of ipsilateral basal ganglia seen in neuroimaging studies in CH may actually be 
suggestive of its important role or the role of the dopaminergic system in CH 
pathophysiology. 
Several lines of evidence support our hypothesis of an impaired dopaminergic system 
in CH. There have been reports of dopamine antagonists, such as Olanzapine, 
Clozapine and Chlorpromazine in the acute and preventative treatment of CH as well 
as recurrence of CH attacks with initiation of Pramipexole, a dopamine agonist (227-
230). Moreover, increased levels of platelet dopamine have been found in ECH 
patients, both during and outside of a bout (231). Furthermore, since dopamine exerts 
an inhibitory effect on prolactin release, blunted 24-hour prolactin production in CH 
patients during a bout and in remission, with reduced response to thyrotropin-releasing 
hormone, provides clues to the possible impairment within this system (232). A recent 
study found impaired increase in growth hormone levels following an apomorphine 
challenge in CH patients outside a bout, suggesting decreased sensitivity of 
dopaminergic neurons (233). 
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From a clinical point of view, dopamine is known to have a major role in regulation of 
physical movement, thus an imbalance may account for the restlessness and agitation 
that is usually associated with CH attacks, whereby patients often report inability to sit 
still. Moreover, the role of dopamine in addiction may somewhat explain the addictive 
personality traits that are seen in CH patients, whereby they have a tendency to 
consume high quantities of cigarettes and caffeine (234). Taken together, these 
findings suggest possible involvement of the dopaminergic system in CH.  
Thus, most of the areas found to show significant increases in rCBF in this study are 
also activated in other pain disorders, including migraine and TAC, and in ongoing 
clinical pain. Since pain is known to be a multidimensional experience, these 
structures may form a system or integrated network of brain regions that encodes 
nociceptive information of CH, in particular the sensory-discriminative, 
affective/emotional and cognitive dimensions of the pain experience. Contrary to 
other pain neuroimaging studies and previous studies on CH, no activations were 
observed in other regions such as anterior cingulate cortex, primary and secondary 
somatosensory cortices, prefrontal cortex or cerebellum, possibly because these 
regions are more involved in the processing of acute pain (195, 216). 
However, even though these structures are acknowledged to have roles in the 
processing of pain, they are also accepted to be multifunctional and known to be 
associated with attention, emotion/motivation-affect, decision-making, sensory 
perception, motor function and cognition in general (235-237). Thus, whilst it is not 
discounted that they may be involved in pain processing, their multifunctional roles 
challenges the belief that activity within this network is purely driven by pain and that 
the changes seen are exclusively related to or caused by it, but likely reflects a salient 
response (235-237). This serves to assist attentional systems, preparing the body to 
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respond to potentially threatening stimuli, and as such, forms an important attribute to 
the pain experience (235-237). In CH, increased rCBF within this functionally 
coupled network may suggest a state of heightened awareness in anticipation of the 
next imminent attack. 
It is now known that the brain is plastic in nature, with the ability to adapt both 
structurally and functionally to incoming stimuli (238-244). Such changes can be seen 
in chronic pain disorders whereby structural imaging studies, specifically VBM, have 
demonstrated changes in grey matter volume in distinct brain regions, namely the 
orbitofrontal cortex, insula, cingulate cortex and dorsal pons, suggesting a common 
basis (238). A recent VBM study in CH has reported similar grey matter changes in 
chronic sufferers, with both increased and decreased volumes observed in ECH 
patients in a bout, whilst those outside a bout had the least marked changes (245). 
Interestingly, there is a degree of overlap in the structural abnormalities from the 
VBM study with the changes seen in this study, thus supporting the concept of 
neuroplastic change in CH patients whereby repeated attacks can lead to a dynamic 
change even in the absence of pain. 
Meanwhile, the subsequent reductions in rCBF seen following the GONB may reflect 
a winding down of this system, as was observed in patients with paroxysmal 
hemicrania following indomethacin (246). Matharu and colleagues postulated that the 
central structures that are important in generating an attack are relatively activated 
during the interictal state but at subthreshold level for pain generation, with an attack 
being triggered once a threshold for pain is reached (246). The same mechanism is 
likely to exist in CH, with the GONB having a potent effect in deactivating this 
excitable system, possibly through neuroplastic changes. Indeed, neuroplasticity is 
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known to be a dynamic process and there have been reports of reversal of grey matter 
abnormalities following pain relief in several chronic pain disorders (241, 247). 
Furthermore, our psychometric results showed a trend for improvement of anxiety and 
depressive symptoms in our patient cohort. Thus, as it is clear that some of the 
structures, like the insula, amygdala and parahippocampal region, are involved in 
processing affect and emotions, the changes seen following treatment may partly be 
attributed to this finding. Hence, it may be important in future studies to compare the 
clinical, psychometric and neuroimaging endpoints together, possibly by performing a 
regression analysis to account for this factor.  
At present, any explanations for the increased rCBF observed in the frontal, temporal, 
parietal and occipital cortices following the GONB are highly speculative. The fairly 
large representation in the occipital cortex is surprising, particularly since the patients 
did not receive any visual stimuli during scanning and scans were performed in a dark 
room. Therefore, it is postulated that these activations may be associated with relief of 
pain following treatment. A previous fMRI study looking at neuronal specificity of 
acupuncture response showed several areas of activation, which included brain 
regions involved in pain processing, as well as parts of the occipital, temporal and 
parietal cortices, which they postulate may be associated with the functional 
organization of thalamo-cortical relays related to acupuncture-induced analgesia 
(248). Further work comparing responders and non-responders to the GONB will need 
to be undertaken to shed light on the interpretation of this finding. 
The main limitation of this neuroimaging study was the small sample size, which is 
considered borderline for detecting significance in fMRI studies. This is more so when 
one takes into account that three of the patients did not respond to the GONB. Hence, 
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the study was unable to make a comparison between responders and non-responders, 
which would have allowed us to make a better judgment of the effects this treatment 
has on brain function. Due to this small sample size and the large heterogeneity within 
the sample, the analysis of the psychometric data was largely underpowered, thus a 
descriptive statistical approach was undertaken to present the findings. Another 
limitation is the possible confounding order effect that due to methodological 
difficulties could not be controlled for. Due to the design of the study, whereby 
patients were scanned before and after they have had a GONB, it was not possible to 
randomize the order of the scans. However, considering the findings from this study, 
whereby the structures activated were those that are known to be involved in pain 
processing, it is unlikely that this was a significant confounding factor. Furthermore, 
to the best of my knowledge, there have been no previous reports of rCBF changes 
that were specific to and involved a considerable number of structures relating to pain 
processing. 
This study has identified several structures that show increases in rCBF during the 
interictal period in CH patients, with subsequent reductions following the GONB. 
This includes the posterior hypothalamus, which has been long been suspected to have 
a role in CH pathophysiology. However, of more interest are the changes seen in the 
basal ganglia and brainstem, which although have also been reported in previous 
studies, have often been overlooked as structures involved in the general processing of 
pain. Whilst the roles of these structures in the pathophysiology of CH remain 
unknown, the fact that they were activated in the headache-free state suggests that 
they may have pivotal roles in the underlying mechanisms of this highly disabling 
disorder. 
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Chapter 3  Saccadometry study 
 
3.1 Introduction 
The study of saccadic latency in a number of neurological disorders has 
demonstrated its potential of being used as a biomarker to aid in diagnosis and 
monitoring of disease progression and response to treatment. In Huntington’s 
disease for example, which is a neurodegenerative disorder, saccadometry has been 
shown to have good discriminative power, being able to distinguish 
presymptomatic and symptomatic patients from healthy controls (70). Moreover, 
with the use of more challenging saccadic tasks, presymptomatic patients can be 
differentiated from the symptomatic group, with the added possibility that it may 
also be able to predict the onset of symptoms in the former clinical group (71). 
Furthermore, saccadometry has been tested in patients with Parkinson’s disease 
who underwent subthalamic nuclei stimulation, and has been shown to be a useful 
tool in providing objective measures of treatment outcome (72). Similarly, it may 
provide a useful measure of cognitive fitness following anaesthesia (249). 
Within the headache field, saccadic latency studies have only been used to 
investigate migraine, with earlier studies failing to provide evidence for differences 
between migraine groups and between migraineurs and controls (79, 80). However, 
later studies demonstrated that there were significant differences in saccadic 
latency between migraineurs and controls (75, 78). In particular, migraineurs had 
longer latencies with high variability in their reaction time compared to controls, 
and more errors made looking in the wrong direction (78). On the other hand, 
another study using the same protocol as will be described for our study, found 
smaller variability in saccadic latency distributions between migraineurs and 
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controls, with significantly less early saccades generated by the former (75). These 
differences may be attributed to methodological differences between the two 
studies, specifically the different saccadic tasks employed. To the best of our 
knowledge, studies of saccadic reaction time in other headache disorders have not 
been evaluated. 
Owing to the success of saccadometry in the investigation of these various 
neurological disorders and the simplicity of both the task itself and the collection of 
large data sets, a study of saccadic reaction time in CH patients was performed, 
with the hope that it will improve our understanding of the underlying mechanisms 
of this disorder. Thus, the aim of this study was to investigate for possible 
differences in cross-sectional reaction time distributions of horizontal saccadic eye 




Forty-two patients who attended the headache clinic at The National Hospital for 
Neurology and Neurosurgery, London and satisfied the ICHD-II diagnostic criteria 
for CH were recruited into the study (7). Ethical approval for the study was 
obtained from the South East Research Ethics Committee. Informed consent was 
obtained from all patients prior to commencement of the study. Age- and sex-
matched controls were taken from a pre-existing database of a recent study using 
the same protocol. 
3.2.b Data acquisition 
Saccadic latency recordings were made using a miniaturised, head-mounted, non-
invasive, infrared reflection oculometer (12-bit resolution, sampling rate 1kHz, 
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low-pass filtered at 250 Hz, signal-to-nosie ratio 45 dB), as shown in Figure 3.1. 
Since the recording device is head-mounted, the target display moves with head 
movement and thus no head restraints were required. The oculometer has three 
low-power red lasers that projected high contrast 13 cd m-2 target dots onto a light-
coloured background, subtending 0.1°, in a horizontal line at ± 10° to the midline; 
to a first approximation these angles are independent of the distance between 
subject and background. The study was carried out in the clinical setting, with 
patients seated one metre from a blank, non-reflective wall, with minimal auditory 
or visual stimuli (in a non sound-proof room). Two sets of 100 saccadic horizontal 
eye movements were recorded for each patient. Each set of trial began with a self-
calibration process, with ten preliminary trials to either side, followed by the actual 
run. This consisted of presentation of a central target, onto which the patients 
fixated. After a random fore period of 1 - 2 seconds, this central target disappeared 
and jumped either to the left or right (chosen at random to avoid anticipation). The 
patients were instructed to track the moving target with a saccade. Depending on 
the patients’ response, the target remained for 200 milliseconds after the end of the 
resultant correct saccade, or in the case of an incorrect or absent response, for 1 
second, whichever was the shorter. Patients were instructed to track the movement 
of the target with their eyes as quickly as possible without compromising accuracy. 
Only one clinical visit was required for the study. 
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Above, clinical photographs of oculomotor in use. Below, schematic illustration of 
study task, showing (i) the central fixation target (red circle), which after a random 
foreperiod of 1–2 seconds, disappeared and jumped randomly to the left or right. 
Patients were required to track this target with a saccade (dashed ring indicates 
fixation on target. Adapted from Chandna and colleagues (75). 
.  
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3.2.c Inclusion and exclusion criteria 
• Male or female CH patients 
• Aged between 18 and 60 years in good general health apart from suffering 
from headaches. 
• Diagnosis of CH according to ICHD-II diagnostic criteria. 
• Must not have any other neurological disorder such as stroke, multiple 
sclerosis, epilepsy, psychiatric disorders, visual disorders or concussion within 
the past year. 
• Not on any CH prophylactic medication or antidepressants, currently or in the 
last month. 
• No headache during testing. 
3.2.d Data Analysis 
The recorded saccadic latency measurements were downloaded from the oculometer 
to a PC using LatencyMeter, a program that automatically triages data by eliminating 
trials with aberrant profiles due to blinks, head movements, inattention etc. Following 
this preprocessing step by LatencyMeter, it was then exported to SPIC (Saccadic 
Programming and Instrumentation Computer), the latency analysis software.  
Saccadic latency varies between trials randomly, but produces a skewed distribution 
when plotted as a histogram.  However, the reciprocal of latency usually follows a 
normal distribution, whose best-fit values of mean µ and standard deviation σ can be 
estimated within SPIC by minimisation of the Kolmogorov-Smirnov statistic. Some 
patients also show a small subset of early saccades of unexpectedly short latency, 
which can be described by its standard deviation, σE.   
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Thus, the entire distribution for each patient can be completely described by just 3 
parameters - µ, σ and σE.  Each parameter can then be compared between the CH 
population and the control population using parametric and non-parametric tests 




There were 35 males and 7 females in the CH patient group, with a mean age of 41.7 
± 11.5 years. The mean duration since onset of CH was 13.7 years (range 3 – 42 
years). Meanwhile, the control group consisted of 20 males and 7 females, with mean 
age of 44.0 ± 14.5 years. There were no significant differences in age (two-sample t-
test, p = 0.498) and gender (p = 0.351) between the CH patients and control groups.  
3.3.b Recinormality of reaction time distributions 
Using the SPIC software, Kolmogorov-Smirnov one-sample test demonstrated that the 
reaction time distributions of the CH patient group and control group did not differ 
significantly from a recinormal distribution (p > 0.05), thus supporting the LATER 
model and the use of the three parameters (µ, σ and σE) to describe the reaction time 
distributions. An example of a reciprobit plot from a CH patient is shown in Figure 
3.2.
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Figure 3-2 A reciprobit plot showing the recinormal distribution of saccadic 





















3.3.c Reaction time distributions between left and right saccades 
The Shapiro-Wilk test was performed to assess normality of the reaction time 
distributions, which revealed that µ followed a normal distribution, whilst σ and σE 
departed significantly from normality. Therefore, a two-sample t-test was performed 
to compare differences in mean between saccades made to the right direction and 
those made to the left. This showed that there were no significant differences in mean 
saccadic latency with respect to the direction of the saccade. Meanwhile, Mann-
Whitney U test was performed to compare for differences in σ and σE between the two 
groups, which also showed no significant differences, as shown in Table 3.1. Thus, the 
averages of saccades made in both directions were used for analysis. 
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Right saccade Left saccade p – value1 
Mean saccadic 
latency, µ 




1.34 ± 0.08 1.32 ± 0.09 0.569 
Standard deviation 
of early saccadic 
latency, σE 
0.32 ± 0.16 0.32 ± 0.16 1.003 
SE = standard error 
1Based on two-sample t-test and Independent Samples Mann-Whitney U test 
3.3.d Reaction time distributions between CH groups 
Within the CH patient group, there were 17 patients who had the episodic variant, 
whilst 25 patients had CCH. Normality testing using the Shapiro-Wilk test revealed 
that all the three distribution parameters departed significantly from normality. 
Therefore, a Mann-Whitney U test was performed to compare the parameters between 
the two groups. There were no significant differences in any of the parameters of the 
reaction time distributions, as shown in Table 3.2. Thus, all CH patients were 
considered as a single group. 
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ECH CCH p – value1 
Mean saccadic 
latency, µ 




1.38 ± 0.14 1.40 ± 0.11 0.960 
Standard deviation 
of early saccadic 
latency, σE 
0.56 ± 0.31 0.16 ± 0.16 0.157 
SE = standard error, ECH = episodic cluster headache, CCH = chronic cluster 
headache 
1Based on Independent Samples Mann-Whitney U test 
3.3.e Reaction time distributions between male and female patients 
There were 35 males and seven females in the CH group. Normality testing using the 
Shapiro-Wilk test showed that µ followed a normal distribution, whereas σ and σE 
departed significantly from normality. Therefore, two-sample t-test and Mann-
Whitney U tests were performed to compare the parameters between the two groups 
respectively. There were no significant differences in any of the parameters of the 
reaction time distributions, as shown in Table 3.3, though due to the small sample size 
within the groups, this should be treated with caution. 
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Males Females p – value1 
Mean saccadic 
latency, µ 




1.39 ± 0.10 1.40 ± 0.23 0.974 
Standard deviation 
of early saccadic 
latency, σE 
0.27 ± 0.15 0.60 ± 0.60 0.592 
SE = standard error, CH = cluster headache 
1Based on two-sample t-test and Independent Samples Mann-Whitney U test 
3.3.f Reaction time distribution between CH patients and controls 
The Shapiro-Wilk test for normality showed that µ conformed to a normal 
distribution, thus the two-sample t-test was used to compare for differences between 
the CH patient and control groups. On the other hand, both σ and σE deviated from 
normality, thus the Mann-Whitney U test was performed to compare differences in 











CH patients Controls p – value1 
Mean of saccadic 
latency, µ 




1.39 ± 0.09 1.07 ± 0.07 0.005 
Standard deviation 
of early saccadic 
latency, σE 
0.34 ± 0.16 2.74 ± 0.53 <0.001 
SE = standard error, CH = cluster headache 
1Based on two-sample t-test and Independent Samples Mann-Whitney U test 
 
There were significant differences in all three parameters between the CH patient 
group and the control group, as shown in Figure 3.3. For µ, CH patients had a 
significantly longer mean saccadic latency (5.56 ± 0.13) compared to controls (5.02 ± 
0.18). Similarly, CH patients have a significantly higher σ (1.39 ± 0.09) compared to 
controls (1.07 ± 0.07). 
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Figure 3-3 A 3D scatter plot showing saccadic reaction time distributions of 
cluster headache patients and controls 
CH = cluster headache, µ = mean of saccadic latency, σ = standard deviation of 




Meanwhile, only four CH patients exhibited an early saccade compared to 15 controls, 
which was considered to be statistically significant (Fisher’s exact test for early 
saccades, p < 0.001). When considering only those individuals that exhibited an early 
saccade (4 CH patients, 15 controls), the Shapiro-Wilk test for normality revealed that 
their σE distributions was normally distributed. A two-sample t-test showed that there 
was a significant difference in the σE distribution (p = 0.026), with controls having a 
significantly higher σE (4.76 ± 0.32) compared to CH patients (3.38 ± 0.46). 
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3.3.g Log likelihood ratios for sensitivity and specificity 
A binomial logistic regression analysis was performed to calculate log likelihood 
ratios (LLR) to predict the probability that an arbitrary saccadic reaction time 
distribution could be correctly or falsely attributed to the CH population. The formula 
generated was  
LLR = a µ + b σ + c σE + d, 
where a = 1.42 
 b = 2.69 
 c = -1.36 
 d = -8.74 
From the above equation, σ proves to have the greatest weight, with µ and σE having 
nearly similar contributions to the LLR. A sensitivity/specificity plot (Figure 3.4) 
gives a visual representation of the good discriminative power of using saccadometry 
in CH, with optimum criterion LLR value of 0.9 yielding the best sensitivity and 
specificity values (81% true positives). 
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Figure 3-4 Sensitivity/specificity plot showing percentage probability of being 
correctly diagnosed as having CH using saccadometry. Percentage probability of 
being correctly diagnosed as having CH (y-axis) is plotted against the criterion LLR. 




To the best of my knowledge, this is the first study to examine saccadic reaction time 
in CH patients. Significant differences were found between the CH patient population 
and control group in their reaction time distributions. In particular, CH patients had a 
significantly longer mean saccadic latency with greater variability in reaction time 
compared to controls. Furthermore, a smaller proportion of CH patients exhibited an 
early saccade, with a reduction in the variability of reaction time of these early 
saccades, compared to controls.  
Saccadic eye movement is controlled by a number of brain regions, which includes the 
superior colliculus (SC) that lies on the superior aspect of the brainstem, the basal 
ganglia (BG) and cerebral cortices (occipital, parietal and frontal) (250, 251). Visual 
input from the retina is conveyed to the SC, which triggers the oculomotor nuclei to 
initiate movement. However, the decision-making processes of the cerebral cortices 
and basal ganglia holds up this saccadic eye movement by exerting descending 
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inhibitory inputs to the SC, with movement being initiated only once a decision about 
“where to look” has been made. Thus, the SC constitutes the ‘‘final common 
pathway’’ for saccadic generation (250).  
This finding of an increase in the mean saccadic latencies in CH patients suggests that 
saccadic information is processed at a slower rate in this population. A delay in the 
decision-making process can occur within any of the neural pathways involved in 
saccadic generation. However, the reduced proportion of early saccades in CH 
patients suggests the presence of a tight inhibitory control over the SC, with few 
spontaneous saccades managing to escape this control. Since the inhibitory input to 
SC stems mainly from the BG, it is therefore highly likely that this subcortical region 
is contributing to the impairment in saccadic reaction time distributions in this 
population. This correlates with the findings from the fMRI study (Chapter 2) that 
shows significant increases in rCBF in the BG during the interictal period, thus further 
supporting a possible role for this brain region to be involved in the pathophysiology 
of CH.  
With regards to the increased variability in the reaction time distributions, there is 
neurophysiological evidence that links activity within locus coeruleus, which is a 
brainstem nucleus, to changes in σ (252). A previous study using the same protocol in 
a group of migraineurs found no differences in mean saccadic latency compared to 
controls, although there was reduced variability in saccadic latency distributions, with 
significantly less early saccades generated by the former (75). Since locus coeruleus is 
the principal site for noradrenaline synthesis in the brain, the authors hypothesized 
that this may reflect a functional deficit in the noradrenergic systems of migraineurs 
that influences reaction time (75). In the fMRI study discussed in chapter 2, 
significant increases in rCBF were also observed within the pons in CH patients, 
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encompassing locus coeruleus, thus possibly explaining the increased variability 
found in this study. Indeed, Andrea and colleagues postulated that CH may be due to a 
dysfunction of the noradrenergic system and reported efficacy of Clonidine, an alpha-
2-adrenergic presynaptic agonist as a preventative treatment, even though a follow up 
study failed to confirm this finding (253, 254). A similar drug, Tizanidine has also 
been reported to have good efficacy in CH albeit that this was in an open-label study 
(255). There have also been reports of reduced levels of platelet adrenaline and 
noradrenaline in CH patients during remission, during the interictal period in a cluster 
bout and during an acute attack compared to controls (256). Hence, whilst there may 
be a functional deficit in the noradrenergic system in migraine, there may be 
impairment involving both the noradrenergic and dopaminergic systems in CH. 
Studies in other disorders affecting the BG, such as Parkinson’s disease and 
Huntington’s disease have also shown similar changes in saccadic latencies, with 
increases in mean and/or variability (70, 71, 73, 257). The authors have suggested that 
the high variability in saccadic latency distribution in PD reflects heterogeneity of the 
disorder, suggesting that the extent of underlying pathology may affect different 
elements that controls saccadic eye movement, which influences the degree of 
variability seen (73). Likewise, the degree of impairment or neurotransmitter 
imbalance within the noradrenergic and dopaminergic systems in CH patients may 
also partly explain the high variability in saccadic latency distribution seen. 
Apart from characterising the neurological function in CH patients, the findings from 
this study also demonstrate that saccadometry has the potential to be used as a 
diagnostic tool. The sensitivity and specificity analysis performed suggested that 81% 
of individuals could be correctly assigned a diagnosis of CH by saccadometry alone. 
However, it should be borne in mind that the clinical features of CH are relatively 
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stereotyped and thus the key to diagnosing them is a detailed and systematic patient 
history. Thus, whilst the use of saccadometry as a tool in conjunction with a detailed 
history may help with diagnosis, particularly of complex or atypical cases of CH, its 
use in isolation as a diagnostic tool is limited at this stage. 
Similar to the neuroimaging study, the small number of patients in this study may be a 
limiting factor. However, this issue is partly overcome by the large number of 
saccadic trials performed per patient (200 each), thus allowing generation of a large 
dataset. Furthermore, the study sample was very heterogeneous, although comparison 
of saccadic distributions between ECH and CCH failed to show any significant 
differences. The male to female ratio of the sample was also disproportionate owing to 
the disorder having a predilection for males, although it has been reported that there 
are no known significant differences in saccades across gender (78). As reaction time 
can be influenced by external stimuli, the experimental conditions were ensured to be 
conducive to and consistent across patients, thus minimizing any possible 
confounding effects. 
In conclusion, saccadometry is a non-invasive, quantitative discriminatory measure 
that is simple to perform (both for clinician and patient) and has proven to be a 
sensitive indicator of underlying neural impairments in CH patients. This study has 
found significant differences in the main distributions of saccadic latencies of CH 
patients, with reduction in early saccade generation. These abnormalities in saccadic 
reaction time distributions suggest neural impairment possibly involving both the 
noradrenergic and dopaminergic systems. However, any conclusions or functional 
interpretations regarding the structures or neural mechanisms that may explain the 
changes seen in saccadic reaction time distributions in this study must necessarily be 
very speculative at this stage. 
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Chapter 4  Development and validation of a CH specific 
quality of life scale 
 
4.1 Introduction 
In CH, assessment of HRQoL is currently limited to use of generic scales, such as the 
SF-36 (3, 4, 162, 258). Although generic instruments have the advantage of allowing 
comparisons with other medical conditions and healthy controls, they may not 
necessarily capture the specific burden of a headache disorder. Thus attempts have 
been made at adopting the migraine-specific HRQoL instruments for use in CH 
patients, since they share the same dominant symptom (headache). Ertsey and 
colleagues used the MSQ version 2.1 to assess HRQoL in ECH patients during and 
after their cluster bout (4). They found that, as expected, there was a highly significant 
difference in HRQoL between CH patients and controls; however, surprisingly, the 
difference between CH patients and migraineurs was not significant. Therefore, this 
raises the question of the sensitivity of using migraine-specific HRQoL scales in CH, 
particularly in light of the differences between the two disorders in terms of pain 
intensity and frequency (4). For this reason, the aim of this study was to develop and 
validate a new CH-specific HRQoL tool, which may better reflect the true nature of 
the impact of this highly disabling disorder on patients’ daily life, as existing generic 
and migraine-specific HRQoL measures have failed to show specificity and sensitivity 
in capturing and highlighting the burden in this patient group (4, 162). 
4.2 Methods 
Ethical approval for this study was obtained from The North West London Research 
Ethics Committee. Informed written consent was obtained from all participants prior 
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to enrolment in the study. Data was collated in an electronic database and all statistical 
analyses were performed using SPSS software version 18. The steps employed in the 
development and validation of the scale have been described by Guyatt and colleagues 
and have been used in the development of other disease-specific HRQoL measures 
(90, 259, 260) A three-step approach was utilised; first item generation, second item 
reduction and scale development, and finally scale validation and reliability testing. 
4.2.a  Item generation 
A comprehensive review of the literature was conducted and existing headache-
specific HRQoL scales were studied to generate an overview of the areas of life 
impacted by CH. This was followed by an in-depth semi-structured interview of 24 
CH patients (M:F 2.6:1, mean age 46.3 years), diagnosed according to the diagnostic 
criteria of the International Classification of Headache Disorders (ICHD-II), who 
attended the headache clinic at The National Hospital for Neurology and 
Neurosurgery, London (7). The areas covered during the interview included pain 
characteristics, aspects of the patient’s life that were affected by their headaches, their 
support system; both practical and emotional, and their outlook on life. These 
processes allowed generation of a preliminary questionnaire, which was then 
discussed with a panel of experts with an interest in headache. Any ambiguous or 
similar items were eliminated or grouped together, before a final set of items were 
agreed upon. A 54-item questionnaire was subsequently drafted, each with a range of 
five possible answers on a Likert scale: never, occasionally, sometimes, often and 
always, addressing areas of life impacted by CH within the past month. A visual 
analogue scale was added to the end of the questionnaire to rate overall satisfaction 
with life (0= extremely dissatisfied, 100= extremely satisfied). Subsequently, a pilot 
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study was conducted with 24 patients with CH to assess the face validity and clarity, 
and the questionnaire was then adjusted accordingly and reduced to 47-items.  
4.2.b  Item reduction and scale development 
There were two sources of CH patients for this study: (i) Patients with a diagnosis of 
CH attending the headache clinic at The National Hospital for Neurology and 
Neurosurgery, London and (ii) an invitation letter to participate in the survey was 
posted out to CH patients via OUCH UK (The Organisation for the Understanding of 
Cluster Headache, United Kingdom). Those who responded to the invitation letter 
were contacted via telephone and had their headaches phenotyped. A booklet of 
questionnaires, which included the 47-item CH-QoL questionnaire was then given or 
posted out to all participants who satisfied the ICHD-II diagnostic criteria for CH 
(n=521). Details on demographics, headache history and characteristics were collected 
from the questionnaires. A number of other frequently utilised and previously 
validated generic or disease specific HRQoL instruments were also included in the 
booklet to allow assessment of convergent validity of this new scale, including the SF-
36 Health Survey Questionnaire (SF-36), the EQ-5D Questionnaire and the Migraine-
Specific Quality of Life Questionnaire Version 2.1 (MSQ v2.1), the Migraine 
Disability Assessment Test (MIDAS) and the Headache Impact Test (HIT-6). 
Standard procedures for item reduction were employed. The first step in item 
reduction involved removing items based on their inter-item correlations. This is 
common practice in scale development and is done to retain items with the best inter-
item correlations, thus allows shortening of the instrument, whilst simultaneously 
improving homogeneity and reliability estimates (261-263). Items that showed low 
inter-item correlations (r < 0.1) were excluded as this demonstrated that they were 
poorly correlated with the underlying scale, thus were less likely to be measuring the 
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same construct as the rest of the scale. On the other hand, any items that showed high 
inter-item correlations (r > 0.7) were examined for content similarity. The least 
clinically sensible item was excluded, as theoretically, items that correlated too highly 
with each other implies that they are measuring the same underlying dimension (261, 
264).  
Next, an exploratory factor analysis was performed to determine the underlying key 
domains of the 47-item questionnaire. Since there was reason to believe that these 
domains would correlate with each other, oblique rotation was employed for the 
analysis. An eigenvalue cut off point >1 was used to extract underlying factors, and 
any items that loaded highly (above 0.4) on a factor was considered relevant. 
4.2.c  Scale validation and reliability testing  
Convergent and divergent validity were assessed by measuring the Pearson’s 
correlation of the underlying subscales of the CH-specific HRQoL questionnaire with 
the subscales of SF-36 and MSQ v2.1. Meanwhile, Spearman’s correlation test was 
employed to assess validity of the questionnaire and the EQ-5D, due to the ordinal 
nature of the latter. Convergent and divergent validity are components of construct 
validity; providing a measure of the ability of the questionnaire to examine its 
intended constructs i.e. HRQoL in CH patients. Hence, convergent validity was 
assumed if there was a high correlation between subscales measuring the same 
construct, whilst divergent validity was assumed when there was low correlations on 
unrelated subscales.  
Known-group validity was examined by assessing how the mean scores of the scale 
and its subscales were related to the various categories of MIDAS and HIT-6, by 
using one way ANOVA test followed by post hoc analysis with the total and subscale 
scores as dependent factors. This form of validation illustrates the ability of the 
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questionnaire to discriminate across groups. The MIDAS assesses disability in three 
domains, namely paid work or school, household and family, social or leisure 
activities. Headache sufferers are then categorized into four groups, depending on the 
frequency of disability in these domains due to their headaches; little or no disability, 
mild disability, moderate disability and severe disability. Similarly, the HIT-6 
categorizes headache sufferers into four groups depending on the impact of their 
headache on the same domains, namely little or no impact, some impact, substantial 
impact and severe impact. 
The internal consistency is a measure of reliability; specifically how well items in the 
questionnaire that are supposed to measure the same construct are in yielding 
consistent results. This was assessed by the Cronbach’s coefficient alpha (α), with 
high values suggesting measurement of a single construct (103). Reliability can also 
be assessed by the item-test correlation of a subscale, which measures how well items 
within that subscale are in measuring its intended construct. The recommended criteria 
for good internal consistency is α > 0.70 (265), whilst for item-test correlations values 
should be greater than 0.40 (266). 
A same copy of the 47-item questionnaire was sent out to 75 randomly selected 
respondents two weeks after they first completed the questionnaire, to allow 
assessment of the test-retest reliability of the new scale, using two-way mixed, single 
measure intra class correlation coefficients (ICC 3,1). Two weeks was chosen as the 
follow-up period, as it was assumed that this would be long enough a lapse to avoid 




4.3.a  Subjects 
A total of 406 completed questionnaires were received, giving a response rate of 
77.9%. From this total, 148 patients (36.5%) were recruited from the headache clinic 
and 258 patients (63.5%) were recruited through the patient organisation. About fifty-
nine percent of the responders (239 patients) had ECH and 41.1% (167 patients) had 
CCH. The mean age of the study sample was 52.4 years (range 20.5 - 84.4). There 
were 68.2% males and 31.8% females, with a mean age of onset of CH of 33.0 years 
(range 8 - 69).  
4.3.b  Item reduction and generation of subscales 
Eight items had low inter-item correlations of < 0.10, and were subsequently removed 
from the scale (Table 4.1). 
 
Table 4-1 Items with low inter-item correlations 
 
• Generally enjoyed the things that you do? 
• Had to give up something that you enjoyed like alcohol or smoking? 
• Felt happy or satisfied with your personal life? 
• Had to be alone during a cluster headache episode? 
• Been restless, could not sit still, paced up and down? 
• Felt less sensitive to (or more tolerant of) pain? 
• Felt stronger as a person as a result of coping with cluster headache? 
• Contributed to household duties e.g. housework, cooking, etc? 
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Meanwhile, two pairs of items had correlations above 0.70; one pair was asking about 
work, whilst another was looking at prognosis. The items “felt unable to complete 
duties at work” and “felt that you were losing control over your health and over your 
own life” were retained as they were felt to be more clinically sensible. 
The exploratory factor analysis produced five factors, consisting of 37 items, which 
explained 59.18% of the variance. One factor with an eigenvalue of 1.13 (explaining 
3.05% of the variance) was removed as it only had one item (avoided potential 
headache triggers e.g. alcohol, bright lights, perfume, noise) loading onto it and 
therefore was considered insufficient to produce a meaningful subscale (267). The 
remaining factors and items were then examined to determine if there was any scope 
for further reduction of the number of items to produce a more meaningful and user-
friendly scale. Eight items were omitted as they failed to gain significant loading (> 
0.40) on any of the factors created (Table 4.2).  
 
Table 4-2 Items removed due to poor factor loading 
 
• Felt negative or pessimistic about the future? 
• Had to rely on family and close friends for help? 
• Experienced a general lack of motivation to do things? 
• Felt that you were losing control over your health and over your own life? 
• Felt depressed, sad or tearful? 
• Felt frightened or worried about getting a headache in public? 
• Felt less interested in sexual relations? 
• Felt frustrated? 
 
This resulted in a 28-item questionnaire CH-specific HRQoL scale (CHQ), which 
explained 56.14% of the variance (Table 4.3). The Cronbach’s alpha was calculated 
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and compared for the factors prior to, and after removal of these items, to ensure that 
it did not compromise the internal consistency of the scale (265). Expert opinion was 
also sought throughout this process to ensure there was no removal of clinically 
relevant items. 
Based on the results of the factor analysis, nine items were grouped onto a factor 
addressing various ‘Restrictions of activities of daily living’ (ADL), such as avoiding 
leaving the house, making plans and inability to complete duties at work. Twelve 
items described ‘Impact on mood and interpersonal relationships’, such as feelings of 
being dismissed by others and worthlessness, including any suicidal tendencies. Two 
items loaded on a ‘Pain and anxiety’ factor that addressed the pain of the CH and any 
associated anxiety such as dreading that the headache not going away. Finally, a ‘Lack 
of vitality’ (five items) factor addresses problems related to energy and cognition, for 
example difficulties in thinking clearly and concentration. 
!! 130!
Table 4-3 Results of the principal component factor analysis of the scale 
 















Avoided leaving the house 0.76    
Avoided making plans due to 
unpredictability of CH e.g. 
holidays 
0.72    
Felt unable to complete duties 
at work 
0.66    
Had difficulty in getting 
involved in leisure activities 
e.g. cinema, theatre, etc? 
0.63    
Avoided crowded and noisy 
places e.g. public transport, 
pubs, etc 
0.57    
Felt that the severity of cluster 
headache affected your daily 
activities 
0.56    
Been less involved in family 
affairs e.g. interaction with 
children, planning holidays 
0.54    
Been unable to socialise/spend 
time with friends and family 
0.46    
Been unable to achieve your 
daily goals and carry out 
routines and chores 
0.42 
 
   
Felt less respected by others  0.89   
Had problems with close 
personal relationship 
 0.73   
Felt you were a burden on 
family and friends 
 0.71   
Felt self-conscious and 
uncomfortable about your 
appearance after a cluster 
headache attack (eg 
swelling/redness of eyes and 
facial sweating, etc) 
 0.68   
Felt that others are dismissive 
of your cluster headaches 
 0.61   
Felt aggressive  0.53   
Felt bad about yourself, lost 
self-confidence or felt 
worthless 
 0.53   
Felt like harming yourself or 
suicidal 
 0.53   
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Been irritable, impatient or less 
tolerant 
 0.53   
Been forgetful e.g. missed 
appointments 
 0.49   
Been unable to take care of 
your appearance (eg take a 
bath, put make-up on, change 
clothes etc) 
 0.49   
Felt isolated, lonely or 
vulnerable 
 0.45   
Found your pain is unbearable 
if untreated 
  0.67  
Dreaded that the headache 
would not go away 
  0.48  
Felt lacking in energy and 
constantly tired 
   -0.88 
Felt sleepy, worn out or less 
able to concentrate due to 
nocturnal attacks of CH 
   -0.72 
Had problems concentrating 
e.g. reading paper, watching 
TV, etc 
   -0.62 
Been unable to think clearly    -0.60 
Felt tense or anxious    -0.48 
% of variance explained 43.11 5.59 4.06 3.38 
ADL = activities of daily living, CH = cluster headache 
 
4.3.c  Construct validity 
There was good intercorrelation between the subscales derived from the factor 
analysis, as shown in Table 4.4. This ranged from 0.52 – 0.75, supporting internal 
construct validity. Meanwhile, the subscales and total score had a moderate to strong 
negative correlation with the VAS. This negative correlation was expected as their 
scores ran in opposite direction (higher VAS indicates better HRQoL whereas higher 
total score indicates poorer HRQoL). 
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0.69* 1.00     
Pain and 
anxiety 
0.52* 0.53* 1.00    
Lack of 
vitality 
0.75* 0.69* 0.52* 1.00   
Total score 0.89* 0.93* 0.64* 0.85* 1.00  
VAS -0.52* -0.58* -0.30* -0.43* -0.57* 1.00 
ADL = activities of daily living; VAS = visual analogue scale 
*correlation is significant at the 0.01 level 
 
The scale was assessed for convergent and divergent validity by measuring correlation 
of the subscales with the relevant subscales of the SF-36, EQ-5D and MSQ (Table 
4.5). With regards to the SF-36, the ‘Restrictions of ADL’ factor of the scale 
correlated significantly with the social role functioning (SF) (r = -0.47, p < 0.001), 
mental health (MH) (r = -0.51, p < 0.001) and emotional role functioning (RE) 
subscales (r = -0.41, p < 0.001). The ‘Impact on mood and interpersonal relationships’ 
subscale of the scale correlated with SF (r = -0.52, p < 0.001), RE (r = -0.50, p < 
0.001), vitality (VT) (r = -0.49, p < 0.001) and MH (r = -0.67, p < 0.001) subscales. 
The ‘Lack of vitality’ subscale of the scale correlated with VT (r = -0.43, p < 0.001) 
and MH (r = -0.50, p < 0.001).  All the correlations were negative as the scale and SF-
36 were scored in different directions. 
Meanwhile, all of the subscales correlated significantly with all of the EQ-5D domains 
with the correlations having small to moderate magnitudes, except for the pain and 
anxiety subscale of CHQ and the mobility domain of EQ-5D, thus supporting 
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convergent validity. The highest correlation observed was between the ‘Impact on 
mood and interpersonal relationships’ subscale of the scale and anxiety/depression 
item of the EQ-5D (r = 0.54, p < 0.001). In relation to the MSQ, the subscales 
correlated significantly with the role restrictive and emotional functioning domains. In 
particular, there was a good correlation between the ‘Impact on mood and 
interpersonal relationships’ subscale with the emotional functioning subscale of the 
MSQ (r = 0.65, p < 0.001). Furthermore, the total score of the scale and total MSQ 
scores were well correlated (r = 0.61, p < 0.001). 
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Table 4-5 Correlation coefficients between the subscales and the EQ-5D and SF-
36 generic and MSQ v2.1 migraine-specific quality of life measures 
 










EQ-5D     
Mobility 0.28** 0.27** 0.07 0.21** 
Self-care 0.31** 0.39** 0.10* 0.27** 
Usual activities 0.35** 0.43** 0.14** 0.29** 
Pain/discomfort 0.19** 0.30** 0.11* 0.15** 
Anxiety/depression 0.39** 0.54** 0.28** 0.38** 
SF-36     
Physical functioning 
(PF) 
-0.28** -0.37** -0.11* -0.24** 
Role physical (RP) -0.23** -0.32** -0.05 -0.17** 
Bodily pain (BP) -0.23** -0.31** -0.12* -0.22** 
General health (GH) -0.34**  -0.46** -0.15** -0.32** 
Vitality (VT) -0.37** -0.49** -0.22** -0.43** 
Social functioning 
(SF) 
-0.47** -0.52** -0.21* -0.43** 
Role emotional (RE) -0.41** -0.50** -0.21** -0.39** 
Mental health (MH) -0.51** -0.67** -0.37** -0.50** 
MSQ v2.1     
Role restrictive 
(RR) 
0.52** 0.53** 0.29** 0.45** 
Role preventive 
(RP) 
0.56** 0.52** 0.28** 0.42* 
Emotional 
functioning (EF) 
0.49** 0.65** 0.41** 0.47** 
ADL = activities of daily living, EQ-5D = The European Quality of Life scale, SF-36 
= Short Form 36-item Health Survey, MSQ v2.1 = Migraine-Specific Quality of Life 
Questionnaire Version 2.1 
Pearson’s correlation test was used for SF-36 and MSQ v2.1 and Spearman’s 
correlation test used for EQ-5D 
** correlation is significant at the 0.01 level 
* correlation is significant at the 0.05 level 
 
4.3.d  Known-group validity 
The questionnaire was examined for known-group validity by assessing the 
relationship between the mean scores of the scale and its subscale with the MIDAS 
and HIT-6 groups. 
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i MIDAS 
With regards to the MIDAS, there was a linear increase in mean total scores of the 
scale, indicating poorer HRQoL, with increasing disability grade (Table 4.6). The 
assumption of homogeneity of variance was violated, thus a Welch F test was 
conducted instead of the oneway ANOVA test. The difference was statistically 
significant as determined by this test (Table 4.7). Similarly, oneway ANOVA and 
Welch F tests demonstrated there were statistically significant differences between the 
disability groups in all but one of the subscales (pain and anxiety), thus post hoc 
analysis was not conducted on this subscale.  Games-Howell post hoc comparisons 
revealed there were statistically significant differences (p < 0.05) between little/no and 
severe, as well as mild and severe disability groups in all subscales. There was also 
statistically significant difference (p < 0.05) between moderate and severe disability 
groups in the total and restriction of activities of daily living subscales. Meanwhile, 
there were no statistically significant differences between little/no and mild, little/no 
and moderate, as well as mild and moderate disability groups in all subscales.  
ii HIT-6 
The oneway ANOVA and Welch F tests demonstrated statistically significant 
differences between the four groups in all subscales as well as in the mean total score. 
Games-Howell post hoc comparisons revealed there was statistically significant 
difference (p < 0.05) between little/no and severe impact groups in all subscales. 
There were also statistically significant differences (p < 0.05) between some and 
severe, as well as substantial and severe impact groups in all subscales except for pain 
and anxiety. Differences were also seen between little/no and substantial impact group 
in impact on mood and interpersonal relationship subscale. There were no statistically 
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significant differences between little/no and some, as well as some and substantial 
impact groups in all subscales. 
 
















MIDAS      
Little or no 
disability 
19.98 16.59 6.29 12.42 55.45 
Mild 
disability 
19.71 16.26 6.33 12.47 55.63 
Moderate 
disability 
20.18 20.69 6.1 14.18 62.0 
Severe 
disability 
25.45 25.32 6.78 15.0 72.87 
HIT-6      
Little or no 
impact 
18.07 10.41 5.19 10.0 43.0 
Some 
impact 
18.58 14.93 6.3 12.07 51.47 
Substantial 
impact 
20.0 17.76 6.07 12.74 56.19 
Severe 
impact 
24.69 24.45 6.81 14.91 71.47 
ADL = activities of daily living, MIDAS = The Migraine Disability Scale, HIT-6 = 
The Headache Impact Test 6 items  
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Table 4-7 Oneway ANOVA and Welch F test results across the MIDAS and HIT-
6 groups 
 











MIDAS      
F-statistics F (3,55) = 16.94 
F (3,336) = 
19.38 
F (3,56) = 
2.58 
F (3,59) 
= 10.87  
F (3,51) 
= 16.48 
p value < 0.001 < 0.001 0.062 < 0.001 < 0.001 
HIT-6      
F-statistics F (3,61) = 11.33 
F (3,363) = 
27.17 
F (3, 66) 
= 7.07 




p value < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 
ANOVA = analysis of variance, MIDAS = The Migraine Disability Scale, HIT-6 = 
The Headache Impact Test 6 items, ADL = activities of daily living 
 
4.3.e  Internal consistency and reproducibility (Reliability)  
The reliability estimates (Cronbach’s coefficient alpha) and corrected item to total 
correlations of the items to their resulting subscale are shown in Table 4.8. The scale 
had a Cronbach’s coefficent alpha (α) of 0.95, which was well above the 
recommended criteria of 0.70. Meanwhile, the α values for the subscales ranged from 
0.52 – 0.91, with the pain and anxiety subscale not reaching the benchmark. The item-
test correlations of the subscales ranged from 0.37 – 0.78, thus most were above the 
recommended criteria of 0.40, except for the two items under the pain and anxiety 
subscale. There was no effect on α if any item were deleted from the subscales, thus 
all items were retained in their respective subscales. 
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Table 4-8 Item to total correlations and Cronbach’s coefficient alpha for the scale 
 




Restriction of ADL  0.91 
Avoided leaving the house 0.67  
Avoided making plans due to 
unpredictability of CH e.g. holidays 
0.66  
Felt unable to complete duties at work 0.70  
Had difficulty in getting involved in leisure 
activities e.g. cinema, theatre, etc? 
0.78  
Avoided crowded and noisy places e.g. 
public transport, pubs, etc 
0.63  
Felt that the severity of cluster headache 
affected your daily activities 
0.68  
Been less involved in family affairs e.g. 
interaction with children, planning holidays 
0.67  
Been unable to socialise/spend time with 
friends and family 
0.73  
Been unable to achieve your daily goals and 
carry out routines and chores 
0.69  
Impact on mood and interpersonal 
relationships 
 0.90 
Felt less respected by others 0.72  
Had problems with close personal 
relationship 
0.71  
Felt you were a burden on family and 
friends 
0.73  
Felt self-conscious and uncomfortable about 
your appearance after a cluster headache 
attack (eg swelling/redness of eyes and 
facial sweating,etc) 
0.65  
Felt that others are dismissive of your 
cluster headaches 
0.50  
Felt aggressive 0.59  
Felt bad about yourself, lost self-confidence 
or felt worthless 
0.63  
Felt like harming yourself or suicidal 0.59  
Been irritable, impatient or less tolerant 0.63  
Been forgetful e.g. missed appointments 0.58  
Been unable to take care of your appearance 
(eg take a bath,put make-up on,change 
clothes etc) 
0.55  
Felt isolated, lonely or vulnerable 0.71  
Pain and anxiety  0.52 
Found your pain is unbearable if untreated 0.37  
Dreaded that the headache would not go 
away 
0.37  
Lack of vitality  0.85 
Felt lacking in energy and constantly tired 0.69  
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Felt sleepy, worn out or less able to 
concentrate due to nocturnal attacks of CH 
0.61  
Had problems concentrating e.g. reading 
paper,watching TV,etc 
0.64  
Been unable to think clearly 0.70  
Felt tense or anxious 0.66  
ADL = activities of dailiy living, CH = cluster headache 
 
Fifty-six completed questionnaires were received (71.7% response rate) for the 
assessment of test-retest reliability. The mean age of this subsample was 55.7 years 
(range 34.7-79.1). There were 66.1% males and 33.9% females, with a mean age of 
onset of CH of 36.4 years (range 12.0-66.0). Test-retest reliability testing of the scale 
was performed on the data collected from respondents who completed the 
questionnaire on two occasions, which showed significant correlation coefficients 
between the two assessment occasions. Two-way mixed, single measure intra class 
correlation coefficient (ICC 3,1) was 0.87. The intra class coefficients for the 
subscales ranged from 0.71 – 0.84. Cronbach’s alpha was also satisfactory for the 
scales on both occasions (Table 4.9). 
 
Table 4-9 Cronbach’s coefficient alpha and test-retest reliability at the first and 
second assessments 
 






Restriction of ADL 0.91 0.93 0.85 p < 0.001 
Impact on mood and 
interpersonal 
relationships 
0.90 0.87 0.83 p < 0.001 
Pain and anxiety 0.52 0.63 0.71 p < 0.001 
Lack of vitality 0.85 0.80 0.80 p < 0.001 
ADL = activities of daily living 
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4.4 Discussion   
Several studies have demonstrated that HRQoL is significantly impaired in patients 
with CH (3, 4, 161-164).  However, these studies have all used either generic HRQoL 
scales such as the SF-36, or migraine-specific scales that may not necessarily be able 
to capture the true effects of CH, and may therefore be underestimating the actual 
impact of the disorder on HRQoL. Indeed, some issues that are specific to CH are not 
addressed through the use of these scales, for example suicidal tendencies, which is 
prevalent among CH sufferers. Circadian periodicity is another distinct feature in this 
disorder, with patients usually being woken up around the same time every night, at 
the onset of rapid eye movement (REM) sleep, which can have a major impact on 
patients with CH and therefore should be addressed and included in HRQoL 
assessments in this patient group.  
In the current study, a CH-specific HRQoL scale, the CHQ, was developed and 
validated. Items for the scale were generated from an in-depth literature review and 
semi-structured patient interviews, allowing CH sufferers to express their views about 
the various aspects of their lives that they felt were affected by the disorder and should 
be highlighted in such a disease specific HRQoL scale. This was followed by a review 
by a panel of experts with an interest in headaches to include items that were 
considered clinically relevant. These steps allowed development of a scale that is 
based on both patient and clinician input, thus ensuring good content and face validity.  
Exploratory factor analysis yielded five factors that explained 59.18% of the variance. 
However, since the fifth factor only had a single item loading on it, it was considered 
insufficient to produce a meaningful subscale and was consequently removed (267). A 
further eight items were subsequently removed as they failed to load significantly (> 
0.40) on any factor. 
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Thus, four subscales explained the resultant CH-specific HRQoL scale, namely 
restriction of activities of daily living (nine items), impact on moods and interpersonal 
relationships (12 items), pain and anxiety (two items) and lack of vitality (five items) 
subscales. These were shown to have good intercorrelations (range 0.52 – 0.75), 
supporting good construct validity. In terms of convergent validity, the subscale 
scores showed good correlation with those of other widely used HRQoL scales that 
have already been shown to have good validity and reliability, specifically the SF-36, 
EQ-5D and MSQ. Although some of the CHQ subscales did show weak correlation (r 
< 0.30) with the other HRQoL subscales, this was not surprising as the actual contents 
of these subscales may be different across the questionnaires used, despite them 
having similar titles or themes (268). 
Known group validity was assessed based on the mean total and subscales scores of 
the CH-specific HRQoL scale in the MIDAS and HIT-6 groups. In terms of the 
MIDAS, there was a statistically significant difference in mean total scores between 
the disability groups, with the severely disabled having significantly higher scores 
compared to the others. This suggests that greater headache-related disability is 
associated with poorer HRQoL in CH patients, with the impact being most evident in 
the severe disability group. The same pattern was seen with the restriction of activities 
of daily living subscale, since the MIDAS is effectively a measure of headache impact 
on daily function, thus they are measuring the same construct. This correlation 
supports convergent validity of this subscale. On the other hand, the change in the 
mean scores of the pain and anxiety subscale was not significant between the four 
disability groups. This may be because the pain of each CH attack is almost always 
excruciating that it is unaffected by any associated headache-related disability.  
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With regards to the HIT-6, there were statistically significant differences in mean total 
and subscale scores between the four impact groups. The change in mean scores of 
total and subscales were greatest between the little/no, some or substantial and the 
severely impacted groups, except for pain and anxiety subscale. HIT-6 is a measure of 
the functional impact of headaches, thus it is not surprising that those who are 
severely impacted also have significantly poorer HRQoL. Since HIT-6 also includes 
items such as feeling too tired and feeling fed up or irritated because of headaches, the 
changes in mean scores were also seen in the impact on moods and interpersonal 
relationships and lack of vitality subscales, reflecting good convergent validity. 
Moreover, the fact that there were significant changes in the mean total score of the 
scale between the four different groups of the MIDAS and HIT-6 scales also 
demonstrates that it has good discriminative property in respect to the magnitude or 
severity of associated disability. 
The Cronbach’s coefficient alpha for the scale was 0.95, which was well above the 
recommended criteria. This indicates that all items in this scale are measuring the 
same construct, specifically HRQoL. The subscales also had high α values, in the 
range of 0.85 – 0.91, with the exception of pain and anxiety subscale that had α value 
of 0.52.  This may be due to the fact that this subscale only consisted of two items, 
with one measuring pain (found your pain is unbearable if untreated) and the other 
assessing anxiety (dreaded that the headache would not go away). Thus the variability 
in the contents of this subscale is likely to account for this low internal consistency. 
Although there was an item on anxiety (felt tense or anxious) in the lack of vitality 
subscale, this item had poor loading (0.059) on the pain and anxiety subscale. 
Furthermore, this item had very good item-total correlation in its existing subscale 
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(0.66) and would actually reduce the internal consistency of the subscale if deleted. 
Thus this item was retained in the lack of vitality subscale. 
A second copy of the same questionnaire was completed by a random sample of 
respondents two weeks later to assess its test-retest reliability. This time period was 
similar to that employed in the migraine-specific quality of life measure (MSQOL) 
development and validation study (99). Intra class correlation coefficients ranged from 
0.71 – 0.84, which is considered acceptable and suggests good intra rater reliability 
across time. Moreover, the Cronbach’s coefficient alpha ranged from 0.63 - 0.93 on 
the second assessment, indicating that the scale has good consistency with time. 
A limitation of the quality of life study was that about a third of the study population 
comprised patients attending a tertiary referral centre; hence medically intractable 
cases might be over-represented in this sample. Of the 148 patients recruited from the 
headache clinic, 64.2% had CCH, which is significantly greater than is expected in the 
general population (8). Thus this sample may not be totally representative of the CH 
population in the community. However, this bias enabled data to be collected from a 
fair proportion of CCH sufferers (41.1%), who due to the recurring nature of their 
headaches are likely to be more disabled by this disorder, giving us a better picture of 
the extent of the impact on patients quality of life. There may also be response bias as 
the CH-specific HRQoL was sent out together with the other scales in the same 
booklet, thus all questionnaires might have been completed simultaneously. However, 
previous studies using the same measures, for example, the SF-36 Health Survey have 
shown similar levels of impairment as our sample population. 
To the best of my knowledge, this is the first scale developed to objectively measure 
HRQoL specifically in patients with CH. Following administration to a large sample 
of patients with the disorder, the scale has been shown to have good construct validity, 
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discriminative property, internal consistency and test-retest reliability. The scale was 
intended to be brief and user-friendly (it takes about 10 minutes to complete the 
questionnaire) so that it can be used in the clinical setting as well as in clinical trials as 
a patient-reported outcome measure. 
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Chapter 5  Quality of life in cluster headache 
 
5.1 Introduction 
Quality of life studies in patients with CH have shown limitations in normal daily 
functioning as well as social functioning (3, 162, 166). The excruciating nature of CH 
attacks, which are considered to be worse than migraine, correlated with marked 
limitations in role and emotional functioning, with studies showing a high prevalence 
of depressive symptoms and suicidal tendencies in CH patients (3, 4, 161, 164).  More 
than 70% of patients have reported that they have been severely impacted by their 
headaches, with restrictions in various life domains including paid work, household 
duties, social, leisure and family activities (164). This impairment continues even 
outside of the cluster bout, with considerable impact on social and family life, having 
to frequently miss social events and family gatherings. In terms of paid work, CH has 
led to reduced ability to work, limitations in career, loss of jobs and early retirement 
(161, 163). Due to their disability, CH patients have also had to depend highly on 
family and friends for help and support. Thus it is not surprising that almost all of the 
CH patients in a previous study reported having had to make some form of lifestyle 
change due to the disorder (163). It is therefore striking that the effect of CH on 
HRQoL in these studies were less marked, though this should be treated with caution, 
as their sample sizes were small. Furthermore, there were no significant differences 
found in the HRQoL between ECH patients during a bout and CCH patients (161, 
162), which was not expected considering the lack of remission in the latter. This 
study is therefore set out to describe the sociodemographic and headache 
characteristics of a large cohort of CH patients and specifically to assess their HRQoL, 
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in particular trying to identify any differences between ECH and CCH patients in 
terms of their reported HRQoL. 
5.2 Methods 
 
5.2.a  Subjects 
Data were collected as part of the CH-specific HRQoL scale development and 
validation study. Four hundred and six patients with CH who were recruited and 
responded to the postal questionnaire were involved. Patients received a range of other 
measures within the booklet of questionnaires that they received as part of the scale 
development study, including HRQoL instruments, headache-specific HRQoL and 
disability scales, social support instrument and measures of psychological health. 
5.2.b  Questionnaires included in booklet 
 
i Demographics 
Demographic data on age, gender, marital status, employment status, current 
occupation or job done for the longest period and years of education were collected 
using a custom-made questionnaire. Data on smoking status was also collected as it is 
well known that a high percentage of CH sufferers engage in this habit. 
ii Headache characteristics 
Headache history including age of onset of CH, information on when the current bout 
started or last bout was, length of remission period, laterality and location of CH 
attacks, pain severity, frequency and duration, associated cranial autonomic 
symptoms, associated nausea or vomiting, existence of warning symptoms prior to 
attacks and any coexisting headache disorders were also evaluated as part of the 
custom-made questionnaire. Remission period over the past year was assessed as 
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either having no remission or remission lasting less than or more than one month. The 
side of CH attacks can be either strictly right-sided or left-sided, side shifting between 
attacks or bilateral. Pain severity was assessed using a five-point scale, ranging from 
mild, moderate, severe, very severe to excruciating. Participants had to indicate what 
cranial autonomic symptoms they experienced with their attacks, with available 
options including redness or watering of the eye, runny or blocked nose, drooping of 
eyelid, small pupil, swelling of eye, facial redness or sweating or ear discomfort. 
There was also a tick box for associated agitation or restlessness. If they had any 
warning symptoms before an attack, they were required to state what the warning 
symptom was and how long it lasted for.  
In addition, participants were asked if they were any relieving factors for their pain 
and their current abortive and preventive medications. They were also queried on the 
year their CH diagnosis was made, who made the diagnosis and the number of doctors 
they saw before a CH diagnosis was made. Furthermore, their opinion regarding 
satisfaction with current treatment, their GP and OUCH were also assessed. 
• Are you satisfied with your current treatment? 
• Do you feel your GP is knowledgeable about your condition?  
• Do you feel your GP appreciates how painful your CH can be? 
• Do you think OUCH provided adequate information about CH?  
• Do you think OUCH provided adequate support for you? 
A ten-point scale was included to evaluate how much CH has changed their life in 
general, with one being least affected and ten being most affected, followed by a ten-
!! 148!
point scale assessing how much they have been affected in social (such as friends), 
professional (such as work) and private (such as family) domains. 
iii Generic HRQoL instruments 
The EQ-5D and SF-36 Health Survey were utilized to evaluate the influence of the 
headache in general on HRQoL. 
The EQ-5D and SF-36 Health Survey were used to assess the impact of their CH on 
HRQoL in general. The EQ-5D has five domains; mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression, each with three possible response options; no 
problems, some or moderate problems or extreme problems. In addition, there is a 
visual analogue scale, with 0 being the worst imaginable and 100 being the best 
imaginable current health state (96).  
The SF-36 Health Survey contains 36 self-administered items, measuring functions in 
eight domains, namely physical functioning (PF), role-physical (RP), bodily pain 
(BP), general health (GH), vitality (VT), social role functioning (SF), emotional role 
functioning (EF) and mental health (MH). The subscales are scored on a scale of 0 to 
100, with higher scores indicating better HRQoL (94). 
iv Headache-specific HRQoL instrument 
The Migraine-Specific Quality of Life Questionnaire (MSQ v2.1) was utilized to 
examine the impact of CH specifically on HRQoL since a measure for CH was not 
available. This is a 14-item measure, divided across three domains; role restrictive, 
role preventive and emotional functioning, which has been shown to have good 
internal consistency and construct validity (101). The total possible score ranges from 
14 to 84, with higher scores indicating poorer HRQoL. 
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v Headache-specific disability instruments 
Measures of disability provide an alternative method of assessing the impact of a 
disorder, and an inverse relationship between disability levels and HRQoL have been 
described (108). The instruments used to measure the degree of headache-related 
disability in this study were the Migraine Disability Assessment (MIDAS), the 
Headache Impact Test (HIT-6) and the Henry Ford Disability Inventory (HDI) 
questionnaires. 
The MIDAS measures the number of days of disability due to headaches within the 
past three months, in terms of missed days and reduced productivity by 50% or more 
in various aspects of daily living. The areas covered are paid work or schoolwork, 
household duties and social, leisure or family activities. Scores are categorized into 
four disability grades; little or no disability (0-5 days), mild (6-10), moderate (11-20) 
and severe (>21) disability (269). 
 The HIT-6 is a six-item questionnaire used to measure the adverse impact of 
headaches in various domains; role and social functioning, cognitive functioning, 
vitality and psychological distress, as well as an item on pain severity. The scores 
range from 36 to 78, and functional impact due to headaches can then be categorized 
into four groups; little or no impact (< 49), some impact (50 – 55), substantial impact 
(56 – 59) and severe impact (60 – 78) (270). 
The HDI is a 25-item questionnaire, divided into emotional and functional subscales, 
which is used to quantify the impact of headache on daily living, with higher scores 
reflecting greater disability caused by their headache (271). 
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vi Measures of psychological health 
Previous studies have shown that there is a high prevalence of psychiatric comorbidity 
in headache sufferers. Thus in order to capture this effect in this sample of CH 
patients, a number of psychological health-related measures were utilized, including 
the HADS, the Starkstein Apathy scale (AS), the Beck Hopelessness Scale (BHS) and 
the General Health Questionnaire (GHQ-28).  
The HADS is a widely used measure of anxiety and depressive symptomatology, 
consisting of seven items measuring anxiety alternating with seven depressive items. 
These were scored separately and scores of ≥ 8 defined anxiety and depression 
respectively (272). The Apathy scale (AS) has 14 items for screening and assessing 
the degree of apathy, with possible scores ranging from 0 to 42, and a cut-off score of 
14 defining presence of low and high apathy (273). The BHS provides a measure of 
hopelessness or pessimism about the future. It consists of twenty items scored either 
true or false, thus having a possible total score ranging from 0 to 20, with higher 
scores reflecting greater hopelessness. Based on the scores, three levels of 
hopelessness can be ascertained; normal (0 – 3), mild hopelessness (4 – 8), moderate 
hopelessness (9 – 14) and severe hopelessness (15 – 20) (274). The GHQ-28 is a 28-
item self-report measure of the common symptoms of mental health, specifically 
anxiety, depression, social withdrawal and somatic symptoms, which is used to screen 
for those who are at risk of or likely to have psychiatric disorders. The items are 
scored using a binary scoring method, with the first two available response options 
having a score of 0 and the last two responses having a score of 1. The total possible 
score ranges from 0 to 28, with scores ≥ 4 indicating psychiatric caseness (275). 
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vii Other instruments used 
Two measures related to pain were included in the booklet of questionnaires, namely 
the McGill Pain Questionnaire (MPQ) and the Pain Behaviour Checklist (PBC). The 
MPQ is a measure of the subjective pain experience that includes 78 item describing 
quality of pain, divided across four domains, namely sensory, affective, evaluative and 
miscellaneous aspects of pain. The scores can be treated statistically and the total 
possible score ranges from 0 to 78, with higher scores indicating worse pain (203). 
The PBC is a 54-item scale that has been validated to measure the behavioural 
response of chronic pain patients. It is divided across three domains; help-seeking, 
avoidance and complaint behaviour (276). 
The Rosenberg Self-Esteem Scale (RSES) is a widely used measure of self-esteem 
that includes both positive and negative feelings about ones’ self. The questionnaire 
consists of ten items, each with a 4-point Likert response scale. Five items measure 
self-deprecation and another five assesses positive self-esteem, with lower scores 
indicating lower self-esteem (277). 
The practical and emotional support system available to the participants was assessed 
using The Short Social Support Questionnaire, whereby they had to list down their 
sources of support, such as family or friends and rate their level of satisfaction with 
the support received on a 6-point scale, with 1 being very dissatisfied and 6 being very 
satisfied (modified from Jahanshahi and Marsden (278) and Sarason and colleagues 
(279)).  
The level of participants’ acceptance of and ability to adjust to their CH was measured 
using the Acceptance of Illness scale. This is an 8-item questionnaire describing the 
negative feelings associated with chronic disorders, with higher scores reflecting 
greater acceptance and better adjustment to their headaches (280).  
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Meanwhile, to assess the influence of stigma due to their CH, the stigma scale was 
included in the booklet of questionnaires. This contains six items, scored from 0 to 3, 
which assesses how their headache affects their interaction with others, such as 
avoidance behaviour, feelings of self-consciousness, unattractiveness and being 
different compared to others. A total score greater than 12 suggests severe stigma 
(281). 
5.2.c  Analysis 
Data was collated in an electronic database and all statistical analyses were performed 
using SPSS software version 18. Mean, median, standard deviation and range or 
number and percentage values are presented for the sociodemographic and headache 
characteristics. Comparisons between these characteristics were performed using two-
sample t-tests for continuous variables and Chi-square tests for categorical variables. 
A Shapiro-Wilk test was performed to test for normality of the data and appropriate 
parametric and non-parametric tests were applied accordingly to make comparisons 
between groups. Statistical tests were considered significant if p < 0.05. 
5.3 Results 
 
5.3.a  Demographics 
The sociodemographic characteristics of the study sample are presented in Table 5.1. 
About fifty-nine percent of the participants had ECH and 41.1% had CCH. The mean 
age ± SD of the study sample was 52.4 ± 12.3 years (range 21 – 84 years). There were 
68.2% males and 31.8% females, with no significant differences in gender ratio 
between ECH and CCH participants. The groups differed in their employment status, 
with a greater percentage of CCH participants being unemployed (34.5% vs 5.1%, p < 
0.001), whereby a high proportion was due to their disability. Occupation classes were 
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categorized according to the National Statistics Socio-economic Classification (NS-
SEC) of higher occupation, intermediate occupation and lower occupation. There 
were significant differences between ECH and CCH patients in their occupation class, 
with more ECH patients having higher occupation compared to CCH patients (55.4% 
vs 39.1%, p = 0.009). There were no significant differences between groups in marital 
or smoking status and years of education, with > 65% having at least secondary level 
education. 
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Table 5-1 Sociodemographic characteristics of participants 
 
Characteristic Total  
(n = 406) 
ECH  
(n = 239) 
CCH 
(n = 167) 
p values1 
Age, mean ± SD (range) 52.4 ± 12.3 
(21 – 84) 
52.7 ± 12.7 
(23 – 84) 
52.0 ± 11.9 
(21 – 84) 
0.607 
Gender (male: female) 2.1: 1 2.1: 1 2.3: 1 0.655 
Marital status, n (%)    0.364 
Single 60 (14.9%) 32 (13.5%) 28 (16.8%)  
Married/cohabiting 304 (75.2%) 184 (77.6%) 120 
(71.9%) 
 
Widowed 12 (3.0%) 8 (3.4%) 4 (2.4%)  
Divorced/separated 28 (6.9%) 13 (5.5%) 15 (9.0%)  
Employment status, n (%)    < 0.001 
Employed 228 (56.9%) 159 (67.4%) 69 (41.8%)  
Retired 85 (21.2%) 55 (23.3%) 30 (18.2%)  




61 (15.2%) 8 (3.4%) 53 (32.1%)  
Never employed 19 (4.7%) 10 (4.2%) 9 (5.5%)  
Occupation class, n (%)    0.009 
Higher occupation 191 (48.7%) 128 (55.4%) 63 (39.1%)  
Intermediate 
occupation 
68 (17.3%) 39 (16.9%) 29 (18.0%)  
Lower occupation 122 (31.1%) 59 (25.5%) 63 (39.1%)  
Never employed 11 (2.8%) 5 (2.2%) 6 (3.7%)  
Years of education, n (%)    0.104 
1 – 11 109 (27.4%) 57 (24.2%) 52 (32.1%)  
12 – 13 73 (18.3%) 39 (16.5%) 34 (21.0%)  
14 – 17 167 (42.0%) 107 (45.3%) 60 (37.0%)  
18 +  49 (12.3%) 33 (14.0%) 16 (9.9%)  
Smokers, n (%) 186 (45.8%) 105 (43.9%) 81 (48.5%) 0.363 
ECH = episodic cluster headache, CCH = chronic cluster headache, SD = standard 
deviation 
1Based on two-sample t-tests for continuous variables and Chi-square tests for 
categorical variables 
 
The results of comparison of the sociodemographic characteristics with the CH-
specific HRQoL questionnaire are shown in Table 5.2. Patients’ current age were 
binned into three groups, specifically patients < 45 years old, between 46 and 59 years 
old and > 60 years old. There were significant differences in mean total HRQoL 
between the three age groups, with younger patients having poorer HRQoL. No 
significant differences were found in mean total HRQoL scores between males and 
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females (64.0 ± 21.2 vs 68.4 ± 21.7, p = 0.078). Oneway ANOVA test showed that 
there was a significant difference in mean scores within the marital status groups, with 
Hochberg GT2 post hoc comparison test showing that the difference was highly 
significant between the single and widowed groups. There were also significant 
differences in HRQoL scores according to employment status and occupation class, 
with the unemployed group being greatly affected in the former, whilst in the latter, 
the greatest difference in HRQoL was between the higher and lower occupation 
classes.  No meaningful differences were found based on the years of education of the 
CH patients in this study. 
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Table 5-2 Comparison of CH-specific HRQoL scores and sociodemographic 
characteristics 
 
Characteristic Total HRQoL score p values1 
 Mean SD  
Current age  < 0.001 
< 45 years 73.3 18.5  
46 – 59 years 65.2 20.3  
> 60 years 55.6 22.7  
Gender  0.078 
Male 64.0 21.2  
Female 68.4 21.7  
Marital status  0.008 
Single 71.5 19.9  
Married/cohabiting 64.0 21.5  
Widowed 51.3 21.2  
Divorced/separated 71.6 20.1  
Employment status  < 0.001 
Employed 64.7 20.6  
Retired 58.0 21.6  
Unemployed 77.8 17.1  
Never employed 59.2 27.7  
Occupation class  0.007 
Higher occupation 61.5 22.1  
Intermediate 
occupation 
66.6 17.4  
Lower occupation 70.3 21.5  
Never employed 70.8 21.0  
Years of education  0.889 
1 -11 66.1 23.3  
12 - 13 66.7 20.9  
14 - 17 64.4 20.5  
18 +  65.4 21.6  
SD = standard deviation, CH = cluster headache, HRQoL = health related quality of 
life 
1Based on two-sample t-tests and oneway ANOVA and Welch F tests 
 
5.3.b  Headache characteristics 
The mean age of onset of CH of the whole study sample was 33.0 ± 13.0 years (range 
8 – 69 years). Participants with CCH had a significantly later age of onset of their 
headaches compared to the ECH group (mean ± SD, 35.0 ± 12.8 vs 31.5 ± 13.2 years, 
p = 0.007), as shown in Table 5.3. The pain was strictly unilateral in 86.6% of 
patients, with right-sided attacks being commoner than the left. Attacks were side 
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variable in 9.6% of patients, while 15 patients (3.7%) had pain occurring on both sides 
during the same attack. The median duration of attack was 25.0 minutes, however two 
patients reported that their untreated attacks lasted seven hours. The majority (> 70%) 
of patients described the intensity of their headaches as excruciating. There were no 
meaningful differences in the number of attacks per day between ECH and CCH 
patients. 
 
Table 5-3 Headache characteristics of participants 
 
Characteristic Total  
(n = 406) 
ECH  
(n = 239) 
CCH 
(n = 167) 
p values1 
Age at onset, mean 
± SD (range) 
33.0 ± 13.0  
(8 – 69) 
31.5 ± 13.2  
(9 – 64) 
35.0 ± 12.8  




   < 0.001 
No 
remission 
143 (35.8%) - 131 (78.9%)  
< 1 month 50 (11.8%) - 35 (21.1%)  
> 1 month 207 (52.5%) 239 (100.0%) -  
Side of cluster 
headache, n (%) 
   0.045 
Right 205 (50.6%) 129 (54.0%) 76 (45.8%)  
Left 146 (36.0%) 87 (36.4%) 59 (35.5%)  
Alternating 39 (9.6%) 18 (7.5%) 21 (12.7%)  




25.0 (1 – 
420) 
22.5 (1 – 420) 25.0 (5 – 
420) 
0.078 
Severity, n (%)    0.067 
Mild 1 (0.2%) - 1 (0.6%)  
Moderate 15 (3.7%) 4 (1.7%) 11 (6.6%)  
Severe 29 (7.1%) 18 (7.5%) 11 (6.6%)  
Very severe 61 (15.0%) 34 (14.2%) 27 (16.2%)  
Excruciating 300 (73.9%) 183 (76.6%) 117 (70.1%)  
Daily frequency, 
median (range) 
3.0 (1.0 – 14) 3.0 (0.3 – 14) 3.0 (0.1 – 14) 0.786 
ECH = episodic cluster headache, CCH = chronic cluster headache, SD = standard 
deviation 
1Based on two-sample t-tests and Independent Samples Mann-Whitney U test for 
continuous variables and Chi-square tests for categorical variables 
2Duration of remission period without medications on board 
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Headaches were focused mainly in the orbital, supra-orbital, temporal and frontal 
regions, although half of the study sample also experienced pain in the maxillary and 
mandibular distributions of the trigeminal nerve (Table 5.4). As per the diagnostic 
criteria for CH, many patients in this sample reported having associated cranial 
autonomic features, the most frequent being lacrimation, eyelid ptosis and 
conjunctival injection (Table 5.5). Patients with CCH reported a significantly greater 
occurrence of facial sweating, facial redness and ear discomfort compared to their 
episodic counterparts. A substantial proportion of patients (88.7%) also reported 
feeling restless or agitated with the headaches, while a third had associated 
gastrointestinal symptoms, specifically nausea or vomiting.  
 
Table 5-4 Location of pain in cluster headache patients 
 
Location Total (n = 406) ECH (n = 239) CCH (n = 167) 
Orbital 248 (61.1) 142 (59.4) 106 (63.5) 
Supra-orbital 263 (64.8) 152 (63.6) 111 (66.5) 
Frontal 154 (37.9) 82 (34.3) 62 (37.1) 
Temporal 296 (72.9) 181 (75.7) 115 (68.9) 
Parietal  128 (31.5) 74 (30.9) 54 (32.3) 
Occipital 64 (15.8) 33 (13.9) 31 (18.6) 
V2/V3 203 (50.0) 118 (49.4) 85 (50.9) 
Ear 32 (7.9) 18 (7.5) 14 (8.3) 
Neck 43 (10.6) 25 (10.4) 18 (10.8) 
ECH = episodic cluster headache, CCH = chronic cluster headache, V2/V3 = second 
and third divisions of the trigeminal nerve 
Results are presented as number of patients (percentage)  
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Total (n = 406) ECH (n = 239) CCH (n = 167) 
Lacrimation 355 (87.4) 208 (87.0) 147 (88.0) 
Eyelid ptosis 292 (71.9) 177 (74.1) 115 (68.9) 
Conjunctival 
injection 
276 (68.0) 159 (66.5) 117 (70.1) 
Rhinorrhoea 267 (65.8) 159 (66.5) 108 (64.7) 
Nasal congestion 219 (53.9) 130 (54.4) 89 (53.2) 
Facial sweating 203 (50.1) 104 (43.5)* 99 (59.3)* 
Eyelid swelling 142 (35.0) 92 (38.5) 50 (29.9) 
Facial redness 136 (33.6) 69 (28.9)* 67 (40.1)* 
Nausea or 
vomiting 
134 (33.2) 82 (34.3) 52 (31.1) 
Ear discomfort 122 (30.0) 60 (25.1)* 62 (37.1)* 
Miosis 91 (22.4) 58 (24.3) 33 (19.8) 
Agitation or 
restlessness 
360 (88.7) 210 (87.9) 150 (89.8) 
ECH = episodic cluster headache, CCH = chronic cluster headache 
Results are presented as number of patients (percentage)  
*Statistically significant difference between ECH and CCH, p < 0.05 
 
More than half of the patients had a warning symptom before the onset of their CH 
(57.5%), which was usually within 10 – 30 minutes prior to an attack, although a 
small proportion of ECH patients reported having symptoms up to a month before. 
Amongst the symptoms reported were feelings of a dull ache or mild pain, feeling 
tired, irritable or nonspecifically unwell, stiffness or soreness particularly of the neck, 
onset of cranial autonomic symptoms or restlessness, paraesthesia or allodynia, 
feeling hot or sweaty, yawning and migraine-related features such as photophobia, 
phonophobia or nausea. 
Almost a third of the patients in this sample (30.7%) suffered from another form of 
headache, the most common being migraine. Other types of headache reported were 
tension-type headache (nine patients), SUNCT (three patients) and short-lasting 
unilateral neuralgiform headache with autonomic symptoms (SUNA) (two patients). 
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Meanwhile three patients reported having primary stabbing headache, new daily 
persistent headache and Bechet-related headache respectively. 
Relieving factors that can improve the pain or shorten the CH episode were reported 
by 35.4% of patients. This includes applying pressure or massage, particularly of the 
eye and neck, applying either hot or cold compresses such as ice packs, having a bath 
or shower, cooling down by having some fresh air or being in an air-conditioned 
room, having a caffeine drink such as coffee or Red Bull, banging the head against the 
wall or floor, pulling the hair, keeping busy and distracting ones’ self from the pain 
and being in a dark room. 
In terms of medications, more than half of the study sample used subcutaneous 
Sumatriptan and high dose and high flow oxygen as abortives. Other types of 
abortives used included Sumatriptan nasal spray, Zolmitriptan nasal spray, oral 
triptans, Lidocaine drops, non-steroidal anti-inflammatory drugs (NSAID) and 
opioids. Meanwhile, Verapamil was the commonly used preventive medication. 
Most patients had their diagnosis of CH made by neurologists and headache 
specialists. This was more so for CCH patients (82.7% vs 58.2%, p < 0.001), whilst 
GPs were more comfortable in diagnosing ECH (34.5% vs 14.2%, p < 0.001). Other 
specialists seen for diagnosis were ENT doctors and dentists. An average of 3.8 
doctors was seen before a definitive diagnosis was made, with the median duration to 
diagnosis being 4.3 years (range 0 – 46 years). Patients with ECH had a longer 
diagnostic delay compared to CCH patients (5.0 vs 3.0 years, p = 0.018).  
Patients’ satisfaction with their current treatment, their GP and OUCH is shown in 
Table 5.6. With regards to satisfaction with current treatment, about three-quarters of 
patients reported being satisfied (77.4%). About 45% of patients feel their GP are 
knowledgeable and appreciates how painful CH can be. The majority thought that 
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OUCH provided adequate information about the disorder; with significantly more 
ECH patients reporting that OUCH provided adequate support (88.7% vs 79.7%, p = 
0.018) compared to CCH patients. 
 
Table 5-6 Satisfaction of cluster headache patients with their treatment, their GP 
and OUCH 
 
Domain Total  
(n = 406) 
ECH  
(n = 239) 
CCH  
(n = 167) 
p values1 
Current treatment 298 (77.4) 185 (80.8) 113 (72.4) 0.054 
GP:     
knowledgeable 176 (44.6) 108 (46.6) 68 (41.7) 0.341 
appreciative 196 (49.4) 120 (51.3) 76 (46.6) 0.361 
OUCH:     
adequate 
information 
366 (93.6) 220 (95.2) 146 (91.3) 0.113 
adequate 
support 
307 (85.0) 189 (88.7) 118 (79.7) 0.018 
ECH = episodic cluster headache, CCH = chronic cluster headache, GP = general 
practitioner, OUCH = Organisation for the Understanding of Cluster Headache 
1Based on Chi-square tests for categorical variables 
Results are presented as number of patients (percentage)  
 
Cluster headache has a significant impact on patients’ lives, with CCH patients 
reporting a greater impact than ECH patients (median score 10 vs 8, p < 0.001). This 
impact spans across various life domains, including social, professional and private 
dimensions (Table 5.7). 
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Table 5-7 Median scores (interquartile range) of impact of cluster headache on 
daily living 
 
Domain Total (n = 406) ECH (n = 239) CCH (n = 167) p values1 
General 9 (7 – 10) 8 (7 – 10) 10 (8 – 10) < 0.001 
Social  8 (6 – 10) 7 (5 – 8) 9 (8 – 10) < 0.001 
Professional 8 (7 – 10) 8 (6 – 9) 10 (8 – 10) < 0.001 
Private 8 (6 – 10) 8 (5 – 9) 9 (7 – 10) < 0.001 
ECH = episodic cluster headache, CCH = chronic cluster headache 
1Based on Independent Samples Mann-Whitney U test 
Median scores based on a 1 – 10 visual analog scale 
 
A comparison of age of onset of CH and duration of illness with the CH-specific 
HRQoL questionnaire revealed that there were significantly higher mean total HRQoL 
scores in patients with earlier onset of headaches compared to those who developed 
CH later in life, as shown in Table 5.8, with Gabriel post hoc comparison test showing 
that the difference was highly significant between those who developed CH at a 
younger age and those who developed them at ≥ 41 years. There were no meaningful 
differences found based on the duration of illness. 
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Table 5-8 Comparison of CH-specific HRQoL scores and age of onset and 
duration of illness 
 
Characteristic Total HRQoL score p values1 
 Mean SD  
Age of onset, years  < 0.001 
≤ 20  73.0 18.8  
21 - 30 67.9 20.7  
31 - 40 64.4 21.9  
≥ 41 57.0 21.6  
Duration of illness, years  0.345 
≤ 10 67.6 20.6  
11 - 20 65.8 21.5  
21 - 30 65.6 20.9  
≥ 31 61.2 23.5  
CH = cluster headache, HRQoL = health related quality of life, SD = standard 
deviation 
1Based on oneway ANOVA tests 
 
5.3.c  Generic HRQoL instruments 
The generic HRQoL instruments used were the EQ-5D and SF-36 Health Survey. 
There were significant differences (p < 0.001) in EQ-5D scores between ECH and 
CCH patients in all domains, as shown in Figure 5.1. Forty-one percent of CCH 
patients reported problems in walking about compared to only 11.7% of ECH patients. 
Moreover, 30.5% of CCH patients had problems with self-care, such as washing or 
dressing themselves, compared to a mere 7.5% of ECH patients. Furthermore, more 
than 70% of CCH patients had problems with performing their usual activities, had 
some pain or discomfort and felt anxious or depressed. There was also a significant 
difference in the VAS score between ECH and CCH patients (p < 0.001), with the 
former have a median score of 72.0 and the latter 40.0 on a 0 to 100 scale, reflecting 
poorer health state in CCH. 
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Figure 5-1 Percentage of patients having problems in EQ-5D domains 
EQ-5D = The European Quality of Life scale, ECH = episodic cluster headache, CCH 

















































Chronic CH patients had significantly reduced HRQoL compared to their episodic 
counterparts, as evident from the significantly lower scores in all domains of the SF-
36 Health Survey (p < 0.001). As a whole group, the domains most affected were 
vitality, role physical and bodily pain, whilst the least affected was physical 
functioning (Figure 5.2). 
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Figure 5-2 Mean SF-36 scores of ECH and CCH patients, and the whole study 
sample 
Error bars represent standard error of the mean 
SF-36 = Short Form 36-item Health Survey, ECH = episodic cluster headache, CCH = 


































































5.3.d  Headache-specific HRQoL instrument 
The MSQ v2.1 is scored from 0 to 100, with higher scores indicating better HRQoL. 
Patients with CH scored poorly on the MSQ v2.1, with the total median score for the 
whole group being 47.1 (range 0 – 80). The domain that had the lowest score was the 
role restrictive domain. Chronic CH patients scored significantly lower (p < 0.001) in 
all the three domains compared to ECH patients, as shown in Table 5.9. 
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Table 5-9 Median scores (interquartile range) of MSQ v2.1 scale for the study 
sample 
 
MSQ domain Total ECH CCH p values1 
Role 
restrictive 
42.9 (20.0 – 
65.7) 
54.3 (29.3 – 
80.0) 





60.0 (35.0 – 
75.0) 
65.0 (45.0 – 
80.0) 





46.7 (20.0 – 
73.3) 
60.0 (31.7 – 
80.0) 
26.7 (6.7 – 
53.3) 
< 0.001 




31.4 (18.9 – 
53.9) 
< 0.001 
MSQ v2.1 = Migraine-Specific Quality of Life Questionnaire Version 2.1, ECH = 
episodic CH, CCH = chronic CH 
1Based on Independent Samples Mann-Whitney U test 
 
5.3.e  Headache-specific disability instruments 
The results of the statistical analysis of the headache-specific disability instruments 
used in the study are presented in Table 5.10.  
The median MIDAS score for the whole study sample was 30.0 (range 0 - 270), with 
CCH patients having significantly higher scores than ECH patients (84.0 vs 13.0, p < 
0.001). Based on the MIDAS disability grades, over half of the patients reported being 
severely disabled (56.8%), 8.1% were moderately disabled, 5.3% were mildly disabled 
and 29.8% reported minimal disability (Figure 5.3) 
Patients with CCH had significantly higher mean HIT-6 score compared to ECH 
patients (65.0 vs 62.0, p < 0.001). The median HIT-6 score for the whole group was 
63.0 (range 40 – 78), reflecting severe impact of headaches on patients’ lives. The 
HIT-6 classification demonstrated that the majority of patients were severely impacted 
by their headaches (70.5%), 10.6% reported substantial impact, 11.9% had some 
impact whilst only 7.0% had little or no impact (Figure 5.4) 
There were also statistically significant differences (p < 0.001) in the median HDI total 
scores between ECH (64.0) and CCH patients (76.0), as well as in the emotional and 
functional subscale scores. As a group in general, patients with CH had a median total 
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HDI score of 68.0 (range 4 – 100), indicating profound disability due to their 
headaches.  
 
Table 5-10 Results of statistical analysis of the MIDAS, HIT-6 and HDI scales 
 
Scale Total ECH CCH p values1 
MIDAS 30.0 (3 – 104) 13.0 (0 – 53) 84.0 (27 – 
173) 
< 0.001 
HIT-6 63.0 (58 – 68) 62.0 (55 – 67) 65.0 (61 – 70) < 0.001 
HDI     
emotional 49.0 (44.0 – 
52.0) 
48.0 (44.0 – 
52.0) 
50.0 (45.0 – 
52.0) 
0.022 
functional 50.5 (48.0 – 
56.0) 
51.0 (48.0 – 
56.0) 
50.0 (48.0 – 
55.0) 
0.031 
total 68.0 (54.0 – 
82.0) 
64.0 (50.5 – 
76.0) 
76.0 (63.5 – 
88.0) 
< 0.001 
MIDAS = The Migraine Disability Scale, HIT-6 = The Headache Impact Test 6 items, 
HDI = The Henry Ford Headache Disability Inventory, ECH = episodic cluster 
headache, CCH = chronic cluster headache 
Scores shown are median scores (interquartile range) 
1Based on Independent Sample Mann-Whitney U test 
 
Figure 5-3 Headache-related disability assessed by the MIDAS scale 
MIDAS = The Migraine Disability Scale, ECH = episodic cluster headache, CCH = 





Figure 5-4 The impact of cluster headache according to HIT-6 grades  
HIT-6 = The Headache Impact Test 6 items, ECH = episodic cluster headache, CCH = 





























According to the CH-specific HRQoL questionnaire, the mean total HRQoL scores 
for the study sample increased significantly with the MIDAS and HIT-6 classification 
groups (Table 5.11). Games-Howell post-hoc comparisons on the MIDAS scale 
revealed that the little or no and mild disability groups were significantly different 
from the severe disability group. Similarly, for the HIT-6 scale, the severely impacted 
group was significantly different from the others. Thus severe headache-related 
disability was associated with significantly diminished HRQoL. 
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Table 5-11 Comparison of CH-specific HRQoL score across MIDAS and HIT-6 
classification groups 
 
Scale Total HRQoL score p values1 
 Mean SD  
MIDAS   < 0.001 
Little or no disability 55.5 24.7  
Mild disability 55.6 16.1  
Moderate disability 62.0 16.6  
Severe disability 72.9 17.4  
HIT-6  <0.001 
Little or no impact 43.0 21.2  
Some impact 51.5 24.0  
Substantial impact 56.2 22.3  
Severe impact 71.5 17.6  
MIDAS = The Migraine Disability Scale, HIT-6 = The Headache Impact Test 6 items, 
CH = cluster headache, HRQoL = health related quality of life 
1Based on Welch F tests 
5.3.f  Measures of psychological health 
Anxiety and depression was measured by the HADS, which revealed that 64.1% of 
the patients had anxiety scores of ≥ 8, whilst 52.7% had depression scores of ≥ 8 
(Table 5.12). The median anxiety score was 10.0 (range 0 – 21) and the median 
depression score was 8.0 (range 0 – 21). Chronic CH patients had significantly higher 
scores than ECH patients on both domains (anxiety 12.0 vs 8.0, p < 0.001, depression 
11.0 vs 6.0, p < 0.001). More than three-quarters of CCH patients (78.4%) had anxiety 
scores of ≥ 8 compared to 53.9% of ECH patients, whilst 71.6% of the former had 
depression scores of ≥ 8 compared to 39.3% in the latter. 
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Table 5-12 Anxiety and depression scores of patients 
 
 Total ECH CCH p values1 












8.0 (4 – 12) 6.0 (2 – 10) 11.0 (7 – 14) < 0.001 
Percentage of 
patients with scores 
≥ 8 
    
Anxiety 64.1 53.9 78.4 < 0.001 
Depression 52.7 39.3 71.6 < 0.001 
ECH = episodic cluster headache, CCH = chronic cluster headache, HAD = Hospital 
Anxiety and Depression 
1Based on Independent Samples Mann-Whitney U test and Chi-square test 
 
The results of the Starkstein apathy scale are shown in Table 5.13. About 45% of 
patients had apathy scores of ≥ 14, indicating high apathy. There were significantly 
more CCH patients who had high apathy scores than ECH patients (56.5% vs 38.4%, 
p = 0.001), with the median apathy score in the former group being 16.0 (range 1 – 
37) and the latter group having a mean apathy score of 11.0 (range 1 – 33). 
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Table 5-13 Results of the Starkstein apathy scale 
 









    0.001 
Low apathy 54.4 61.6 43.5  
High apathy 45.6 38.4 56.5  
ECH = episodic cluster headache, CCH = chronic cluster headache 
1Based on Independent Samples Mann-Whitney U test and Chi-square test 
 
The median BHS score for the whole study sample was 5.0 (range 0 - 20), with CCH 
patients having significantly higher scores than ECH patients (9.5 vs 4.0, p < 0.001), 
as shown in Table 5.14. Based on the BHS classification grades, 21.1% of patients 
reported having feelings of severe hopelessness, 14.8% had moderate hopelessness, 
27.5% had mild hopelessness and 36.6% reported minimal hopelessness. 
  
Table 5-14 Results of the Beck Hopelessness Scale 
 









   < 0.001 
Minimal 36.6 47.6 21.3  
Mild 27.5 28.8 25.6  
Moderate 14.8 12.7 17.7  
Severe 21.1 10.9 35.4  
ECH = episodic cluster headache, CCH = chronic cluster headache 
1Based on Independent Samples Mann-Whitney U test and Chi-square test 
 
Patients with CCH had significantly higher median GHQ-28 scores compared to ECH 
patients (10.0 vs 5.0, p < 0.001), greatly exceeding the cut-off score ≥ 4 for this scale, 
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whilst the group as a whole had a median score of 7.0 (range 0 – 28), as shown in 
Table 5.15. Almost three-quarter of CCH patients (73.2%) scored ≥ 4, whereas 56.1% 
of ECH patients (p = 0.001), suggesting high proportion of patients having probable 
distress due to their headaches. 
 
Table 5-15 Results of the GHQ-28 scale 
 








   0.001 
Non-case 36.8 43.9 26.8  
Probable 
distress 
(scores ≥ 4) 
63.2 56.1 73.2  
GHQ-28 = The General Health Questionnaire 28-items, ECH = episodic cluster 
headache, CCH = chronic cluster headache 
1Based on Independent Samples Mann-Whitney U test and Chi-square test 
 
Meanwhile, a comparison of the mean total HRQoL scores of the CH-specific HRQoL 
questionnaire between patients who reported associated anxiety or depression and 
those who did not, demonstrated that there were significant differences between the 
groups (Table 5.16). Patients with associated anxiety had significantly higher mean 
total HRQoL scores (78.9 ± 15.6 vs 54.6 ± 19.7, p < 0.001). Similarly, patients with 
associated depression also had poorer HRQoL (79.0 ± 16.1 vs 58.2 ± 20.7, p < 0.001) 
compared to those without.  
A similar pattern was seen with apathy, with those reporting high apathy having 
significantly higher mean total HRQoL scores than the low apathy group (73.3 ± 19.4 
vs 58.1 ± 20.2, p < 0.001). There was a linear increase in mean total HRQoL scores 
based on the classification groups of the BHS scale, with the severe hopelessness 
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group having significantly poorer HRQoL than those reporting minimal hopelessness. 
Patients who had probable psychological distress on the GHQ-28 scale also had 
significantly higher mean total HRQoL score than those without (71.5 ± 19.0 vs 54.3 
± 21.1, p < 0.001). 
 
Table 5-16 Comparison of CH-specific HRQoL scores with measures of 
psychological health 
  
Scale Total HRQoL score p values1 
 Mean SD  
HADS - Anxiety  < 0.001 
Non-case 54.6 19.7  
Case 78.9 15.6  
HADS - Depression  < 0.001 
Non-case 58.2 20.7  
Case 79.0 16.1  
Starkstein apathy  < 0.001 
Low 
apathy 
58.1 20.2  
High 
apathy 
73.3 19.4  
BHS  < 0.001 
Minimal 53.7 21.2  
Mild 64.0 19.0  
Moderate 69.0 16.3  
Severe 83.4 12.6  
GHQ-28  < 0.001 
Non-case 54.3 21.1  
Probable 
distress 
71.5 19.0  
CH = cluster headache, HRQoL = health related quality of life, SD = standard 
deviation, HADS= Hospital Anxiety and Depression scale, BHS = Beck Hopelessness 
Scale, GHQ-28 = The General Health Questionnaire 28-items 
1Based on Independent Samples Mann-Whitney U test and Kruskall-Wallis oneway 
ANOVA test 
 
5.3.g  Other instruments used 
The median total score or pain rating index (PRI) of patients measured by the MPQ 
was 45.0 (range 0 – 74). Chronic CH patients had significantly higher ratings of pain 
compared to episodic patients (48.0 vs 43.0, p = 0.028), although only sensory pain 
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showed meaningful differences between the two groups (Table 5.17). The PBC 
revealed that there were also significant differences in patients’ reported behaviour to 
their pain, with CCH patients having higher median scores in all components, namely 
help-seeking behaviour, avoidance behaviour and complaint behaviour.  
A higher proportion of CCH patients reported having low self-esteem on the RSES 
(44.8% vs 19.1%, p < 0.001) compared to their episodic counterparts. The median 
score of this scale was 18.0 (range 0 - 30) for the whole group, with significantly 
lower scores in the chronic group (15.0 vs 20.0, p < 0.001). 
Episodic and CCH patients reported no significant differences in the number of people 
they could count on to provide support and their satisfaction with the support 
provided, as assessed by the social support scale. They have on average 2.0 people 
whom they can count on for practical support, with a satisfaction score of 6.0. 
Meanwhile, they could count on a similar number of people for emotional and mental 
support, with a satisfaction score of 6.0. 
The Acceptance of Illness scale showed that 79.7% of patients had low scores, 
reflecting lack of acceptance and poor adjustment to their CH. This was more so for 
patients with chronic compared to ECH (89.4% vs 72.2%, p < 0.001). The median 
scores for the whole group and the ECH and CCH patients are shown in Table 5.17. 
The degree of stigma associated with CH is also significantly greater in CCH patients 
compared to episodics (mean ± SD, 11.3 ± 3.9 vs 8.6 ± 3.8, p < 0.001), as evaluated 
by the stigma scale.  
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Table 5-17 Results of statistical analysis of the MPQ, PBC, RSES, social support, 
Acceptance of Illness and stigma scale 
 
Scale Total  ECH CCH p values1 
MPQ     
Sensory 23.0 (15 - 
29) 
21.0 (14 – 
28)  
24.5 (17 – 
31) 
0.018 
Affective 9.0 (5 – 11) 9.0 (5 – 11) 9.0 (6 – 11) 0.086 
Evaluative 5.0 (4 - 5) 5.0 (4 – 5) 5.0 (4 – 5) 0.497 
Miscellaneous 10.0 (7 – 
13) 
9.0 (6 – 13) 10.0 (7 – 
13) 
0.449 
Total 45.0 (34 – 
56) 
43.0 (33 – 
56) 
48.0 (35 – 
58) 
0.028 
PBC     
Help-seeking 3.0 (1 – 4) 2.0 (1 – 4) 3.0 (2 – 4) 0.001 
Avoidance 16.0 (9 – 
22) 
13.0 (4 – 
20) 
19.0 (12 – 
24) 
< 0.001 
Complaint 7.0 (5 – 8) 7.0 (3 – 8) 7.0 (6 – 9) 0.007 







Percentage of patients 
based on scores 
   < 0.001 
Low self-esteem 29.6 19.1 44.8  
Normal range 54.9 58.9 49.1  
High self-esteem 15.5 22.0 6.1  
Social support     
Practical     
Number of 
people 
2.0 (0 – 8) 2.0 (0 -8) 2.0 (0 – 8) 0.913 
Satisfaction 
score (scale 
1 - 6) 
6.0 (1 – 6) 6.0 (2 – 6) 6.0 (1 – 6) 0.672 
Emotional and 
mental 
    
Number of 
people 
2.0 (0 – 9) 2.0 (0 – 9) 2.0 (0 -9) 0.943 
Satisfaction 
score (scale 
1 - 6) 
6.0 (1 – 6) 6.0 (1 – 6) 6.0 (1 -6) 0.583 
Acceptance of Illness 21.0 (15 – 
28) 
24.0 (19 – 
30) 
17.0 (12 – 
23) 
< 0.001 
Percentage of patients 
based on scores 
   < 0.001 
Low score 79.7 72.2 89.4  
Medium score 11.6 17.2 4.3  
High score 8.6 10.5 6.2  
Stigma scale, mean ± SD 9.7 ± 4.1 8.6 ± 3.8 11.3 ± 3.9  < 0.001 
MPQ = McGill Pain Questionnaire, PBC = Pain Behaviour Checklist, RSES = The 
Rosenberg Self-Esteem Scale, ECH = episodic cluster headache, CCH = chronic 
cluster headache, SD = standard deviation 
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1Based on Independent Sample Mann-Whitney U test, two-samples t-test and Chi-
square tests 
Values are median scores (interquartile ranges), unless stated otherwise 
 
A comparison of the RSES and Acceptance of Illness scale with the CH-specific 
HRQoL scales yielded the results shown in Table 5.18. Oneway ANOVA test with 
Hochberg’s post-hoc comparison showed that patients with low self-esteem on the 
RSES had significantly poorer HRQoL compared to those with normal and high self-
esteems. Similarly, those who had low scores on the Acceptance of Illness scale, 
reflecting poor acceptance and adaptation to their headaches, had significantly higher 
mean total HRQoL scores compared to those with medium and high scores. 
 
Table 5-18 Comparison of CH-specific HRQoL scores with the RSES and 
Acceptance of Illness scale 
 
Scale Total HRQoL score p values1 
 Mean SD  
RSES  < 0.001 
Low self-esteem 80.9 13.6  
Normal range 62.4 19.8  
High self-esteem 48.4 19.7  
Acceptance of Illness  < 0.001 
Low score 71.4 17.6  
Medium score 44.3 16.2  
High score 37.5 19.3  
CH = cluster headache, HRQoL = health related quality of life, RSES = The 
Rosenberg Self-Esteem Scale, ECH = episodic cluster headache, CCH = chronic 
cluster headache, SD = standard deviation 
1Based on oneway ANOVA test and Kruskall-Wallis oneway ANOVA test 
 
5.4 Discussion 
This study was carried out to describe the sociodemographic and clinical 
characteristics of a large cohort of CH patients and specifically assess the impact or 
burden of their headache on their quality of life. HRQoL is a subjective assessment by 
patients of the impact of their headaches and its treatment on a range of life domains, 
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including physical, emotional, social and functional well-being. Thus, in order to 
cover all these aspects, a number of different instruments to measure these various 
dimensions of HRQoL were utilized. The instruments used included generic HRQoL 
scales, headache-specific HRQoL and disability scales, measures of psychological 
health and a range of other instruments measuring pain, pain behaviour, self-esteem, 
social support, acceptance of illness and stigma. To my knowledge, this is the largest 
study describing the characteristics and HRQoL of CH patients to date. 
 
Sociodemographic and headache characteristics 
The male to female ratio of the study sample was slightly lower than that reported 
elsewhere (2.1:1 vs 2.5 – 7.2: 1), possibly owing to increased awareness of the 
disorder in females, although a male preponderance still exists (1, 8). More than half 
were gainfully employed, although there were a significantly higher proportion of 
CCH patients who were unemployed, mainly due to disability. This is in accordance 
with the results from published studies, which have found that up to a third of CCH 
patients had lost their jobs due to their headache and are receiving invalidity 
allowance (161-163). Moreover, there were significantly less CCH patients in higher 
occupation class, which is in agreement with previous reports of career limitations in 
this group (161, 163). 
Episodic CH patients in this study had a slightly higher mean age of onset (31.5 years) 
compared to a previous large prospective study (28.4 years) (8). However, in line with 
that study, patients with CCH also had significantly higher mean age of onset 
compared to episodics (35.0 years) (8). About 10% of patients in this study 
experienced side shifting of their headaches and 3.7% had bilateral attacks, despite 
CH being defined as a strictly unilateral headache. Furthermore, a similar proportion 
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(4.0%) had attacks lasting more than three hours, despite almost all patients having 
access to some form of abortive medication, the commonest being subcutaneous 
Sumatriptan and high dose and high flow rate oxygen. This is longer than the duration 
proposed by ICHD-3 beta for CH of 15 – 180 minutes (5). These differences may 
have arisen because about a third of patients (36.5%) were recruited from the 
headache clinic at The National Hospital for Neurology and Neurosurgery, which is a 
tertiary referral centre for headaches where a number of atypical and treatment-
refractory cases are seen.  
Half of the patients (50.0%) experienced pain in the maxillary and mandibular 
distributions of the trigeminal nerve. This is important from a dental point of view, as 
patients may initially seek dental treatment for the pain.  Indeed, a study found that 
45% of CH patients consulted a dentist prior to neurologic referral (282). Of these, 
18% had unnecessary dental treatment instituted in an attempt to alleviate pain.  
Treatments received included tooth fillings and extractions, splint therapy, orthodontic 
treatment and maxillofacial surgery. Similarly, Bittar and Graff-Radford performed a 
retrospective study of 33 CH patients and reported that 42% of these patients were 
seen by dentists prior to referral to the pain management centre and underwent some 
form of dental treatment, without favourable outcome (283). An oral appliance was 
constructed for six (42%) of these patients, aimed to treat temporomandibular 
disorders (arthromyalgic group). Four patients had teeth extracted, three underwent 
coronoplasty (tooth grinding) procedures, and two had endodontic treatment.  In this 
study, four patients reported consulting and obtaining a diagnosis of CH from a 
dentist, thus dental professionals should always remain vigilant during practice. 
Interestingly, a greater proportion of patients with CCH reported having facial 
sweating, facial redness and ear discomfort associated with their attacks. The reason 
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for this is not known, however, it is speculated that there may be increased 
sympathetic overactivity in this patient group compared to the episodic group. 
More than half of the CH patients reported having a warning symptom, similar to 
previous reports, which can be divided into premonitory and prodromal symptoms 
(164, 284, 285). The former are symptoms prior to a cluster bout, whereas the latter 
are those experienced just before an attack (284). Most of the patients who reported 
prodromal symptoms usually had them within 10 – 30 minutes before their attack. 
This can present in various forms, such as having a dull ache or pain usually local to 
the site of their attack, changes in vitality or mood, stiffness of the neck or shoulders 
or onset of cranial autonomic features or restlessness similar to that experienced 
during an attack. Meanwhile, ECH patients reported premonitory symptoms of a dull 
ache and tiredness up to four weeks before the onset of their bout. Blau and Engel 
(1998) have divided these symptoms into local vasomotor, muscular and neurological 
groups, and proposed that their existence may have pathogenetic implications (285). 
Despite the differences discussed above, the demographic characteristics of CH 
patients in this study are comparable to those that have been reported previously (1, 8, 
164) 
 
Health related quality of life 
The results from this study demonstrate that CH has a significant impact on patients’ 
HRQoL, as evaluated from the various instruments used. The impact is greater for 
CCH patients compared to those with ECH, as shown by the significantly worse 
scores for the former in all generic and headache-specific HRQoL and disability 
scales. This is in contrast to that reported by D’Amico and colleagues who did not 
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find any significant differences in HRQoL between ECH and CCH patients, although 
their sample size was much smaller (56 CH patients) (162). 
On the EQ-5D, patients reported having most problems in the pain/discomfort 
domain, which is in agreement with the excruciating pain intensity reported by > 70% 
of CH patients in this study. This also correlated with the pronounced limitation in 
bodily pain domain of the SF-36 Health Survey and the high total pain rating index on 
the MPQ. 
Patients with CCH had significantly worse scores in all domains of the SF-36 Health 
Survey compared to ECH patients. The domain least affected was physical 
functioning, which measures the ability to perform a variety of physical activities. 
This is in accordance with the findings of previous studies that found that physical 
functioning was well preserved in CH patients, with no significant differences found 
compared to migraineurs, headache-free controls and normative data (3, 4, 162). On 
the other hand, vitality domain, which measures energy level and fatigue, was the 
most affected in this study sample. Taking into account the prevalence of nocturnal 
attacks in this disorder and the mean frequency of daily attacks (3.6) in the study 
sample, this impact on vitality was not surprising. However, CCH patients had lowest 
scores in role physical domain, which suggests that their headaches mostly interfere 
with their usual daily activities.  
This correlated with their scores on the usual activities domain of the EQ-5D, 
whereby 77.1% of CCH patients reported having problems performing usual activities 
such as work, study, housework, family or leisure activities. Furthermore, patients 
scored poorly on the role restrictive domain of the MSQ v2.1, suggesting that their 
CH limits their ability to perform daily activities. Moreover, headache-disability 
scores were all significantly worse in this group, with 76.3% having severe disability 
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on the MIDAS and a profound 83.5% being severely impacted based on the HIT-6 
scale. This is in contrast to the minute differences found in headache-related disability 
between ECH and CCH patients in a previous study (161). This high functional 
impairment experienced by CCH patients may account for the higher levels of 
unemployment seen in this group.  
The high disability associated with this disorder has been well described, which also 
extends to family life (163, 164, 167). Jensen and colleagues found that about 61% of 
patients felt that their headache impacted on their family life and they have had to 
depend on help from family and friends (163). Data from this study show that patients 
are satisfied with the support available around them, having about two people whom 
they can really count on to provide practical and emotional or mental support. This is 
usually their significant other as approximately three-quarters of patients are married 
or cohabiting, though they also usually seek support from parents, siblings, children 
and friends. 
Taking into account the excruciating pain and highly disabling nature of CH, it is 
therefore not surprising that patients have a hard time accepting and adjusting to the 
disorder. This is demonstrated from the high percentage of patients who scored poorly 
on the Acceptance of Illness scale. This suggests that there is a strong negative 
emotion associated with CH. Psychiatric comorbidity in primary headache disorders, 
specifically migraine, is well known, and has also been recently reported in CH (115, 
161, 164, 286). This study found that half of patients reported symptoms of depression 
and about 60% met the HADS criteria for anxiety, with CCH patients fairing worse. 
Similar findings were seen from the anxiety/depression domain of the EQ-5D scale. 
Moreover, about 60% of patients had scores above the cut off point for the GHQ-28 
scale, which is a screening tool for psychiatric disorders and only about a third of 
!! 182!
patients did not report having feelings of hopelessness. Furthermore, patients also 
have low self-esteem and high apathy scores, with about 60% reporting feeling self-
conscious and avoiding other people as a result of their headaches. These findings go 
in line with the agarophobia and suicidal tendencies often described in CH patients, 
whereby Jurgens and colleagues found that 33% of chronic and 15% of ECH patients 
had symptoms of the former, whilst 22% of chronic and 15% ECH patients had the 
latter (161).  
Thus, CH has an impact on physical, mental, social and functional wellbeing, which 
are the elements of HRQoL. This overall impact is reflected in their self-reported 
scores on a visual analog scale, whereby when asked to score how CH has changed 
their life in general on a scale of 1 – 10, with 1 being a little and 10 a lot, the majority 
of patients (83%) scored ≥ 7 and 41% indicated it changed their life a lot (score of 
10). 
 
Effect of these factors on the CH-specific HRQoL scores 
Age of onset of CH had a significant effect on HRQoL, with earlier onset associated 
with poorer outcome. The same pattern was found based on patients’ current age, with 
younger patients (<45 years) having significantly diminished HRQoL. This may be 
due to the related work, family and social commitments that one tends to have around 
this time period, which is often the most productive working, family and social years 
of their life. This explains the significant effect employment status has on HRQoL, 
whereby those who are unemployed feel the most burden since they may no longer be 
able to provide for themselves and their family. Similarly, career limitations due to 
CH have a profound impact on HRQoL. Patients who are single or divorced/separated 
also had poorer HRQoL compared to those who are married/cohabiting or widowed, 
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possibly due to the absence or loss of a reliable support system that they can depend 
on.  
There was no significant difference in HRQoL based on the duration of the disorder. 
This is in concordance with the finding from this study that CH patients have poor 
acceptance of their headache, thus the impact on their HRQoL remains consistent 
throughout the years that they suffer with the disorder. Furthermore, the poorer their 
acceptance of their CH, then the worse their HRQoL tends to be. 
An inverse relationship between disability and HRQoL has been previously reported 
in migraines, though its effect on CH has not been studied (108, 126). The data from 
this study supports this relationship, with patients who were severely disabled or 
impacted by their headaches having significantly diminished HRQoL.  
With regards to emotional and mental wellbeing, patients who had any psychiatric 
complaints, such as symptoms of anxiety, depression, apathy, hopelessness or had low 
self-esteem had significantly poorer HRQoL compared to their non-symptomatic 
counterparts. This is further supported by the significantly diminished HRQoL scores 
in patients who met the criteria for probable psychiatric distress on the GHQ-28 scale. 




This study has therefore provided detailed information of the sociodemographic and 
clinical characteristics of a large cohort of CH patients. Furthermore, it provides 
supporting evidence of the significant impact CH has on patients’ HRQoL and the 
high prevalence of psychiatric complaints patients have. This impact is significantly 
greater in patients who have CCH than those who suffer the episodic variant, which is 
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not surprising as their headaches are unremitting. The effects that certain variables 
have on reported HRQoL have also been described. These are likely to play a role in 
predicting or determining HRQoL in this population, although further work is 
required to assess the weight or magnitude of effect they have on HRQoL. In 
particular, the consistent diminished HRQoL scores in patients exhibiting symptoms 
of emotional or mental distress highlights the importance of proper headache 
management, which requires not only management of the headache pain itself, but 
also of any associated comorbidity. 
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Cluster headache is known to be an excruciatingly painful headache disorder, which 
although is often remitting, can still have a huge impact on patients’ lives. Even 
though the disorder can be managed quite effectively, it remains largely empirically 
based. Thus there is great emphasis on and a high degree of interest in trying to 
unravel the pathophysiological basis of the disorder and in assessment of the burden it 
imposes on patients’ lives. The aim of this thesis was to improve understanding of the 
underlying mechanisms in CH through a range of different studies. This chapter 
summarizes the findings from the various studies within this thesis and discusses the 
limitations and future directions in this field. 
6.1.a  Summary of findings 
 
i Neuroimaging study 
The GONB is a widely used transitional treatment in CH, with proven efficacy and 
safety (53, 56, 62, 63, 65). An fMRI study utilizing ASL was conducted in CH 
patients receiving their first GONB to map and identify changes in rCBF relating to 
brain responses prior to and following the treatment. As evident from previous 
functional neuroimaging studies in CH, the hypothalamus is likely to have a pivotal 
role in CH pathophysiology (18, 19, 29, 37, 40, 41). From this fMRI study, the 
posterior hypothalamic area was also found to demonstrate significant increases in 
rCBF during the interictal period, thus further supporting the previous findings. 
Moreover, there were significant increases in rCBF in a number of brain regions 
previously activated in other pain studies. In particular, increases were observed in the 
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left orbitofrontal cortex, left basal ganglia, left amygdala, left hippocampus and 
parahippocampal gyrus, left lateral posterior thalamic and pulvinar nuclei and 
bilaterally in the brainstem prior to the GONB. Since each of these regions are known 
to have a role in various aspects of pain processing, specifically the sensory-
discriminative, affective/emotional and cognitive processing of pain, as well as in the 
salience detection system, it is likely that these regions represent an interconnected 
network of structures that integrates the pain experience of CH, reflecting a central 
permissive state that can lead to attacks. Similar to the previous study on paroxysmal 
hemicrania, it is hypothesized that this system remains activated at a subthreshold 
level in the interictal CH period, and attacks triggered once a threshold level for pain 
is reached (246). Following the GONB, there were reductions in rCBF in these 
regions, suggesting a possible winding down of this network.  
ii Saccadometry study 
The saccadometry study showed that the reaction time distributions of CH patients 
differed significantly from age- and sex-matched controls in all measurement 
parameters. In particular, the mean saccadic latencies of CH patients were longer with 
greater variability compared to controls. However, significantly less CH patients 
exhibited an early saccade, with smaller variability in the distribution of the early 
saccades compared to controls. These findings suggest that there is delay in the 
decision-making process of saccadic information in this population. Whilst this delay 
can occur within any of the neural pathways involved in saccadic generation, the 
reduced proportion of early saccades in CH patients suggests that the basal ganglia 
may have a role in contributing to this impairment. This is because the basal ganglia is 
tonically inhibitory and exerts descending inhibitory input to the SC, which 
constitutes the “final common pathway” for generation of saccades (74, 250). Thus 
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the longer mean saccadic latencies and reduced proportion of early saccades in CH 
may reflect the presence of a tight inhibitory control over the SC, which stems from 
the basal ganglia. 
As far as the increased variability is concerned, a previous study in migraineurs found 
reduced variability in reaction time distributions compared to controls, which they 
attributed to a functional deficit in the noradrenergic system (75). Whilst this is also 
likely to explain the findings of this study, it is also possible that variability may arise 
from the extent of underlying pathology in CH, which may affect different elements 
controlling saccadic generation, as was proposed by Barker and Michell (73). 
iii Quality of life study 
Due to the high disability and impact often reported by CH patients and the lack of a 
specific HRQoL measure in this patient group, a self-administered “Cluster headache 
specific quality of life” (CHQ) scale was developed and validated. A three-step 
approach was employed in the scale development: item generation; item reduction and 
scale development; and, scale validation and reliability testing. A literature review, 
semi-structured patient interviews and expert panel consultation yielded a 54-item 
questionnaire, which was pre-tested in a sample of CH patients and subsequently 
reduced to 47 items. In stage 2, the revised scale was administered to CH patients 
attending a tertiary headache clinic and those registered with a patient group. A total 
of 406 completed questionnaires were received. To assess test-retest reliability, a 
subsample (N=56) completed the scale on a second occasion, two weeks after the first. 
Item reduction and exploratory factor analysis led to 28-items, grouped into four 
subscales labeled “restriction of activities of daily living”, “impact on mood and 
interpersonal relationships”, “pain and anxiety”, and “lack of vitality”.  The final CH-
specific HRQoL scale, the CHQ, demonstrated satisfactory internal consistency 
!! 188!
(Cronbach’s alpha > 0.5) and test-retest reliability (correlation coefficient > 0.7), with 
good internal construct validity (range 0.52 – 0.75) and convergent validity with other 
HRQoL measures. 
Using the same patient dataset, the sociodemographic and headache characteristics of 
CH patients was also described. Of particular interest was an assessment of their 
HRQoL, specifically to evaluate for differences between ECH and CCH patients. The 
sociodemographic and headache characteristics of CH patients in this study are 
comparable to those reported in previous studies (8, 164). This study found that 
younger patients and those who had an earlier age of onset of their CH had 
significantly diminished HRQoL, possibly owing to the greater impact it has on the 
productive years of life. Patients who were single or divorced/separated also had 
poorer HRQoL compared to those who were married/cohabiting or widowed.  
In terms of HRQoL, the findings from this study support previous studies that 
reported that CH is associated with high disability and has significant impact on 
patients’ lives (3, 162, 166). There was an inverse relationship between disability and 
HRQoL, with those who were severely disabled or impacted by their headaches 
having significantly diminished HRQoL. Moreover, patients with CCH were shown to 
have significantly poorer HRQoL compared to ECH patients, as evident from their 
significantly worse scores in all generic and headache-specific HRQoL and disability 
scales. This high functional impairment may account for the higher levels of 
unemployment reported by CCH patients, which then impacts further on their HRQoL 
as they are unable to provide for themselves and their family, thus creating a vicious 
cycle. Furthermore, CH patients were found to have a hard time accepting and 
adjusting to their headaches, therefore it was not surprising that at least half of them 
reported symptoms of depression and anxiety, with CCH patients faring worse. This 
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theme of an associated psychiatric comorbidity was consistent across all the measures 
used in this study, with substantial reports of having feelings of hopelessness, low 
self-esteem and high apathy associated with the headaches, which had a significant 
impact on HRQoL. 
iv Overall conclusions based on findings 
The attempt of this thesis was to gain further insight into the underlying processes 
involved in CH by taking a mixed methods approach in the assessment of the disorder, 
using fMRI and saccadometry studies, whilst also studying the disability and resultant 
impact it has on patients’ quality of life. The increase in rCBF in the posterior 
hypothalamus observed in the fMRI study, which was performed during the interictal 
state, further supports the view that this structure may have a crucial role in CH 
pathophysiology. Previous neuroimaging studies have reported ipsilateral 
hypothalamic activation in CH, which is in keeping with the unilaterality.of attacks 
that are characteristic of this disorder (18, 19, 29, 37). Considering that the majority of 
patients in this study had left-sided attacks, these lateralized increases in rCBF on the 
left side may reflect this laterality, although further work with a larger dataset is 
required to confirm or refute this finding. 
Of interest to note were the increases in rCBF in other brain structures during this 
state. In particular, increases were observed in the orbitofrontal cortex, basal ganglia, 
amygdala, hippocampus, parahippocampal gyrus and posterior thalamus, which were 
all strictly unilateral, whilst that in the brainstem was bilateral. The increases in rCBF 
in these structures, which are known to have various roles in the processing of pain, 
were somewhat unexpected given that patients were headache-free during scanning. 
Therefore this implies that during a bout, there are neuroplastic changes within the 
central nervous system of CH patients leading to a persistent activation of this system, 
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and hence reflecting a central permissive state that can lead to attacks, with 
subsequent reductions in rCBF occurring following treatment, in this case, a GONB. 
The discrete clusters of increased rCBF in the left basal ganglia extending to the left 
posterior hypothalamus and in the brainstem involving the red nucleus and substantia 
nigra somewhat answers the debate about the exact location of activation seen in the 
landmark PET study by May and colleagues (18, 287). This study provides evidence 
that both the posterior hypothalamus and the midbrain tegmentum show changes 
during the interictal state. Given that these structures are known to be involved in the 
processing and modulation of pain, they are therefore likely to form part of a network 
that is crucial in CH pathophysiology. Moreover, similar observations have also been 
reported in PET studies of PH and HC, whose clinical features overlaps with the 
TACs, thus suggesting a shared pathophysiology (44, 246). 
Another interesting finding from this thesis was the correlation between the 
neuroimaging and saccadometry data. In particular, the basal ganglia or its constituent 
nuclei is a region that has been repeatedly reported to be activated in neuroimaging 
studies of CH, although not much emphasis has been placed on these observations, 
possibly due to the assumption that this region has a role in pain processing in general 
(17, 19, 37). However, findings from the fMRI study showing increases in rCBF 
during the interictal period when patients are headache-free begs the question of 
whether it has a more important role to play in CH. Furthermore, metabolic changes 
within the basal ganglia have also been reported in a PET study of CH patients 
scanned in and out of a bout compared to healthy controls, which the authors 
speculate may be associated with a dysfunction of the pain-modulating circuits in CH 
patients (288).  
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Brainstem activations have also been previously reported in CH and the other TACs, 
thus implying their probable crucial role in the underlying pathophysiology (44, 156, 
217, 220). Indeed, the saccadometry study findings of increased mean saccadic 
latencies in CH patients, with reduced number of early saccades, suggest that the basal 
ganglia is exerting greater inhibitory control over the SC, and therefore is holding up 
the generation of visual saccades. Meanwhile the higher variability in saccadic 
reaction time is suggestive of a dysfunction within the noradrenergic system. 
As previously discussed, there have been several reports of impaired dopaminergic 
and noradrenergic systems in CH. Dopamine agonist and antagonists have been 
shown to initiate and control CH attacks respectively (227-230). Increased levels of 
platelet dopamine have been observed in ECH patients, both during and outside of a 
bout, with blunted 24-hour prolactin production in CH patients and reduced response 
to thyrotropin-releasing hormone (231, 232). A recent study also found impaired 
increase in growth hormone levels following an apomorphine challenge in CH 
patients outside a bout, suggesting decreased sensitivity of dopaminergic neurons 
(233). Therefore, taking into account that the substantia nigra, one of the nuclei within 
the basal ganglia, is the main source of dopamine within the brain, it is therefore 
tempting to speculate that the basal ganglia or possibly the dopaminergic system has 
an important contribution to the neural mechanisms underlying CH. Meanwhile, 
reports of efficacy of Clonidine and Tizanidine as preventative treatments, and altered 
platelet levels of adrenaline and noradrenaline in all stages of CH also suggest the 
possibility of dysfunction within the noradrenergic system (253, 255, 256). Hence, it 
is proposed that there may be impairment involving both the noradrenergic and 
dopaminergic systems in CH. 
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In light of these findings, a reinterpretation of the structures thought to be involved in 
CH pathophysiology may be necessary. Whilst the hypothalamus, which has long 
been viewed as the central generator of the disorder, may have a pivotal role, it is 
highly likely that other structures, such as the basal ganglia and/or brainstem, may act 
in synchrony with it and therefore have crucial roles in CH pathophysiology. 
With regards to quality of life, this thesis provides evidence to support that CH is a 
highly disabling disorder, with significant impact on everyday life. This impact is 
greater for patients who have the chronic variant, which was expected, due to the 
recurring nature of their headaches with no significant remission periods. There were 
also high levels of psychiatric comorbidity associated with this disorder, with 
diminished scores on all measures of emotional and mental well-being. Furthermore, 
these symptoms feed into and influence their HRQoL scores. Therefore, this 
reinforces the need for proper headache management, which takes into account these 
comorbidities along with providing pain relief. 
It was therefore befitting that the first patient reported outcome measure to assess 
quality of life specifically for CH was developed and validated. A three-step approach 
was employed in the development of this scale, which following standard item 
reduction procedures, led to the final 28-item CHQ scale. The scale consisted of four 
domains, namely “restriction of activities of daily living”, “impact on mood and 
interpersonal relationships”, “pain and anxiety”, and “lack of vitality”, and has been 
demonstrated to have satisfactory internal consistency (Cronbach’s alpha > 0.5) and 
test-retest reliability (correlation coefficient > 0.7), with good internal construct 




6.2 Clinical implications and future research 
 
6.2.a  Neuroimaging study 
The fMRI study will be continued to allow for further recruitment of patients to 
enable a fair comparison between responders and non-responders to the GONB. In 
doing so, this will also circumvent the issue of the order confound. Additionally, this 
study is also intended to be expanded by adding another scanning session (outside of a 
bout), either before or after they have had the GONB, which would further account for 
the potential confounding order effect. 
Since the increase in rCBF seen in this study was confined to the left posterior 
hypothalamus, despite some patients having right-sided attacks, larger patient 
numbers would also be able to peter out analysis depending on laterality of attacks. 
On the other hand, future studies could also render recruitment of patients to be as 
homogeneous as possible, for example including those having strictly left-sided 
attacks only, to test for presence of true ipsilateral activation. Another interesting 
question that arises from this study is the role of the increases in rCBF seen in the 
brainstem of CH patients. A resting-state BOLD fMRI study can be undertaken in the 
future to test the hypothesis of functional connectivity between the spinal trigeminal 
nucleus and the hypothalamus. 
6.2.b  Saccadometry study 
As previously mentioned in Chapter 3, a sensitivity and specificity analysis performed 
on the saccadometric data showed that up to 81% of individuals could be correctly 
assigned a diagnosis of CH by saccadometry alone, therefore suggesting its potential 
to be used as a diagnostic tool. However, this was in comparison to a group of healthy 
controls. Since CH in the main has highly stereotypical characteristics, diagnosis of 
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the disorder is largely based on a detailed clinical history. Thus the use of 
saccadometry on its own in diagnosis of CH is limited at this stage. Further work on a 
larger dataset, with inclusion and comparison to other headache disorders may allow a 
better determination of its sensitivity and specificity, and it may then have a better 
place as a tool to aid diagnosis of complex cases. A comparison of saccadic reaction 
time distributions of CH patients with those having other headache disorders may also 
allow identification of the underlying neural mechanisms of the different headache 
disorders. 
Following on from the correlations seen between the neuroimaging findings and the 
saccadometry data, it is of interest to determine for changes, if any, in saccadic 
reaction time in CH patients inside and outside of a bout, as well as following 
treatment, such as the GONB. Hence, there is intention to extend the saccadometry 
study to run in parallel with the neuroimaging study, thus hopefully allowing an 
improved understanding of the functional impairment and neural mechanisms 
involved in CH. Depending on the results from this future study, there may also be 
potential in using saccadometry as an objective measure to monitor change following 
preventive or surgical treatment, as has been done in Parkinson’s disease (72). 
6.2.c  Quality of life study 
With regards to future work, the next stage in the validation of the CHQ will be an 
assessment of its sensitivity to capture change in HRQoL over time and following 
medical and surgical treatments of CH. Further studies will also need to be performed 
in other community populations as the development and validation of this scale was 
based solely on a sample of CH population in the United Kingdom. Additionally, 
further work on identification of factors that predict quality of life in CH would be 
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valuable in steering clinical management to focus on aspects of the disease that would 
help enhance quality of life of the patients with CH.  
6.3 Final conclusion 
CH is a highly disabling primary headache disorder and one of the main challenges 
faced by clinicians and patients is the poor understanding of its underlying 
mechanisms. Until such a time when the pathophysiological basis of the disorder is 
unraveled and treatment can be focused on the cause, current management centers on 
pain relief and improvement of quality of life of those affected. The various studies 
performed within this thesis have allowed us a better insight into the possible 
mechanisms associated with this disorder, as well as the significant impact it has on 
patients’ lives. However, whilst this thesis has managed to identify several structures 
and hypothesized on the possible systems that may be dysfunctional, further work 
needs to be undertaken to clarify their potential role in CH pathophysiology. To allow 
better assessment of this impact, the CHQ scale has been developed, which is intended 
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APPENDIX A: Quality of life booklet of questionnaires 
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